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Abstract 
 
Clinical outcomes in patients with rheumatoid arthritis (RA) are substantially improved 
by early therapeutic intervention; however many individuals still develop co-morbidities 
with a significant socio-economic costs.  In other conditions, there is a focus on disease 
prevention.  Identification of the earliest signs of disease, or even those at risk of 
disease, remains challenging due to the heterogeneity of presentations and the 
complexities of RA pathogenesis.  In working towards RA prevention an understanding 
of the pathology prior to clinical disease is required.  If risk of subsequent disease could 
be accurately quantified, the opportunity to intervene with therapy that might delay or 
even prevent disease becomes feasible. 
 
This thesis outlines a programme of work primarily focusing on individuals with systemic 
autoimmunity, but no synovitis.  By studying an ‘at-risk’ group, the stages and 
phenotypes prior to disease can be described.  Clinical, imaging, molecular and cellular 
biomarkers will be considered in an attempt to characterise individuals risk and assist in 
the prediction of RA development.  
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1. Introduction  
1.1 Background 
Rheumatoid arthritis (RA) is an autoimmune disease characterised by a chronic 
inflammatory arthritis (IA).  Inadequately treated, it results in joint destruction with 
subsequent deformity, disability and substantial socio-economic costs.  However, RA 
outcomes are significantly improved if treated at the earliest point or ‘window of 
opportunity’ [1-5].   This concept draws parallels with cancer management, where early 
initiation of therapy equates to less disease burden and leads to maximum effect of 
therapy [1].   In RA, this translates to suppressing the inflammation before the 
irreversible joint damage occurs.  Advancement in chronic disease management has 
explored the concept of arresting or reversing disease. Examples from cardiovascular 
disease (CVD) demonstrate how targeting ‘at-risk’ individuals aims to prevent future 
disease [6].   
 
Prevention of RA is a novel approach which is still in its infancy.  It is acknowledged, that 
the complexities of RA pathogenesis need to be better understood for prevention to be 
achieved.  Data from observational cohorts allows an understanding of the factors 
involved in the different phases of RA development.   By establishing the risks and 
initiators of disease, insights on when and how to intervene can be developed.   
 
This thesis focuses on a cohort of individuals defined as being ‘at risk’ of RA.  This was 
defined on the basis of the presence of non-specific musculoskeletal symptoms plus 
systemic autoimmunity, specifically, the presence of anti-citrullinated protein 
antibodies (ACPAs).  Individuals were recruited into a prospective observation cohort 
from 2007 and subsequently followed-up during which time a proportion developed the 
signs and symptoms of clinical inflammatory arthritis.  Markers associated with disease 
progression to inflammatory arthritis were identified (Figure 1).   
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1.2 Structure of Thesis 
Chapter Two: Literature review 
Following a brief review of the pathogenesis, natural history and prognosis of RA, this 
chapter focuses on the populations ‘at risk’ of RA.  It aims to review what has been 
established in these cohorts and the concept of risk stratification and early intervention.   
 
Chapter Three: Methods: Study Design and Population 
The study design adopted to recruit, investigate and observe the study population is 
described here, including methods for acquiring the clinical and imaging data.  Methods 
relating to specific biomarkers e.g. microarray analysis, flow cytometry, are described in 
the appropriate chapter (Chapters five and six respectively).   
 
Chapter Four: Magnetic Resonance Imaging in individuals with systemic autoimmunity 
and arthralgia: MRI as an imaging biomarker 
In this chapter, the MRI characteristics of the at-risk cohort are reported.  The chapter 
aims to consider whether MR imaging findings can predict future progression to RA.   
 
Chapter Five: MiRNA profiling of matched samples in individuals with systemic 
autoimmunity and arthralgia who progress to RA 
In this chapter, microRNA profiling of at-risk individuals is reported.  It aims to identify a 
signature which is associated with progression to RA.   
 
Chapter Six: T-cell subsets in individuals with systemic autoimmunity and arthralgia: an 
immunological biomarker 
In this chapter, the immunological phenotype (through T-cell subset quantification) of 
at-risk individuals is reported.  Associations to progression to RA and potential clinical 
utility of T-cell subsets as a biomarker is discussed. 
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Chapter Seven: Concluding remarks and future directions 
The final chapter is a summation of the conclusions drawn from each chapter of this 
programme of work.  Recent developments within the field are explored as well as the 
potential avenues for future work.  
- 4 - 
 
(c)  
Systemic 
Autoimmunity 
(c)+(d) +/- (a)+(b) 
 Clinical factors 
 MRI characteristics 
 Cellular & Molecular 
o T cell subsets 
o MicroRNA 
o Anti-CarP 
(d) 
Symptoms 
 No IA 
       
(a) 
Genetics 
 
(f) 
Rheumatoid 
arthritis 
(e) 
Unclassified 
Arthritis 
Predictors of 
disease 
progression 
 
 
(b) 
Environmental 
 
Figure 1 Schematic illustrating inflammatory arthritis continuum with at-risk terminology and highlighting cohort characteristics studied 
in this thesis. 
Presented are the categorises of risk as defined by the EULAR at-risk task force [153].  The central box defines the categorises of individuals 
that were considered in this programme of work.  Individuals with systemic autoimmunity and symptoms were recruited.  These individuals 
may also have genetic factors and environmental exposures. 
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2. Literature Review 
Review Criteria 
This review considers the pathogenesis, natural history, diagnosis and prognosis of RA; 
specific focus is given to the development of RA in at-risk individuals and the strategies 
to consider for disease prevention as a future approach. 
 
The Cochrane library, Embase and Medline databases were searched using keywords 
and subject headings including rheumatoid arthritis, secondary prevention, primary 
prevention, risk factors, arthralgia, preclinical arthritis, biological markers, 
autoantibodies, develop*/prevent*/predict* arthritis.  The search included articles 
published from 1946 to the present and was restricted to human subjects and the 
English language.  Additional data of interest was sourced from published abstracts and 
articles.  Data generated from this review has been published [7].  Subsequently, articles 
of interested have been sourced to update the review. 
2.1 Rheumatoid Arthritis 
RA is a chronic inflammatory autoimmune disease affecting the medium and small joints 
in a symmetrical pattern.  The synovium is the primary site of the characteristic 
inflammatory pannus formed from the invading immune cells (T cells, macrophages and 
B cells).  This synovial inflammation, or synovitis, results in pain, swelling and stiffness 
observed in active RA joints.  Tissue destruction of cartilage, bone marrow and 
connective tissues results as the pannus spreads to the articular surface and erodes the 
bone with the assistance of osteoclasts.  The resultant joint damage has been shown to 
correlate with disability, particularly in late disease.  Radiographic damage can be 
present from as early as 3 months from disease onset [8, 9].  Furthermore, the 
dysregulated immune system and inflammatory milieu can cause systemic effects on 
blood vessels and organs, including those in the cardiovascular and respiratory systems 
[10].  Systemic inflammation contributes to an increased cardiovascular risk, which is at 
a magnitude comparable to diabetes mellitus [11].  If sub-optimally controlled, RA 
causes joint damage, deformity, functional impairment and disability [12, 13].  It is 
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recognised that limiting disease burden and inflammation improves outcome and 
maintains function.  Considerable advances have been achieved in the last 25 years with 
early identification of disease, optimal treatment strategies and immunotherapies such 
as the biologic agents [14].  As such, an individual diagnosed today is likely to have a 
more favourable outcome than in the past and is likely to achieve a state of low disease 
activity or even remission [15]. 
 
2.1.1 Epidemiology 
RA affects approximately 0.5-1% of the population with 5-50/100,000 people developing 
RA each year.  There is considerable geographical variation [16].  Northern European 
countries have higher prevalence and incidence rates compared to southern Europe, 
whilst north America has the highest overall reported rates [17].  In particular, a high 
occurrence of RA is reported in the native American-Indian populations; 5.3% in the 
Pima Indians [18] and 6.8% Chippewa Indians [19].  A UK study reported RA prevalence 
at 1.16% in females and 0.44% in males, which suggested a decline in incidence in 
females since the 1950s [20, 21].  This decline has also been noted in the United States 
[22].  The recently published classification criteria for RA and treat to target approach in 
disease management may well be responsible for some of these observations.   
 
2.1.2 Aetiology & Pathogenesis 
Despite progress in the understanding of specific pathways implicated in established 
disease, the exact aetiology of RA remains unknown.  The current hypothesis describes 
how individuals with genetic susceptibility interact with environmental determinants 
resulting in an adverse immune state.  A ‘triggering event’ subsequently leads to T-cell 
activation, loss of systemic tolerance and the presentation of disease [23].  Identifying 
which trigger might evoke disease has proved complex due to the multifactorial nature 
of disease initiation.  Recently, the concept of localised mucosal prior to systemic 
autoimmunity has been introduced [24].   This is primarily attributed to the interaction 
of environmental factors at various mucosal sites.  There are however several caveats 
to the current hypothesis including whether all individuals require a mucosal trigger 
prior to systemic disease or whether a break in immune tolerance is possible through 
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this mechanism.  Therefore, much remains to be elucidated to complete our 
understanding of disease initiation.  Specific aetiological factors relating to this thesis 
will be discussed in this section.   
 
2.1.2.1 Autoantibodies 
The presence of autoantibodies in the sera of patients, although not specific for RA, is 
one of the hall marks of the disease.  Autoantibodies targeting the Fc portion of human 
IgG, termed as ‘rheumatoid factor’ (RF), were the first to be discovered in the blood of 
affected individuals [25, 26].  Since its discovery, RF has been consistently reported as a 
marker of disease progression and radiographic damage [27, 28].  High titres of RF have 
also been associated with reduced function and disability [29].   
 
IgM RF (but also IgA and IgG RF) in the joint form immune complexes which are thought 
to initiate a complement cascade.  The resultant increased vascular permeability and 
attraction of chemotactic factors facilitates the influx of immune cells that are integral 
to the adaptive and innate immune pathways.  Their presence alone is not sufficient to 
initiate disease as evidenced by their detection in healthy individuals.  However, at high 
titre they appear to be more specific for disease [29, 30].  Nell et al report high sensitivity 
and specificity for RA diagnosis using the optimum RF cut of ≥50 U/ml [30].   
 
Anti-citrullinated peptide antibodies (ACPAs) refer to antibodies directed against 
multiple citrullinated proteins (e.g. fibrinogen, vimentin, and α-enolase) and potentially 
have a more pathogenic role.  These were first discovered in 1960s under the guise of 
antiperinuclear and antikeratin factor, later shown to be antibodies against a similar 
antigen, citrulline [31-33].  Citrullination is a post-translational modification of arginine 
to citrullline which occurs in the presence of high calcium by the enzyme 
peptidylarginine deiminase.  It is a physiological process and occurs in health as well as 
disease states.  The second generation cyclic citrullinated peptide (anti-CCP 2) test is the 
most frequently used assay to detect ACPA in clinical practice. 
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ACPAs can be detected in the sera of individuals destined to develop RA years before 
there is any evidence of inflammation and immunity in the joints [34].  Before the onset 
of disease, the epitope recognition profile and isotype usage of the ACPA increases 
implicating their mechanistic role [35-37].  Furthermore, the efficacy of B-cell targeted 
therapies in RA through the depletion of B-cells, and hence autoantibody producing 
plasma cells, adds further credibility to the importance of autoantibodies [38]. 
 
Although animal models do not fully replicate human disease, they contribute to 
evidence supporting the pathogenic role of ACPA.  Murine studies have demonstrated 
the induction of collagen induced arthritis and detection of ACPA following inoculation 
with citrullinated peptides [39-41].  The interaction of HLA shared epitope motif and 
ACPA has also been demonstrated to produce arthritis in murine models [42, 43].   
Whether murine ACPAs have a role in either inducing or aggravating disease is debatable 
[44].  In vitro studies have demonstrated that human ACPA can activate the complement 
system [45].  In addition, interaction between macrophages and ACPA containing 
immune complexes resulting in the production of tumour necrosis factor (TNF) has been 
shown. This provides a potential mechanism for APCA driving inflammatory pathology 
[46].   
 
More recently the role of ACPA in bone loss has been investigated.  One group has 
reported that ACPAs have the potential to specifically bind to and activate osteoclasts 
[47].  The authors demonstrated the activation of osteoclasts and induction of bone loss 
following administration of ACPA isolated from individuals with RA.  Furthermore, the 
binding of ACPA to osteoclasts and their precursors in murine models resulted in pain-
like behaviours prior to the onset of inflammation.  This offers a potential explanation 
for the presence of pain and arthralgia in at-risk individuals prior to the active 
inflammation of RA [48].  Precisely how the effect on osteoclasts contributes to 
inflammation in the synovium remains to be elucidated although several theories have 
been proposed including the release of cytokine IL-8 [49].  It is probable that whilst 
ACPAs are important, several other mechanism of immune stimuli are responsible for 
the establishment of synovial inflammation.  
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2.1.2.2 Genetic risk factors 
As discussed earlier, for ACPAs to have a pathogenic role in disease initiation requires 
an individual to have the appropriate genetic background and exposure to 
environmental factors.  Twin studies have been pivotal in providing evidence for genetic 
associations in RA.  Data suggests the concordance for RA in monozygotic twins is 
between 15-30% and dizygotic twins 5%, with estimates for the heritability at around 
60% [50, 51]. Subsequent studies suggest a slightly lower contribution, with first-degree 
relatives of patients with RA having a threefold increased risk for the development of RA 
[52, 53].    
 
Large genome wide association studies (GWAS) have advanced our understanding of the 
genetic susceptibility to RA [54, 55].  A 2013 GWAS reported 101 genetic loci associated 
with the disease [56].   The majority of genetic associations relate to ACPA positive 
rather than ACPA negative disease.  The most important genetic risk factor for RA 
remains the human leucocyte antigens alleles (HLA DRB1 *0101, *0102, *0401, *0404, 
*0405, *0408, *1001 and *1402) that encode a conserved amino acid motif known as 
the shared epitope (SE).  Overall, HLA-DRB1 accounts for 40% of the genetic component 
of susceptibility of RA. The HLA DRB1 *04 allele has been shown to confer the greatest 
risk of RA development and increased further by the presence of two alleles [57]. 
 
Large association studies reviewing the single nucleotide polymorphisms (SNPs) across 
the major histocompatibility complex have identified the strongest signal to be at amino 
acid position 11, followed by position 71 and 74 [58].  Two other SNPs outside the HLA-
DRB1 region have also been identified as important; amino acid position 9 of HLA-B in 
class I and amino acid position 9 at HLA-DPB1 in class II.  These amino acids are located 
within the peptide binding cleft of the antigen presenting molecules.  SE position 
surrounding and within the binding cleft provides a mechanistic role which is pivotal to 
the ‘shared epitope hypothesis’ [59].  Due to the SE linkage, there is successful antigen 
presentation, T-cell receptor activation and resultant immune response.  Subsequent 
research has identified avid binding of citrulline-containing peptides compared to their 
unmodified counterparts in the binding cleft [43]. This accounts for SE association with 
ACPA positive disease.  More recently, researchers have suggested that the SE may act 
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as a ligand favouring polarisation of T-cell differentiation towards an autoimmune T-cell 
repertoire – specifically the enhancement of Th17 differentiation and inhibition of a 
generation of T regulatory cells [60]. 
 
Studies have shown that HLA-DRB1 SE alleles not only contribute to disease risk but are 
implicated in severity [61].  Similar to disease susceptibility, individuals homozygous for 
HLA DRB1*0404 were four times more likely to have high disease burden with an erosive 
phenotype than SE negative individuals [62].  Not all the HLA alleles have been linked to 
disease risk, HLA DRB1*1301 has been demonstrated to be protective in ACPA positive 
RA [63].   
 
There are genetic associations that have been found outside the HLA region.  The most 
reported is protein tyrosine phosphatase non-receptor 22 (PTPN22) [64, 65], which is 
associated with increased risk of ACPA positive RA [66]. This gene encodes for lymphoid-
specific protein tyrosine phosphatase which down regulates signal transduction from T-
cell receptors.  The variant risk allele (PTPN22 R620W - in which a single base change in 
the coding region results in an amino acid substitution) has been implicated in a number 
of other autoimmune disease [67, 68].  The PTPN22 polymorphism appears to be 
relevant to particular geographical or ethical groups and is absent from many Asian 
populations.  Where present, it can relate to a two-fold risk of developing RA.   
 
Although focus has been predominantly on ACPA positive disease, specific loci have 
been identified in ACPA negative disease including IRF5 (haplotype in the promoter 
region of the interferon regulatory factor 5 gene) and HLA DR3 [69, 70].  From GWAS it 
would appear that ACPA positive and negative disease display significant risk allele 
frequency differences within the HLA region, where as there is more overlap with non 
MHC associations [71].    
 
The fact that concordance between monozygotic twins is, at most, 30% implies that 
other factors besides genetic predisposition act as contributors.  Epigenetic and 
stochastic factors contribute in varying degrees to RA pathogenesis.  A recent analysis 
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using a twin database [72, 73] allowed researchers to conclude that the development of 
ACPA relied largely on environmental and stochastic factors rather than the presence of 
HLA DR-SEs [74].  The authors suggest that the significant effect of HLA-DRB1 alleles is 
not at initial induction of autoimmunity, but in determining disease initiation, as 
illustrated by Figure 2.  Several of these factors are now discussed. 
 
 
Figure 2 Schematic representation of a model for stepwise development of ACPA and 
ACPA-positive RA 
Reprinted by permission from BMJ publishing group [74] Copyright 2015 
 
2.1.2.3 Epigenetics 
In addition to changes in genetic sequence, epigenetics  or ‘outside conventional 
genetics’ refers to the study of potentially heritable alterations in gene expression that 
arise during development and cell proliferation [75].  Importantly with epigenetic 
processes there is no alteration to the underlying DNA sequence.  Simply, it is any 
biological mechanism that switches genes on and off.  Epigenetic processes include DNA 
methylation and posttranslational histone modifications (methylation, acetylation, 
phosphorylation, ubiquitinylation, SUMOylation and poly-ADP-ribosylation) which 
result in added residues or side chains marking regions of genetic code [76, 77].  These 
epigenetic markers are recognised by ‘reader’ proteins that serve as platforms and 
docking sites for effector proteins which facilitate processes such as transcription, DNA 
replication, damage response and chromatin remodeling.  
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The role of epigenetics in RA remains to be elucidated.  It is acknowledged that 
epigenetics has an impact on the expression of cytokines, chemokines and 
metalloproteinases involved in inflammatory disease [78].  Initial epigenetic studies 
have focused on the key effector cells in RA, such as the fibroblast-like synoviocytes 
(FLS).  RA FLS have been shown to have increased levels of histone deacetylase which 
has been shown to regulate the expression of cytokines such as TNF and IL-1 as well as 
account for the high cell proliferation and decreased cell apoptosis [79].  Researchers 
have demonstrated a therapeutic effect of histone deacetylase inhibitors on some 
models of arthritis.  Whilst DNA methylation has been shown to repress transcription by 
inhibiting the binding of transcription factors and is disrupted to varying degrees in RA 
samples [80, 81].   
 
Changes regulated by microRNAs (miRNAs) are another important area of epigenetics.    
MiRNAs are a highly-conserved class of short non-coding RNAs (21-25 nucleotides) that 
serve as transcriptional negative regulators involved in fine tuning of the expression of 
genes for cell differentiation, metabolism and immunity  [82, 83].  It is now thought that 
they regulate at least 30% of messenger RNA [84, 85].  Several miRNA have been 
implicated in RA (reviewed [86]), with miR-155 and -146 being the most widely reported 
[87-89].  
 
2.1.2.4 Environmental contributors 
Potential environmental exposures, can be encompassed in the category of stochastic 
factors (random life events), which are thought to play an important role in the aetio-
pathogenesis of RA.  The contribution of environmental factors to health and disease 
has been studied in many autoimmune diseases [90].   Large observational studies have 
retrospectively identified several environmental risks for RA (Box 1) [91].   
Box 1 Environmental factors that have been associated to risk of RA [91-112] 
Factors generally thought to increase risk of RA 
Silica exposure 
Low UVB exposure 
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Smoking* 
Low alcohol intake 
High BMI‡ 
High birthweight 
Lower socioeconomic status 
Factors generally thought to decrease risk of RA 
Longer breast-feeding duration 
Factors with an indeterminate effect on risk of RA 
Periodontal disease 
Hormones—oral contraceptive§ 
Dietary components—consumption of red meat, proteins, oily fish, fruit, caffeine 
Psychological stress 
Low levels of vitamin D 
*Particularly in seropositive disease.‡ particularly in seronegative disease. §Studies suggest a 
protective effect. 
 
Hormones 
The predominance of autoimmune disease in females suggests that hormones and the 
reproductive system play an important role on disease development [113].  As 
suggested in Box 1, although initial studies suggested a protective effect with oral 
contraceptives, subsequent evidence has been inconclusive [96, 114, 115].  Recent, 
epidemiological studies have demonstrated that longer exposure to the pro-
inflammatory sex hormones (early menarche) and pregnancy are associated with 
increased risk of disease development [97].  Pregnancy can induce remission in a high 
proportion (around 90%) of women, however relapse is frequent post-delivery [116, 
117].  Furthermore, once disease has initiated, subsequent changes to hormone levels 
appears to effect disease severity with multiparty being associated with poorer 
outcomes.    
 
Smoking 
Cigarette smoking is the most widely accepted environmental risk factor for RA and 
demonstrates a significant interaction between environment and genetic factors [118, 
119].  As with HLA-SE and PTPN22 risk alleles, smoking confers the greatest risk to ACPA 
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positive RA.  Studies have demonstrated a multiplicative effect of genetic risk (HLA-SE) 
and smoking [119, 120]. Individuals who possessed two copies of the HLA-SE and 
smoked had a 21-fold increased risk of RA development compared to HLA-SE negative 
non-smokers [119].   
 
The association of disease with smoking as well as the lung abnormalities documented 
in early RA has contributed to the theory that the lung mucosa may be an initiating site 
of disease [121, 122].  This hypothesis suggests that by-products of smoking contribute 
to the citrullination of peptides and hence generation of antigens which evoke an 
autoantibody response.  The identification of inducible bronchus-associated lymphoid 
tissue (iBALT) in patients with pulmonary complications of RA supports the concept of 
localised autoimmunity [123].  Studies have demonstrated citrullinated antigens at the 
lung mucosa of healthy smokers compared to non-smokers [124].  More recently, mass 
spectrometry-based proteomic techniques have identified shared citrullinated antigens 
in both synovial and bronchial samples of RA patients [125].  Whilst histology from the 
lungs of untreated early RA individuals (with no apparent lung disease) confirmed 
lymphocyte aggregates with increased activation markers particularly in seropositive 
individuals [126].  Although a modest study the authors were able to demonstrate these 
changes were largely independent of smoking status suggesting increased citrullination 
at the lung is not solely attributed to smoking.   
 
Involvement of the lungs prior to RA and systemic autoimmunity can be assessed by 
examining first degree relatives (FDRs) – these individuals share both genetic and 
environmental associations.  Preliminary results investigating induced sputum, as a 
marker of lung autoimmunity, demonstrated a greater incidence of autoantibodies in 
the sputa compared to sera [127].  The role of the lung mucosa in RA has incited interest 
and forth coming studies will hopefully provide clarification.  
 
Periodontal disease 
An emerging environmental risk factor for the development of RA is periodontal disease 
and the plethora of microbes found in the mouth [128].  The discovery that one of the 
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main organisms associated with periodontal disease, Porphyromonas gingivalis, 
citrullinates peptides via peptidyl arginine deiminase (PAD) enzymes, thereby forming 
the antigens required for ACPA formation, suggested an association between 
periodontal disease and RA [129].  However, population-based studies report conflicting 
results for this disease association, with confounding factors including smoking and poor 
oral hygiene as well as discrepancies in quantifying periodontal disease by self-reported 
methods [108, 130-132].  Investigative studies have attempted to determine whether 
the presence of P gingivalis precedes RA onset or is merely a bystander.  Thus far, 
evidence suggests titres of antibodies to P gingivalis are associated with the presence of 
RA-related autoantibodies in at-risk individuals [133-135].  It can be hypothesized that 
the generation of ACPA via PAD enzymes contributes to the antibody response and 
triggers systemic disease in a proportion of individuals.   
 
Gut Microbiome 
As detailed in Box 1, specific dietary associations with RA remain inconclusive but 
research has examined the role of the gastrointestinal system microbiome [136, 137].  
The microbiome refers to microorganisms which populate the human body, primarily 
relating to the skin and mucosal organs.  The interaction between the immune system 
and infectious agents is not a new theory, there has previously been work evidencing 
the link between bacteria and viruses including the Epstein Barr virus, proteus species 
and Escherichia coli [138-141].  Whilst the exact mechanism has not been proven, 
molecular mimicry is postulated [142].   
 
Within the gut there are several notable observations from murine models, the first 
reported in the 1970s.  This study described how arthritis prone rats raised in a germ 
free surroundings developed severe inflammatory arthritis whilst those in conventional 
cages (with environmental pathogens) developed a milder form of disease [143].  
Subsequent murine studies have attributed protective and pro-arthritic effects of 
pathogens [144-146].  More recently, in germ free IL‑1 receptor antagonist-knockout 
mice, researchers demonstrated that only those colonized with defined microbiota 
(lactobacillus bifudis) developed rapid onset severe arthritis similar to that seen in non-
germ free rat models [147].  This was shown to be due to an imbalance in T-regulatory 
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cells and Th17 cells.  Investigation into T-cell repertoires within these studies suggests 
that gut bacteria maintain an immune-homeostasis between pro- and anti-
inflammatory T-cell subsets.  Dysbiosis with overgrowth of pathogenic bacteria is 
hypothesised to disrupt the homeostasis; thus contributing to RA development [148]. 
 
In humans, bacterial flora in individuals with early RA appears to be distinct to that found 
in health, other diseases and untreated RA patients, with an abundance of Prevotella 
copri with loss of Bacteroides [149, 150].  Whilst no pathogen has been identified 
capable of citrullination, the notion that dysbiosis and a triggering of gut immune cells 
may have a pathogenic role, which has led to increased research in the microbiome and 
autoimmunity.  Large scale international projects are underway to attempt to map out 
the human microbiome and provide potential answers to its role in health and disease 
[151, 152]. 
 
The concept of environmental factors triggering autoimmunity and an inflammatory 
response in susceptible individuals has been widely accepted (Figure 3).  However, the 
precise cause of the loss of immune tolerance and the perpetuation of this state remains 
unclear.  It may be that particular microbial products, microvascular change, 
biomechanical stress, or most probably a combination of factors, contributes to the 
initiation of synovitis [23].  
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Figure 3 Multistep process and potential triggers to inflammatory arthritis development. 
 Reproduced with permission from [23], Copyright Massachusetts Medical Society.  
 
2.1.3 The inflammatory arthritis continuum 
The natural history of RA can be considered along a continuum with distinct stages of 
progression (Figure 4).  Here, an individual with the genetic predisposition to disease 
can be followed through to exposure of environmental factors and the onset of immune 
mediated disease – an inflammatory arthritis such as RA.   
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Figure 4 Schematic of inflammatory arthritis continuum  
Reproduced from review article  [7]. 
 
As illustrated in the inflammatory arthritis continuum there are several stages prior to 
the diagnosis of RA (Figure 4 a-d).  The figure references the categorises recently 
suggested in the recommendations for terminology of ‘at-risk’ groups [153].  Individuals 
may possess one or several factors that are classified as a risk.  Genetic (a) and 
environmental (b) interactions may interact to increase an individual’s risk of developing 
IA.  An asymptomatic period marked by the presence of systemic autoantibodies (c) and 
other inflammatory markers may occur, enabling the early identification of ‘at-risk’ 
individuals.   Once clinical disease is established individuals can be broadly defined as 
undifferentiated arthritis (e) and RA (f). 
 
At the point of clinically detectable disease, the disease course can be heterogeneous 
namely; persistent, intermittent, relapsing, progressing or remitting.  Often the ability 
to give an exact diagnosis is not possible.  van Aken et al suggested that up to a third of 
individuals with a new IA will be classified as undifferentiated (UA) [154].  One definition 
for UA is ‘an early form of arthritis not meeting classification/diagnostic criteria for a 
more definitive disease’ [155].  From large inception cohorts of IA, the outcome of 
individuals with UA largely reports around one third will develop RA while in up to a half 
the IA will resolve completely [156, 157].  
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2.1.4 Diagnosis  
The diagnosis of RA is based on a clinical assessment involving clinical history, 
examination findings and exclusion of alternative differentials diagnoses.  Laboratory 
tests can also help the diagnosis process and have been included in both the ACR 1987 
and EULAR/ACR 2010 classification criteria for RA [158, 159].  The new criteria in 2010 
(Box 2) was developed following reports of a relatively low sensitivity for the 1987 
criteria detecting early disease [160].  These new criteria have already been evaluated 
in several cohorts. A recent systemic review pooled this data producing an overall 
sensitivity 82% and a slightly lower specificity 61% [161].  
Box 2 The 2010 American College of Rheumatology/European League Against 
Rheumatism classification criteria for rheumatoid arthritis 
 
Target population (Who should be tested?): Patients who…. 
1. have at least 1 joint with definite clinical synovitis (swelling) 
2. with the synovitis not better explained by another disease 
 
Classification criteria for RA (score-based algorithm: add score of categories A–D; a 
score of ≥6/10 is needed for classification of a patient as having definite RA) 
                                                                               SCORE 
A. Joint involvement 
1 large joint 
2-10 large joints 
1-3 small joints (with or without involvement of large joints)  
4-10 small joints (with or without involvement of large joints) 
>10 joints (at least 1 small joint) 
 
0 
1 
2 
3 
5 
B. Serology (at least 1 test result is needed for classification) 
Negative RF and negative ACPA 
Low-positive RF or low-positive ACPA 
High-positive RF or high-positive ACPA 
 
0 
2 
3 
C. Acute-phase reactants (at least 1 test result is needed for classification) 
Normal CRP and normal ESR 
Abnormal CRP or abnormal ESR 
 
0 
1 
D. Duration of symptoms 
<6 weeks 
>6 weeks 
 
0 
1 
Adapted from [158]. 
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With regards to laboratory markers with positive serology for autoantibodies, RF and in 
particular ACPA, are central to the diagnosis of RA.  Whereas RF can be found in other 
diseases and healthy individuals, ACPA has a high specificity for RA and is present in 60-
80% of individuals with RA [162]. Raised inflammatory markers/acute phase reactants 
such as C - reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are typically 
seen in new presentations of RA often in conjunction with thrombocytosis and 
leucocytosis.  An abnormal acute phase reactant gains one score in the new classification 
criteria (Box 2).   
 
The steering group responsible for the new criteria for RA also provided guidance with 
regards to bone erosions.  This is particularly important given the widespread use of 
radiography and ultrasonography in early arthritis clinics.  Conventional radiographic 
examinations remain the ‘gold standard’ for diagnosing joint damage in RA.  Whereas, 
previously erosive disease was one of the criteria for a diagnosis of RA which resulted in 
delays in diagnosis, the new criteria do not stipulate the need for erosion.  In the 
presence of clinical synovitis, ultrasonography can be used to confirm and detect 
subclinical synovial involvement in other joints which may help direct treatment.   
 
Applying the new classification criteria to historical cohorts and registries has 
demonstrated that individuals who were previously diagnosed as UA at presentation 
would now be classified as RA.  The Norfolk Arthritis Registry has reported higher 
incidence rates of RA in both males and females following application of the new 
classification criteria in the inflammatory polyarthritis cohort [163].  Although, the 
overall incidence of RA has been reportedly decreasing, it will be instructive to monitor 
these trends following adoption of the 2010 criteria and the change in definition of 
disease.    
 
2.1.5 Prognosis  
Current treatment strategies aim to treat disease aggressively to prevent joint 
deformity, disability and the psychological implications of chronic disease [164-166].  
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However, RA is a heterogeneous condition and can entail a variable course.  One 
treatment that is effective for one individual will not necessarily be effective for another.  
Identification of prognostic factors associated with poor outcome in disease progression 
and persistence is a priority area of clinical research.  Of equal importance is the 
identification of individuals with a less active disease phenotype in whom milder 
treatment may induce remission with a tailored management pathway.  Whilst this 
concept of personalised medicine has not been fully adopted in early arthritis clinics, 
research has identified presenting features which are associated with protracted disease 
and poorer outcomes.   
 
Several studies have investigated prognostic factors in RA from early arthritis cohorts.  
Clinical factors which have been attributed to a poor prognosis include; erosive disease 
[167], high number of active joints and subcutaneous nodules [168].  Gender appears to 
be inconclusive, although it is generally accepted that females have poorer outcomes 
[169, 170].  Smoking has also been shown to correlate with erosive disease and poorer 
outcomes [171, 172] which, as previously discussed is hypothesised to be due to the 
interactions with ACPA [119].  ACPA titre has been cited to be the greatest contributor 
in a prediction model for disease severity.  This reported a ten times increased likelihood 
of erosive disease compared to ACPA negative patients [173].  Other laboratory 
measurements including high levels of inflammation markers (CRP and ESR) are 
associated with poorer prognosis [174].  Male gender, the absence of erosions and good 
functional scores (e.g. HAQ) have been cited as good prognostic markers for remission, 
while the absence of RF and low number of active joints at diagnosis equate to more 
favourable outcomes [167, 175, 176].  
 
Patients with undifferentiated arthritis are at risk of development of a persistent IA 
fulfilling the criteria for RA.  Researchers have attributed several prognostic markers for 
development of RA, by virtue some of these are those associated with poor RA 
outcomes.  A prediction rule for progression to RA from UA at one year was developed 
using data from an early arthritis inception cohort [156].    Nine factors were identified 
as predictors; age, female gender, distribution of affected joints (favouring classical 
bilateral poly-arthropathy phenotype), tender and swollen joint counts, duration of 
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morning stiffness, level of CRP, and RF and ACPA positivity, these have been validated in 
other cohorts [155].  
 
Although a relatively new area of research, significant works evaluating the stages prior 
to overt inflammatory disease (UA and RA), the ‘preclinical stage’, have been reported.  
This has been driven by the concept of aiming to treat disease at the earliest opportunity 
to obtain best outcome.  The concept of preventing arthritis is now being considered 
[177, 178].  However, before prevention can be implemented an understanding of the 
stages prior to disease onset and the risk of progression to RA is required.   
 
2.2 Classification of ‘at-risk’ cohorts 
The study group for risk factors for RA have defined the key terminology for the different 
phases of disease (Box 3) [153]. An individual may fulfil one or more of the classifications 
e.g. have both genetic and environmental risk factors.  Using this resource it is apparent 
that there are several defined cohorts that could be considered for prevention.  This 
classification provides a suitable foundation for defining ‘at-risk’ cohorts and individuals 
that may be amenable to preventative strategies.  Importantly, that the term pre- RA 
can only be used retrospectively once an individual is known to have developed RA.   
Box 3 Terminology recommended for the phases prior to RA development [153] 
▶ In prospective studies individuals would be described as having:  
           (a) Genetic risk factors for RA  
           (b) Environmental risk factors for RA  
           (c) Systemic autoimmunity associated with RA  
           (d) Symptoms without clinical arthritis  
           (e) Unclassified arthritis  
           (f) RA 
▶ The term ‘arthritis’ is used to denote clinically apparent soft tissue swelling or fluid (not 
bony overgrowth alone). 
▶ (a) to (e) can be used in a combinatorial manner for example, an individual may have 
(a)+(b), or (a)+(b)+(c) or (a)+(b)+(d), etc.  
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▶ The prefix ‘pre-RA with:’ can be used before any/any combination of (a) to (e) but only to 
describe retrospectively a phase an individual was in once it is known that they have 
developed RA.  
 
The at-risk category originally considered were those individuals identified due to the 
presence of systemic autoimmunity through analysis of biobanks of stored sera (at-risk 
category (c)).  First degree relatives fall into several categorises of risk ((a)+(b)+(c)) and 
are easily identifiable through RA probands.  By virtue of increased presentation to 
physicians; individuals with arthralgia or symptoms of arthritis and autoimmunity are a 
further category that has also been evaluated ((c)+(d)).  Further discussions in this 
chapter will focus on these categories of risk, focusing specifically on the latter ((c)+(d)).  
 
2.2.1 Individuals with systemic autoimmunity 
 
Predictors identified in nested case control cohorts 
Several clinical and serological characteristics are associated with an increased risk for 
the development of RA.  Over 20 years ago, del Puente et al reported on the presence 
of autoantibodies prior to disease.  By prospectively following an asymptomatic cohort 
in a population known to have a high risk of RA, rheumatoid factor (RF) was 
demonstrated to be a predictive factor for future development of RA [179].   However, 
it has been the availability of stored blood samples permitting retrospective testing for 
the presence of autoantibodies (reviewed in [180]), which has enabled the greatest 
insight.  Initially studies focused on the presence of RF isotypes but later included other 
markers such as antifillagrin and antikeratin- now known to be part of the antibody 
response to citrullinated peptides [181-186]. 
 
The importance of these autoantibodies was highlighted when Swedish and Dutch blood 
biobanks reported on the positive predictive value (PPV) [34, 187].  By adopting a nested 
case-control method, they analysed serial blood samples in individuals prior to clinical 
disease.  The presence of RF isotypes and citrullinated cyclic peptides antibody (anti-
CCP) were compared to that of age-matched controls.  Prior to clinical diagnosis, 40.5% 
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of the Dutch and 33.7% in the Swedish study group were anti-CCP positive.  The presence 
of autoantibodies predated the onset of RA by up to 14 years. The 5-year PPV for anti-
CCP in the blood donor population was 96.6% and 100% if IgM RF and anti-CCP were 
present.  Translating this to the general population, a positive anti-CCP had a 5-year PPV 
for the development of RA of 5.3%.  The frequency of positive samples increased closer 
to the onset of clinical disease in both cohorts, supporting the concept of a mounting 
immune response.  This is consistent with studies that have reported an expanding 
repertoire of citrullinated antigens evoking autoantibodies in the years prior to disease 
[35, 36, 188, 189].  Whether specific antigens are directly related to development of RA 
has yet to be clarified. 
 
Several large studies in America have adopted the case-control design to identify risk 
factors for chronic disease, primarily cancer and cardiac disease, but also RA. The 
Nurses’ Health Study is one of the largest having had two periods of recruitment 1976 
and 1989 with respective recruitment and prospective follow up of 121,700 and 116,430 
women [190].  Although the main objective was to consider lifestyle choices and 
environmental factors contributing to disease, over a quarter of participants in each 
cohort provided a blood sample.  As with the European biobanks, these studies have 
evaluated many biochemical, immunological and environmental factors that may be 
associated with RA and have demonstrated a mounting immune response from 
cytokines, autoantibodies and inflammatory proteins prior to RA development [184, 
188, 190-198].  Owing to the wealth of data that is available, researchers can adapt their 
study to consider potential new biomarkers or risk factor as the field evolves.  One 
recent study from the Netherlands demonstrated increased bone markers in the serial 
samples obtained prior to the diagnosis of arthritis.  This suggested that there is an 
alteration in bone metabolism, with increased osteoclast activity during the systemic 
autoimmunity phase [199].  Whilst, the Nurses Health Studies’ team analysed vitamin D 
intake and levels (a topical and debated risk factor of autoimmune disease) [102, 200].  
No significant relationship was demonstrated, although there appeared to be a trend 
towards low levels of vitamin D in the months prior to RA diagnosis in a subset of 
individuals.  These and other similar studies have contributed to our understanding of 
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the immune, metabolic and inflammatory response prior to disease although there are 
limitations given reliance on medical records and self-reported questionnaires.   
 
Predictors identified in first degree relatives:  
Similar to findings originally reported with the Pima Indians, RF presence was shown to 
predate diagnosis of RA in FDRs [201].   These individuals often share genetic and 
environmental factors with their RA relatives.  As expected, this group of individuals had 
a higher prevalence of ACPA and RF isotypes compared to healthy controls [37, 202-
207].  From the blood donor studies, individuals considered as ‘high risk’ (2 family 
members with RA) had a PPV for the development of RA over 5 years of 69.4% if anti-
CCP was detected, increasing to 100% if IgM RF was also present [208].  The isotype 
profiles appeared to be different to RA populations, with several reports highlighting a 
predominance of IgA ACPAs [204, 205].  The significance of this has yet to be determined 
but may indicate the mucosa as a site of pathogenesis (discussed Section 2.1.2).   
 
A large cohort of RA probands has been recruited in the United States as part of the 
Studies of the Etiology of Rheumatoid Arthritis project [207].  This cohort has enabled 
researchers to study known as well as possible novel associations and risk factors for the 
development of RA.  Similar to the retrospective blood donor studies, these databases 
are now reporting on other predictors such as cytokine patterns in FDRs [209, 210].  
More recently they reviewed dietary supplementation of omega 3 fatty acids and 
reported a protective effect for the presence of ACPA positivity in probands [211].    A 
similar cohort is now being recruited in the UK [212].  In other autoimmune diseases, 
FDRs have been the focus of preventative trials [213-215].  This is not currently proposed 
in RA, although it is possible that these individuals would be amenable to health 
promotion intervention to avoid the known risk factors of RA.  
 
2.2.2 Individuals with systemic autoimmunity associated with RA and 
symptoms without clinical arthritis: 
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Individuals with musculoskeletal symptoms and autoimmunity (Box 3 (c) and (d)) 
provide a key cohort for understanding of inflammatory arthritis.  Importantly these 
individuals can be assessed clinically and followed prospectively for progression to RA.  
To date, there are two key cohorts which have reported on progression rates and these 
individuals’ characteristics [216, 217]. The initial prospective study detailed the 
characteristics of 147 participants who tested positive for IgM RF and/or ACPA in the 
presence of arthralgia symptoms [216]. A 20% (29/147) rate of progression to arthritis 
in a median of 11 months was reported, with 34.5% fulfilling 1987 ACR criteria for RA 
[159].  Of those who progressed, 90% (26/29) were ACPA positive, giving ACPA positivity 
a hazard ratio of 6.0.  IgM RF was only related to progression in the presence of ACPA.   
The Leeds cohort recruited individuals with non-specific joint pain and ACPA positivity 
resulting in an even higher progression rate of 50% [217].  As the cohorts and duration 
of observation has increased, several characteristics have been evaluated and predictors 
of progression identified.  
 
‘Biomarkers’ is a term frequently used in health sciences when commentating on 
characteristics of disease or outcome.  A definition for a biomarker has been provided;  
‘A characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes, or pharmacologic responses 
to a therapeutic intervention.’ [218] 
A biomarker in the field of prediction can therefore be a physical sign, cellular, genetic, 
or biochemical/molecular alteration that aids diagnosis or prognosis.  Additionally, for a 
biomarker to have clinical utility it should be easily obtainable, highly reproducible, 
sensitive, specific for the outcome and where possible reflect a pathogenic process 
[219].  These specifications are important to consider when translating findings from at-
risk cohorts in to day to day clinical practice.  
 
2.2.3 Biomarkers described in at-risk cohorts 
Table 1 illustrates several biomarkers that have been identified for evaluation of at-risk 
individuals with systemic autoimmunity and symptoms of arthritis.  
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Biomarkers Number 
of cases 
Summary of findings 
Serological immune markers 
 ACPA  & IgM RF [216] 147 90% of those who developed arthritis were ACPA positive (HR 6.0, 95% CI 1.8–19.8).  In ACPA-positive individuals, 
the addition of RF but not SE enhanced the risk of arthritis progression.  No independent association between 
arthritis progression and RF positivity or presence of SE. 
Fine Specificity of  ACPA [220] 
(Reactivity against 5 different 
peptides  derived from fibrinogen, 
enolase and vimentin analysed) 
244 82% of anti-CCP positive individuals and 9% of anti-CCP-negative, RF-positive individuals recognised >1 
citrullinated peptide; these patients had an increased risk of developing arthritis compared with patients who 
recognised 0–1 peptides (OR 2.1, 95% CI 1.0–4.4).  A specific citrullinated peptide associated with progression to 
arthritis was not identified. 
 anti-CarP antibodies [221] 340 Of those positive for anti-CarP antibodies (36% of the study population), 51% developed RA compared with 25% 
of those who were negative.  Presence of anti-CarP antibodies is associated with an increased risk of arthritis 
progression independent of anti-CCP and RF status (HR 1.56, CI 95% 1.06–2.29)  
 FC glycosylation to ACPA [222]  183§ Using serial samples from an ACPA+ arthralgia cohort demonstrated a decrease of galactosylation and an increase 
of core fucosylation of serum ACPA-IgG1 shortly before the onset of RA. 
Gene expression & inflammatory  markers 
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 Gene expression [223] 109 Signatures associated with arthritis development were involved in IFN-mediated immunity and 
chemokine/cytokine activity (OR 21.0, 95% CI 2.8–156.1).  Genes involved in B-cell immunology were associated 
with protection against arthritis progression (OR 0.38, 95% CI 0.21–0.70) 
 Interferon signature [224] 115 IFN signature scores generated by measuring expression of 7 type I IFN response genes demonstrated IFN(high) 
signature was associated with progression to IA in cox regression analysis HR 2.38 (95% CI 1.26 to 4.49; p=0.008)  
after correction ACPA and RF status. 
 B cell signature [225] 115 Expression of CD19, CD20, CD79α and CD79β measured to create a B cell signature.  B cell (high) revealed 
protection compared to B cell (low) signature (HR 0.50, 95% CI 0.26 to 0.98, p=0.042).  Significance lost after 
correction for RF and ACPA status. 
 HsCRP, PCT, SPLA2, TNF-alpha, IL-
6, IL-12p70, IL-10, and IFN- and 
several mRNA biomarkers [226] 
137 A trend was observed with some cytokines but, overall, circulating cytokines did not differ between those who 
progressed to arthritis and those who did not.  No correlation was found between mRNA expression levels of 
inflammatory genes and progression to arthritis  
Lipid profiles 
 TC, HDLc, LDLc, TG, apo A1 and 
apoB [227] 
348 Differences in lipid profiles were noted between those who developed arthritis and those who did not, although 
the difference was not significant for all markers.  A decrease in apoA1 was predictive of development of arthritis 
in anti CCP positive individuals only (HR 0.52, 95% CI 0.29–0.92). 
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  Adipokines in serum and synovium  
[228] 
51 Increased serum Vaspin levels was associated with an increase in progression to IA (HR1.5 95% CI 1.1 to 2.2; p = 
0.020) studied in 27 autoantibody positive individuals.   Synovial expression of adipokines was not associated with 
progression to IA.   
Histology markers 
 Tissue architecture: Synovial knee 
biopsy [229] 
13 Explorative study – No difference in tissue architecture detected between individuals who progressed to arthritis 
and those who did not. 
 Synovial tissue expression [230] 15 Synovial expression of Prostaglandin E2 pathway enzymes were not associated with arthralgia symptoms or 
progression to IA.  
 Lymph node phenotype [231]  20 Lymphoid pro-inflammatory CD8+ T-cells exhibit a less-responsive phenotype in at-risk individuals.  Increase in 
CD8+ memory T-cells in LN accompanied by an increase in non-circulating or recently activated (CD69+) CD8+ T-
cells in LN and matched peripheral blood compared to health.  No risk to progression analysis as no development 
to IA reported. 
 Lymph node phenotype [232] 12 LN assessments in at-risk and RA groups.  Innate lymphoid cell (ILC) profile in the LN changes from a homeostatic 
towards a more inflammatory profile during the at-risk and earliest phase of RA.  No risk to progression analysis 
as no development to IA  reported. 
Imaging markers 
 MRI of knee [229] 13 Explorative study – No difference in inflammation detected on imaging between individuals who progressed to 
arthritis and those who did not. 
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MRI of hands [233] 21§ Subclinical inflammation detected on MRI (particularly in the wrist) in ACPA-positive patients with arthralgia, but 
studies with larger numbers of patients and prospective follow-up are required to determine whether this finding 
predicts development of arthritis. 
MRI of hands and feet [234] 28§ MRI synovitis was present in 93% ≥1 joint(s) and was not associated with progression to IA, median [IQR] 
cumulative synovitis score in those that progressed 9.0 [6.3-13.8] compared to 20 [10.8-21.8] in those that did 
not, OR 0.87 (95% CI 0.76-0.99). There was a temporal relationship between extent of synovitis and time to IA, 
with those with a score 2 of synovitis progressing sooner than a score 1.      
MRI of hands [235] 20§ Synovitis, osteitis and bone erosions were demonstrated in 65%, 35%, and 65% respectively.  Tenosynovitis was 
the most reported pathology present in 80% but none of the controls.  Individuals with ≥2 tendons involved were 
more likely to develop RA.  
US of hands [236] 192 There is a trend of US abnormalities (joint effusion, synovitis, PD and tenosynovitis) in those who progressed to 
arthritis.  This did not reach statistical significance.  Results suggest US better at detecting subclinical 
inflammation compared to clinical examination.  
US of hands [237] 136§ PD was predictive of progression to IA; PD score 2 in a joint equated to a 30-fold increase in risk of developing 
arthritis at that joint (HR 31.3, 95% CI 15.6, 62.9), p<0.001.  At a patient level, progression also occurred sooner 
with a PD score of 2 compared to a zero; median time to clinical arthritis 7.1 months verses 52.4 months, HR 3.7 
(95% CI 2.0,6.9) p=<0.001.  Individuals with erosions also progressed sooner.   
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Table 1 Biomarkers considered in individuals with systemic autoimmunity (anti-CCP and or RF) and arthralgia 
§ All ACPA+ individuals +/-RF (remainder of studies consisted of individuals IgM RF+ or ACPA+) 
Anti-CCP: anti-citrullinated cyclic peptide antibody, ACPA: anti-citrullinated protein antibodies, Anti CarP: Anti-carbamylated protein antibodies , apo A1/B 
apolipoprotein A1/B, BMI: body mass index, HDLc: high-density lipoprotein cholesterol, HsCRP: High-sensitivity CRP, IL-6: interleukin 6, ILC: innate lymphoid cell, INF-
: interferon-, LN: Lymph node,  LDLc: low-density lipoprotein cholesterol, MRI: magnetic resonance imaging, mRNA: messenger RNA, PCT: procalcitonin, PD: power 
PET of hands [238] 29§ Explorative study – 4 patients had at least 1 PET positive joint.  All these individuals progressed to arthritis.  Of the 
remaining 5 who progressed but had negative PET scans 3/5 developed inflammatory arthritis in joint not 
included in the PET scan.  Suggests PET therefore has a clinical utility at detecting subclinical arthritis.   
Micro-CT [239] 15§ Bone mineral density measured by micro-CT was significantly reduced in ACPA positive individuals compared to 
healthy controls.  Analysis of risk of progression not performed due to small number. 
Association with environmental factors/clinical factors 
Smoking and BMI [240] 55 Independently, smoking (HR 9.6, 95% CI 1.3–73.0) and high BMI (HR 5.6, 95% CI 1.3–25.0) were associated with 
arthritis development.  Individuals with both a BMI ≥25 kg/m2 and a history of smoking had a higher risk of 
developing of arthritis compared to never smokers with a BMI ≤25 kg/m2.  The increased risk associated with 
smoking was found to be independent of ACPA status. 
Alcohol intake [241] 361 Alcohol consumption at baseline was inversely related with the risk of development of arthritis; HR 0.80 95% CI 
(0.65 to 0.97).  No associations identified concerning the quantity of alcohol consumed.   
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Doppler, PET: Positron Emission Tomography, RF: rheumatoid factor, SE: Shared epitope, SPLA2: secretory phospholipase A2, TG: triglycerides, TNF-alpha: tumor 
necrosis factor-alpha, TC: Total cholesterol, US: ultrasound 
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2.2.3.1 Serological immune markers: 
Blood sampling is a minimally invasive method of identifying potential characteristics 
which may in the future be used as biomarkers.  Autoantibodies have been one of the 
first biomarkers considered in the at-risk cohorts [35, 216, 220].  More recently novel 
autoantibodies to carbamylated protein (anti-CarP) have been reported in both RA and 
at-risk cohorts [221, 242, 243].  Studies have reported the role anti-CarP in diagnosis and 
prediction, particularly in ACPA negative RA.  Anti-CarP presence demonstrated an 
independent association to RA progression with an at-risk cohort.  Anti-CarP has been 
assayed in the Leeds ACPA+ at-risk cohort as part of a collaborative project [244].  Of the 
123 ACPA+ at-risk individuals tested, 40.6% (50/123) were positive for anti-CarP; 58% 
(29/50) of these progressed to RA during follow-up.  A weak association with disease 
progression was demonstrated HR=1.70 (95% CI 0.91, 3.18), p=0.099.  Although anti-
CarP has been demonstrated to be present before RA in the biobank samples [245], 
further validation in prospective at-risk cohorts is required to ascertain its utility in the 
preclinical setting.  
 
A potential immune marker yet to be considered in at-risk populations are the 
circulating T-cell and B-cell populations.  The role of the immune system - in particular 
lymphocytes, in RA pathogenesis is supported by several factors: i) the presentation of 
antigens by MHC to immune cells, ii) autoantibody and cytokine production, and iii) 
infiltration of lymphocytes in the synovium [59, 246].  Whilst T-cell subsets have been 
considered in RA for prediction remission, relapse and response to therapy [247-250] 
they have not been considered in at-risk cohorts and offer a potential new predictor of 
disease.  
 
2.2.3.2 Genetic markers: 
Genetic markers have also been considered in at-risk cohorts.  One group has reported 
that the HLA-shared epitope (SE) allele is not independently associated with disease 
progression [216].  However, specific gene signatures, particularly those related to 
interferon mediation, have been identified [224].   
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There have however been no reports concerning microRNA (miRNA), a novel biomarker 
that has been evaluated in cancer extensively.  MiRNAs are short non-coding RNAs (21-
25 nucleotides) which regulate hundreds of mRNAs and are one of the key epigenetic 
factors in disease pathogenesis (Section 2.1.2.3).  This regulatory characteristic 
combined with their relative stability and presence in various biological samples renders 
them highly suitable as potential biomarkers.  Specific miRNA related to inflammation 
in RA have been reported, although functional work is still insufficient [251, 252].  Other 
pre-disease states such as Barrett’s oesophagus progressing to oesophageal 
adenocarcinoma, illustrate the potential for specific miRNA signatures to be associated 
with disease risk [253].    
 
2.2.3.3 Histological markers: 
Histological samples provide insights into disease pathogenesis.  Obtaining such samples 
can be invasive and potentially unacceptable to the general population outside of 
research settings.  However, attitudes towards biopsies would change if the clinical 
value of histological markers were appropriately highlighted to patient groups and 
clinicians.  The benefit of synovial samples has been illustrated in early IA cohorts in 
which disease stratification was possible [254-256].  Additionally, synovial pathotype has 
assisted in the development of peripheral biomarkers which predicted response to 
biologic therapy [257].  The clinical utility in at-risk cohorts would be considered high, if 
they can inform risk and assist in tailoring management. 
 
Within the at-risk cohorts, researchers have studied synovial and lymph node tissue 
[229-232].  Studies evaluating the synovium have demonstrated infiltration of T-cells 
[229].  In at-risk cohorts synovial studies have been limited largely due to the lack of 
clinically swollen joints accessible for biopsy.  Furthermore, synovial tissue sampling is a 
highly technical procedure that requires experienced personnel to ensure appropriate 
tissue is selected with minimal discomfort to the participant [258].  Reassuringly, a 
recent review of synovial biopsy procedures reported an overall complications rate of 
0.4% [259].  Ethical considerations are pertinent in these cohorts particularly if the joint 
is not inflamed nor symptomatic.   
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Lymph node biopsies have also been attained from at-risk individuals.  In this study,  the 
newly recognised cell line believed to mediate immunity – the innate lymphoid cells 
(ILC), was reported to be present [260, 261].  The authors demonstrated significant 
differences between the ILC subsets between health, at-risk and RA disease groups 
[232].  However, numbers recruited were small and no progression data was available 
within the at-risk group for the authors to comment on progression risk.  The insights 
into disease pathogenies these studies provide remain greatly valued.  
 
2.2.3.4 Imaging markers: 
Imaging modalities have enhanced our understanding of inflammatory disease.  Clinical 
imaging has good biomarker potential given that several imaging modalities now 
provide dynamic and macroscopic mapping of tissue without the inconvenience and 
possible harm of performing biopsies.   
 
i) Radiographs 
 
Conventional radiographs are frequently used to assess for the presence and monitoring 
of peri-articular damage and erosions in RA.  In early RA it is possible to detect changes 
in joint damage within 3 months with plain radiographs [9].  Radiographic changes at 
baseline are predictive of disease progression in undifferentiated cohorts and in 
individuals with RA predicts future radiographic damage [262, 263].  However, given the 
subtlety of changes that occur prior to disease it is not a sensitive modality to assess 
changes within the joint.  This is likely to explain why there is little data currently 
available regarding radiographs of individuals with autoimmunity but no clinical 
synovitis. 
 
ii) MSK Ultrasonography  
 
Although initially reserved to research use, ultrasound of the joints is now well-
established and common place in many rheumatology departments and early arthritis 
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clinics and is recommended in the assessment of rheumatic diseases [264, 265].  Studies 
have demonstrated that ultrasound is more sensitive than clinical examination [266, 
267].  Visualising the synovium and its vascularity has aided early diagnosis and 
assessment of disease activity.  Ultrasound is also more sensitive at detecting bone 
erosions compared to conventional radiographs.  The ability to examine a joint in 
multiple planes, and the function of power Doppler (PD) assist in the diagnosis of early 
inflammatory disease. 
  
Within at-risk individuals, there have been two key studies which have reported 
ultrasound findings [237, 268].  A study of 192 individuals (ACPA positive and/or RF 
positive arthralgia) demonstrated ultrasound abnormalities (joint effusion, synovitis and 
PD) to be predictive of development to clinical synovitis at a joint level (OR 3.07 (95% CI 
1.05, 8.94), OR 5.45 (95% CI 2.32, 12.8), and OR 5.50 (95% CI 2.32-12.8) respectively 
[268].   Combining the presence of synovitis (grade 2-3) and PD (grade 1-3) increased 
the risk of development to arthritis in that joint to OR 12.9 (95% CI 4.65-36.0) translating 
to a positive predictive value of 35%.  However, ultrasound was not found to be 
predictive of progression to arthritis at a patient level, although there was a positive 
trend.  In contrast, Nam et al reported ultrasound to be predictive at both a patient and 
a joint level [237].  In this study, a core set of 32 joints were scanned in 136 anti-CCP-
positive individuals.  The ultrasound results were kept blinded from the clinical assessors 
to reduce any bias in assessment of clinical synovitis.  Thirty percent had PD in ≥1 joint(s), 
96% had GS in ≥1 joint(s) 21% had ≥1 erosion(s).  Interestingly, there was a high 
prevalence of grey scale change found in the MTPs of healthy controls (n=48) and was 
shown to be less discriminating in the anti-CCP-positive cohort between those who 
progressed and those who did not.  Therefore, the MTP scores were excluded.  A 
baseline scan with a PD score of 2 in a joint equated to a 30-fold increase in risk of 
developing arthritis at that joint (HR 31.3, 95% CI 15.6, 62.9), p<0.001.  At a patient level, 
progression also occurred sooner with a PD score of 2 compared to a zero; median time 
to clinical arthritis 7.1 months verses 52.4 months, HR 3.7 (95% CI 2.0,6.9) p=<0.001.  
Similarly, individuals with an erosion in at least one joint were at greater risk than those 
without; median time to clinical arthritis 7.5 months verses 50.1 months, HR 2.9 (95% CI 
1.7,5.1), p=<0.001.    
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iii) Magnetic resonance imaging (MRI)  
 
MRI has advantages over other imaging modalities and this is reflected in its 
recommended use in diagnosing RA in recent EULAR recommendations [269].  MRI can 
visualise the field of interest in 3 orthogonal planes providing detailed assessment of 
bone and surrounding soft tissue whilst avoids ionising radiation.  Therefore, it follows 
that investigators considered MRI for the at-risk groups to ascertain any subclinical 
disease.   
 
One of the first studies to report MRI findings was conducted in the Netherlands and 
matched synovial biopsy of the knee to MRI findings of the same joint [229].  This small 
explorative study (n=13) of individuals with autoantibodies but no clinical synovitis 
(12/13 having arthralgia) demonstrated no difference in MRI measure compared to the 
healthy control group (n=6).  The negative findings could reflect the joint imaged given 
that knee is rarely the first joint involved in RA, furthermore just under half subjects 
reported symptoms at the joint.  However, the authors defend their conclusions 
extrapolating from data from synovial samples from unaffected RA joints, in which 
increased synovial inflammation is found [270].  However, in disease initiation, imaging 
(and biopsy) of the small joints might provide more insight.  
 
Imaging of the small joints suggests early changes can be seen on MRI in at-risk 
individuals, albeit, thus far, in small cohorts [233, 234].  Krabben et al demonstrated that 
individuals with autoantibodies and arthralgia had higher mean inflammation scores at 
the wrist joints (sum of synovitis and bone marrow oedema scores using OMERACT and 
RAMRIS system) compared to healthy controls; 0.9 vs 2.3 respectively (p<0.001 
confidence intervals not reported) [233].   Interestingly, in the 21 arthralgia autoantibody 
positive group the mean inflammation score in the painful joints was 1.0 and in the 
symptom free 1.2 suggesting symptoms did not reflect MRI features.  Furthermore, 
during follow up 12 individuals developed RA with the inflammation scores not differing 
from those who did not progress to RA.   
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Similarly, a study analysing 28 autoantibody positive arthralgia patient’s MRI scans 
concluded the presence of MRI synovitis was not associated with progression to clinical 
arthritis [234].  In fact, those individuals that progressed to disease state had synovitis 
scores lower than those who did not.  However, there did appear to be a substantive 
relationship when the authors considered time to synovitis in those with a greater 
degree of synovitis in one joint.  Individuals with synovitis score of 2 in at least 1 joint 
developed arthritis within 1 year, and those with scores of 1 developed disease more 
gradually.  These studies demonstrate that MRI is sensitive at detecting subclinical 
inflammation but the specificity remains questionable when considering its role in 
predicting progression to arthritis.   
 
iv)    Positron emission tomography (PET) 
PET is a modality infrequently used in clinical practice when assessing individuals with 
RA.   Small studies have suggested PET imaging offers greater sensitivity at subclinical 
synovitis compared to MRI [271] and potentially detect those at risk of progression to 
RA [272].   
 
v)  Microcomputer tomography (micro CT)  
Similarly, micro CT is a modality currently reserved for research purposes to assess bone 
microstructure and density.  Since the presence of ACPAs and RF have been 
demonstrated to equate to a greater risk of bone erosions in RA [273-276], researchers 
have attempted to assess bone loss in healthy individuals with detectable ACPA 
compared to controls [239].  Here, the ACPA positive group (n=15) had significantly 
greater reduction in bone mineral density and cortical bone thickness with distinct 
changes to cortical bone architecture.  This programme of work challenges the notion 
that synovial inflammation is seen prior to the activation of osteoclasts and bone 
resorption.  Instead, the concept of ACPAs possessing a pathogenic role in which they 
contribute to a reduction in bone integrity before the milieu of cytokines and 
inflammation become established is suggested.  Although yet to be demonstrated in 
vivo; in vitro, ACPAs from RA patients were shown to bind to osteoclasts with a resultant 
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induction in osteoclastogenesis and bone-resorptive activity [47].   Whilst a multitude of 
questions still remain, at-risk individuals provide a unique opportunity to study concepts 
regarding the pathogenesis of RA.   
 
2.2.3.5 Associations with environmental factors:  
Smoking has been identified as a risk for progression to RA in 55 individuals with 
arthralgia and systemic autoimmunity [240].  This study also considered obesity which 
has previously been reported to correlate with an increased risk of future diagnosis of 
RA in the Nurses’ Health Study [277].  In this prospectively followed cohort, both ‘ever’ 
smoking and body mass index (BMI) ≥25 kg/m2 were associated with arthritis 
development; HR (95% CI): 9.6 (1.3 to 73.0); p=0.029 and HR (95% CI): 5.6 (1.3 to 25.0); 
p=0.023 respectively [240].  There were no differences in the titre or antibody status 
between individuals in the two groups.  This analysis included only 55 individuals, and 
validation of these associations in larger cohorts is warranted.   
 
The role of periodontal disease, in particular P gingivalis, has been studied within these 
individuals.  To date, assessments of the immune response in the sera to P gingivalis 
have failed to show a risk to disease progression but has established a significant 
association with the presence of RA-related autoantibodies in individuals at-risk [135, 
278].  This may be due to insufficient powering of studies and the methods used to 
assess for periodontal disease and P gingivalis.  Recently data from population based 
case-control studies in the Swedish biobanks have reported increased levels P gingivalis 
related antibodies in the serial samples prior to disease [279, 280].  Here, the antibody 
response to the P gingivalis virulence factor arginine gingipain were measured as 
opposed to merely P gingivalis antibodies.  Given that chronic periodontitis is estimated 
to affect  approximately 30% of the population, measuring antibodies to P gingivalis did 
not necessarily provide a mechanistic link [281].  Ginigpains are necessary for the 
cleaving of peptides and hence generation of de novo epitopes for citrullination by PPAD 
[282].  Establishing a causal link between periodontal disease, the oral microbiome and 
initiation of disease remains challenging but several studies combing clinical and 
microbial sampling are hoping to provide further evidence [283]. 
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Alcohol has been reported to be inversely associated with the development of RA [112, 
284] and likewise within at-risk cohorts autoantibody positive individuals with no 
alcohol intake had a greater risk to RA development than drinkers [241].  However, 
within our own cohort we did not see a protective effect [217]. 
 
From the biomarkers identified in Table 1, it is evident that it may now be possible to 
identify individuals at potential risk of progression to arthritis in the systemic 
autoimmunity and symptoms risk category.  However, to date, results are limited to a 
few cohorts based in the northern hemisphere.  Data from other geographical regions 
and ethnicities will provide further information and are warranted.   
 
2.3 Risk stratification and model development: 
As documented, no single biomarker has been identified which predicts disease with 
sufficient accuracy to be of clinical value.  A different approach is therefore needed.  The 
ability to risk stratify individuals is an attractive option particularly in light of current 
strategies concerning personalised medicine [285].   This has been undertaken in the 
early phases of inflammatory disease where models have been developed which aid 
prediction of progression from UA to RA [156, 286].  However, recent trials which aimed 
to prevent progression from UA to RA did not risk stratified individuals and may account 
for failure to reach primary endpoints.  A recent re-evaluation of the ‘PROMPT’ study in 
which individuals were treated with methotrexate versus placebo demonstrated that by 
risk stratification of patients, those at high risk would have hypothetically resulted in 
better outcomes [287].  This illustrates the importance of risk stratification prior to 
offering treatment to individuals at risk of RA.   
 
Risk score tools have been developed by determining clinical risk factors associated with 
RA in an autoantibody positive (RF and/or ACPA) cohort.  One recently published scoring 
system, reported a score greater than 7 corresponded to a risk of developing RA within 
1 year of 43% and within 5 years 81% [288].  This scoring system used a minimum of 9 
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variables, which is a relatively large number of data points for performing risk 
stratification.  Some of the variables used may only be recorded in the local research 
clinic in which the model was designed.  The transferability to other cohorts for 
validation has therefore been limited.  Risk stratification of ACPA positive individuals at 
the Leeds research clinic, resulted in a simple tool to be used in primary care and 
rheumatologists to identify ‘at-risk’ individuals early [217].  Several clinical, serological 
and imaging markers were considered in the first 100 patients.  Variables found to be 
substantively associated with progression in univariable analysis were included in the 
multivariable models of progression.  Ultrasound imaging along with selected clinical 
findings and antibody titres resulted in a model in which no individual determined as 
low risk progressed to IA, compared to 72% if categorised as high risks score.  Figure 5 
illustrates the scoring system.   
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This model facilitates the identification of individuals at greatest risk, in whom the use 
of immune modulating therapies could be targeted to prevent disease progression.  The 
results from this analysis require validation in a larger patient cohort.  
 
Criteria Points 
Tenderness of small joints present 1 
EMS ≥ 30 minutes 1 
High level RF and/or anti-CCP 1 
Power Doppler present 1 
Shared epitope present 1 
  
  Total Score 
  Proportion progressing of those who 
progressed to IA within 12m 
  0 0/3 (0%) 
Low 0% 
  1 0/8 (0%) 
  2 7/25 (28%) 
Mod 50% 
  3 9/31 (29%) 
  4 10/19 (53%) 
High 72% 
  5 4/6 (67%) 
Figure 5 Risk stratification model including clinical, serological and imaging biomarkers.  
Demonstration of categorisation of individuals using the clinical risk score. 
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2.4 Intervention studies in ‘at-risk’ cohorts: 
Until very recently, the closest this area of research had to an interventional study were 
large, population-based studies in which the effect of various (non-DMARD) therapeutic 
options were analysed to assess for any reduction in RA development [289-292].  The 
Women’s Health Study prospectively assessed the effect of low-dose aspirin and vitamin 
E supplementation in the prevention of CVD and cancer.  A sub-analysis of this same 
cohort demonstrated that both interventions did not reduce the incidence of RA [289, 
292].  Similarly, a randomised control trial evaluating the effect of postmenopausal 
hormone therapy on CVD, hip fracture and breast cancer outcomes, performed an 
analysis of the incidence of RA [290].  This study, which included 27,347 participants, 
reported a non-significant reduction in the risk of developing RA (HR 0.74; 95% CI 0.57–
1.10) with the use of postmenopausal hormone therapy.  These large population-based 
studies provided information on how prevention therapies could be targeted.  Other 
dietary and supplementary therapies have been assessed in similar cohorts, and could 
provide insights on how prevention strategies for RA could be developed.   
 
2.4.1 Corticosteroids 
As understanding of the preclinical phase advanced, investigators attempted to delay 
and prevent progression to RA.  Bos et al recruited individuals with arthralgia and 
autoantibodies (either ACPA and/or IgM RF) and treated with intramuscular 
glucocorticoids at 0 and 6 weeks [293].   The endpoint chosen was 50% reduction or 
normalisation in autoantibody levels at 6 months.  This was achieved in one patient from 
each group.  Although this intervention was hoped to have an impact on the 
development to RA, long-term follow-up revealed similar percentages in each group.    
 
2.4.2 DMARDs 
 ‘Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis’ (StopRA) is 
a randomised placebo control trial which has recently began recruitment in the United 
States [294].  Individuals with positive anti-CCP titre are recruited and randomised to 
receive hydroxychloroquine or placebo for 12 months.  The end point is the 
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development of rheumatoid arthritis as defined by the ACR/EULAR criteria (score≥6) at 
36 month follow up.  Individuals will be recruited from health fairs, FDRs of RA and 
rheumatology clinics.  No evidence or history of an IA or prior DMARD use are essential 
to the exclusion criteria.   
 
2.4.3 Biologic DMARDs 
Recent reports from trials in early IA and RA advocate the use of early biologic agents 
with induction of remission in 69% to 89% [295, 296].  The ability to maintain remission 
on a reduction or even withdrawal of biologic drug suggests the immunological effect 
can be sustained if disease is treated early.  It can be hypothesised that treating prior to 
disease onset, those at high risk may have a sizeable immunological impact.  There are 
currently two trials underway exploring prevention in antibody positive individuals; the 
PRAIRI study (NTR 1969) using a single dose of 1000mg of rituximab and APPIPRA study 
(EudraCT Number: 2013-003413-18) 52 week therapy with abatacept.  Each of these 
studies have been designed acknowledging current understanding regarding the drugs 
mechanisms of action and evidence from RA or UA trials.  The use of rituximab, a 
depleting anti-CD20 therapy, is effective and well tolerated in early and late stages of 
RA and shows particular efficacy against autoantibody positive disease [297, 298].  B-
cells role in the production of immunoglobulins including RF and ACPA, present many 
years before the onset of clinical disease, is one of the reasons for its application in this 
preclinical phase.  The presence of B-cells and plasma cells in the synovium of active RA 
patients also supports its potential role in disease pathogenesis.  Furthermore, B-cells 
can produce cytokines and can trigger autoimmunity due to their antigen presenting cell 
(APC) function and hence activation of T-cells through co-stimulatory signals.  Similarly, 
abatacept is commonly used therapy in the treatment of both early and late stage RA 
[299, 300].  This fusion protein (consisting of Fc region of immunoglobulin IgG1 and 
CTLA-4 molecule) binds to CD80/ CD86 molecules on the T-cell surface preventing 
activation.  The hypothesis is that preventing APCs from delivering the co-stimulatory 
signal at this pivotal stage of disease initiation could prevent progression to the full 
phenotype of clinical RA. 
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2.5 Summary 
In this chapter, the potential initiating factors involved in the pathogenesis of RA are 
reviewed. The concept of a continuum with distinct stages to the natural progression of 
disease is detailed.  Evidence indicating that patient outcomes are improved through 
early intervention has fuelled research into early disease identification.  Subsequently, 
the opportunity to prevent disease has become an attractive option.  Determining onset 
of disease and optimal intervention time point has now become a research priority. In 
order to address this need, the stages prior to disease and individuals at risk to RA are 
pivotal.  Those with systemic autoimmunity (ACPA+) offer insights into disease 
pathogenesis.  The fact that not all individuals progress to arthritis exemplifies the 
heterogeneity within this at-risk cohort.  Hence, researchers have attempted to identify 
predictors of disease.  This chapter has reviewed the serological, imaging and clinical 
factors which have been considered.  As yet, no single biomarker has been identified as 
solely predictive.  However, the potential to risk stratify individuals using multiple 
biomarkers is a viable option.  This approach would enable the identification of those at 
greatest risk and thus, in whom exposure to therapeutic agents are justifiable.  Ongoing 
research investigating disease pathogenesis and risk identification enables the 
opportunity for innovative therapeutic approaches, strategies for health promotion and 
ultimately concepts in disease prevention to be explored.    
 
2.6 Hypothesis and Aims 
The overarching hypothesis of this thesis states that the development of 
rheumatoid/inflammatory arthritis can be predicted in at-risk individuals be evaluating 
imaging, molecular and cellular biomarkers.  Subsequently, individuals at risk to IA/RA 
can be risk stratified to assist clinical management.  
 
By studying individuals presenting with systemic autoimmunity and non-specific 
musculoskeletal pain this work aims to: 
I. Evaluate the role of MR imaging in the prediction of IA/RA development. 
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II. Explore the change in MiRNA expression along the IA continuum and the 
biomarker potential in predicting IA/RA development. 
III. Establish whether T- cell subset dysregulation is associated with progression to 
IA/RA and assists risk stratification models.   
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3. Methods: Study Design and Population  
The study design and population are detailed in this chapter. Clinical and imaging 
assessments are described.  Specific methods and statistical analysis relating to each 
work stream (e.g. laboratory methods of cellular markers) are detailed in the relevant 
results chapter.  
 
3.1 Ethical Approval  
The study was approved by the Leeds Ethics Committee (research ethics committee 
reference: 06/Q1205/169).  Approval was granted in November 2006.  There have been 
subsequent amendments, the most recent of which in 2014.  
 
3.2 Study Design  
The ‘Co-ordinated Programme to Prevent Arthritis: Can We Identify Arthritis at a Pre-
Clinical Stage?’ is a longitudinal prospective cohort study.  The study comprises of two 
components.  The primary care component is adopted by the UK National Institute of 
Health Research Clinical Research Network.  Recruitment was initially limited to 
Yorkshire, however subsequent approval has been granted at recruitment sites 
throughout the UK.   
 
General practitioners, musculoskeletal physicians, physiotherapists, podiatrists and 
other health professionals are asked to refer individuals presenting with new, non-
specific musculoskeletal (MSK) joint pain.  This includes presentations such as lateral 
epicondylitis, bursitis and shoulder tendonitis.  The primary care component comprises 
of the completion of health questionnaires and blood testing for anti-CCP2.  Those 
participants who are anti-CCP positive are eligible for the second component of the 
study, forming the ‘at-risk’ cohort.   
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3.3 Consent 
Participants are provided with information and given a minimum of 24 hours before 
informed consent is obtained.  They are able to discuss the study with the study team 
by contacting the research helpline telephone number.  Informed consent process is 
confirmed by the signing of the consent forms by the patient and a good clinical practice 
trained research nurse or doctor.  Participants recruited to the main study are invited to 
take part in the affiliated sub-studies.   
 
3.4 Study Population 
3.4.1 At-risk cohort  
In this programme of work, the at-risk cohort (or CCP+) are defined as those individuals 
with non-specific MSK joint pains, who have tested positive for the anti-CCP2 assay.  In 
addition to those identified by primary care, eligible individuals were referred from the 
early arthritis clinics within Yorkshire.  Box 4 outlines the study inclusion and exclusion 
criteria.   Patients included in these analyses were recruited from June 2009 to January 
2016. 
Box 4 Study inclusion and exclusion criteria. 
Primary & Secondary Care subjects 
Inclusion Criteria 
 Age > 18 years 
 Has a new musculoskeletal complaint  
 Capable of understanding and signing an informed consent form 
  Has tested CCP positive 
Exclusion Criteria 
 Patient fulfils 1987 ACR Criteria or the 2010 ACR/EULAR criteria for RA 
 Has a definitive diagnosis of an inflammatory arthritis on referral 
 Patient has tested CCP negative  
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3.4.2 Control Subjects: 
Healthy controls were recruited to the study.  Baseline assessments were performed 
following the same protocol as the subjects with non-specific MSK joint pain and 
autoimmunity (CCP+).  Healthy control subjects attend for one baseline assessment.    
 
3.5 Study Protocol  
The study protocol comprises of a main clinical and imaging study and a biological blood 
sample sub-study (stored serum). Table 2 details the research protocol with reference 
to study visits, clinical parameters, imaging and sampling.  In addition to the listed time 
points, a participant could attend outside of these scheduled visits should they develop 
new signs or symptoms consistent with inflammatory arthritis.   
   
Table 2 Participant Schedule listing study requirements for each visit.  
Study Visit  1 2 3 4 5¥ 6 
Week 0 13 26 39 52 Withdrawal 
Inclusion / Exclusion & Consent  X      
Medical, family & social history X      
Examination, observations - 
height, weight, BP, pulse 
X      
Complaints-directed 
examination 
 X X X X X 
Adverse Events/Medications X X X X X X 
Joint count  X X X X X X 
Early morning stiffness X X X X X X 
Patient Questionnaire : HAQ, 
VAS, Employment 
Questionnaire, EQ5d 
X X X X X X 
ANA, RF X    X X 
Anti-CCP test X X X X X X 
ESR, CRP, Haematology X X X X X X 
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Chemistry, HLA DR4 X      
Stored serum X X X X X X 
Urine X    X X 
X-rays§, MRIβ X    X x 
High Resolution US X  X  X X 
§ X-ray of hands and feet and symptomatic joints as clinically indicated at baseline and repeat 
at 12 months to a maximum of 4 joint regions per visit. 
β In patients with no contraindication to imaging and as facilities allow.  Failure to undergo these 
investigations does not exclude participant from remainder of study.  MRI to be performed at 
time points above unless individual participating in another investigational study in which an 
MRI is to be performed.   
¥ The first year of this longitudinal study is shown in the above schedule.  This is an on-going 
data collection study and subsequent visits after this year will continue at annual intervals with 
the same format as visit 5 (excluding MRI).  If clinical need dictates, the above procedures may 
be performed at more or less frequent intervals. 
 
3.6 Assessments 
3.6.1 Clinical & demographic assessments 
Clinical assessments were performed at 3 monthly time points for the first year and then 
annually or as clinically indicated.  Initial baseline visit allowed collection of demographic 
and medical history data.  Early morning joint stiffness (EMS) and current 
symptomatology (e.g. intermittent symptoms, tendonitis, and arthralgia) were recorded 
at each study visit.  Participants completed patient questionnaire during visits including 
health assessment questionnaire (HAQ), visual analogue score (VAS), employment 
questionnaire and a measure of health-related quality of life measure (EQ5d).   
 
Rheumatologists experienced in the identification of IA (LH, CR and KM) performed the 
examinations.  Assessments included a musculoskeletal examination, 78 joint count for 
tenderness and 44 joint count assessing for swelling.  Physicians were also able to 
comment and record other findings such as tendonitis.  The rheumatologists were 
blinded to the results of the imaging investigations (MRI and ultrasound).  
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Patients were provided with the research helpline number to enable contact with the 
research team should new symptoms of IA develop.  This allowed rapid review by the 
research team rheumatologists and appropriate study investigations to be instigated.   
    
3.6.2 Imaging Assessments 
3.6.2.1 Conventional radiography 
X-rays of hands and feet were performed at baseline.  Follow-up x-rays were performed 
at 1 year and then as clinically indicated.  Any symptomatic joints may be x-rayed if 
clinically appropriate.  Musculoskeletal radiologist reported on the presence of 
abnormalities.  
 
3.6.2.2 High Resolution Ultrasound Scan Protocol 
Examinations were performed by a rheumatologist and an ultrasonographer trained in 
musculoskeletal ultrasonography on a Philips HDI 5000 machine 5–12 and 8–15 MHz 
transducers (later changed to a General Electric S7 machine).  Power Doppler was 
assessed using a pulse repetition frequency set between 700 and 1000 MHz.  The 
rheumatologist and ultrasonographer performing the scans  were blinded to the clinical 
examinations.   
 
Standard protocol required a total of 38 joints to be scanned which consisted of the 
wrists, metacarpophalangeal joints (MCPs), proximal interphalangeal joints (PIPs) and 
metatarsophalangeal joints (MTPs) bilaterally (Appendix A).  Following a preliminary 
analysis of MRI data which indicated that tendon pathology may be an important 
finding, tendon scoring of the hand flexor tendons (at the MCP and PIP level) and the 
extensor carpi ulnaris was introduced. The OMERACT definitions were used to define 
synovitis [301].  For scoring EULAR OMERACT system was applied (semi quantitative 
scale) [302].   
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In addition, if patients had any symptomatic joints that were accessible by ultrasound 
these could be scanned and appropriately scored.   Following baseline assessment, joints 
were scanned at 6 months and then annually or at the development of IA.   
 
3.6.2.3 Magnetic Resonance Imaging Protocol 
MRI scanning was performed on a Siemens MAGNETOM Verio 3.0 Tesla whole body 
scanner (Siemens Healthcare: Erlangen, Germany).  Contrast-enhanced MRI was 
obtained after intravenous injection of 10 mL of gadolinium diethylene-
triaminepentaacetic acid.  Subjects were placed in the prone position with the hand 
extended in front of the body. MRI was performed at baseline and then, if possible, at 
the development of IA.  
  
The protocol included coronal STIR of the hand and wrist to include the MCP joints with 
dedicated fat suppressed coronal T2 images separately acquired of the MCP joints and 
wrist, 3D gradient echo (Double Echo Steady State - DESS) with water excitation, T1 
weighted 3D gradient echo (spoiled gradient echo) with water excitation pre and post 
gadolinium. The 3D sequences were acquired in the coronal plane with isotropic voxels 
allowing multiplanar reconstruction.  Semi-quantitative scoring was performed 
independently by two musculoskeletal radiologists for synovitis, bone marrow oedema 
(BME) and erosions according to the OMERACT RAMRIS [303].  Tenosynovitis was scored 
using a previously described method [304, 305].  The 5 flexor tendons of the digits and 
the wrist flexor tendons were scored.  For reference Figure 6 illustrates the tendons of 
the wrist.  RAMRIS/OMERACT MRI score sheets can be found in Appendix B & C.  
 
- 53 - 
 
Figure 6 Illustration of the anatomy of the wrist extensor and flexor tendons. 
Extensor compartments denoted in Roman numerals from I to VI: (I) extensor pollicis brevis, 
abductor pollicis longus; (II) extensor carpi radialis brevis, extensor carpi radialis longus; (III) 
extensor pollicis longus; (IV) extensor digitorum communis, extensor indicus proprius; (V) 
extensor digiti quinti proprius; (VI) extensor carpi ulnaris. Flexor tendon areas denoted in 
numbers from 1 to 4: (1) flexor carpi ulnaris; (2) ulnar bursa, including flexor digitorium 
superficialis and flexor digitorium profundus; (3) flexor pollicis longus (4) flexor carpi radialis.  
Reprinted by permission from BMJ publishing group, [306] copyright 2007. 
 
Patients were eligible for MR imaging permitting no contraindications had been 
identified and the safety questionnaire completed.  The following exclusions applied; 
presence of pacemaker, surgical clips within the head, certain inner ear implants, neuro-
electrical stimulators or metal fragments within the eye or head. Additionally, subjects 
were excluded if significant renal impairment as assessed by an estimated glomerular 
filtration rate <45ml/min/1.73m2.  Given the potential for allergic or anaphylactic 
reaction to gadolinium contrast, individuals with a history of multiple drug allergies or 
anaphylaxis were also excluded.   
 
3.6.3 Blood sampling 
Routine haematology and biochemistry were requested at specified time points of the 
study.  This included full blood count, kidney/liver function tests, and inflammatory 
markers (CRP,ESR) which were reported using standard reference ranges as per local 
hospital trust.  In addition, serology for RF (measured by nephelometry in IU/ml) and an 
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anti-nuclear antibody screen (multiplex bead technology, bioplex) giving titres of 
antibodies to clinically relevant antigen were collected and reported.  A commercially 
available assay for anti-CCP2 test was used (initially immunocap 250, (Phadia) reference 
range <7U/mL) and later cohort re-evaluated using Bioplex 2200 machine (Bio-rad), 
reference range <2.99U/mL.   
 
HLA DR typing to enable shared epitope status reporting was performed at baseline 
assessment by the Transplant and Immunology Services at St James University Hospital.  
SE (low resolution) was considered positive with the presence of one or two copies of 
the following alleles: HLA- DRB1*01, DRB1*04 and DRB1*10 in the HLA-DRB1 locus.   
 
3.6.3.1 Biological Bloods Sub study 
In the protocol schedule (Table 2) this item is listed as stored serum.  A maximum 73mls 
of blood at baseline and 43mls at subsequent specified time points were collected.   
Blood was drawn into a combination of EDTA, sodium citrate, lithium heparin, serum 
clot activators, and PAXgene/RNA tempus tubes.  After collection blood samples are 
processed for serum, plasma, or used fresh for flow cytometry and other functional 
studies, or stored (-20°C & -80°C) as whole blood for future DNA, RNA extraction 
depending on biomarker types and methods/techniques applicable.  
 
The most recent study protocol amendment in 2014 allowed the annual blood draw 
from consenting participants following their initial 12 month follow-up.   
3.7 Data Acquisition 
Source data is recorded in patients’ health records and study participant folders.  Case 
report forms (CRF)/external electronic data is entered in a Microsoft share point page 
which has been set up for the study. Regular backups of the electronic data are 
performed.  
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Bloods tests performed under the NHS are available on a password protected results 
server.  Research laboratories data is stored on the university server and contains no 
patient identification.   
 
3.8 Data Storage 
The electronic CRF is published and available for download as an excel on the NHS Trust 
protected system.  No identifiable details are published.   
 
3.9 Missing Data 
Every effort will be made to clear missing data, including case note review.  Multiple 
imputations will be employed in the event of any unrecoverable data. 
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4. Magnetic Resonance Imaging in individuals with systemic 
autoimmunity and arthralgia: MRI as an imaging biomarker 
This chapter describes the use of MRI in an at-risk cohort to identify characteristic 
features.  An evaluation of MRI as a predictive biomarker for disease progression is 
reviewed.   
 
4.1 Introduction  
MRI is a sensitive imaging technique that has advantages over both clinical examination 
and conventional radiographs for assessing joint damage (bone erosions, cartilage loss 
and joint space narrowing) and inflammation (synovitis, BME and tenosynovitis), which 
are common features in the earliest stages of RA [307-313].  
 
When MRI has been used to assess small joints in early RA, approximately 70% of 
patients have bone damage at clinical presentation [314].  Tendons involvement has also 
been implicated in early disease with up to 75% of early RA individuals demonstrating 
MRI detected tenosynovitis [310, 315].  One of the advantages of MRI over other 
modalities is the ability to evaluate for the presence of BME (osteitis).  This has been 
associated with progression and prediction of structural damage [266, 269, 316-318].  A 
randomised trial involving 256 methotrexate-naïve patients with RA, demonstrated that 
high baseline synovitis and osteitis were independent predictors of radiographic 
progression at 12 months [319]. Other studies also revealed an association between the 
severity of RAMRIS synovitis and BME with cartilage damage in RA [320, 321].  BME has 
been associated with other poor prognostic markers including ACPA and RF [322, 323].   
 
MRI findings in at-risk populations: 
As reviewed in section 2.2.3, MRI has been considered for differentiating those 
individuals at risk of RA development.  However, studies have thus far, only investigated 
small cohorts (n≤28) which may account for the lack of consistency in the findings.  The 
initial studies suggested that individuals with arthralgia and autoantibodies had more 
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subclinical MRI detected inflammation compared to healthy controls [233, 234].  Whilst 
the authors were unable to correlate baseline MRI features of inflammation to risk of 
progression, further analyses did suggest that the degree of subclinical inflammation 
was greatest in those at closest proximity to IA development [234].  
   
As alluded to in these at-risk groups, there have been insufficient numbers for any robust 
analysis to ascertain whether MRI findings can predict progression to arthritis.  This is 
primarily due to the difficulty in recruiting and imaging at-risk individuals.  Using an 
alternative approach focused on signs and symptoms rather than autoantibody 
presence,  van Steenbergen et al, devised a study in which individuals who were deemed 
to have clinically suspect arthralgia (CSA) were assessed [324].  Baseline imaging 
reported in 44% (41/93) of patients with CSA had MRI detected subclinical inflammation 
of joints of the hand and feet; these individuals would not have been identified through 
clinical and serological markers alone.  Patients were categorised as MRI positive or 
negative dependent on the abnormalities observed in the healthy control reference 
group.  By dichotomising the values for MRI inflammation to present or absent; 66 
patients (45.8%) had a positive MRI.  Univariate analysis of 142 patients demonstrated 
that higher MRI inflammation scores were associated with development of arthritis 
[325].  The presence of MRI inflammation at baseline was associated with progression 
to arthritis (HR 6.12, 95% CI 2.32, 16.19, p<0.001).  This increased incrementally with the 
number of joints/bones involved (HR 1.23 per additional positive joint 95% CI 1.13, 1.33, 
p<0.001).  All three MRI features (BME, synovitis and tenosynovitis) were significantly 
associated with arthritis development with tenosynovitis showing the greatest 
association (HR 7.56 95% CI 3.30, 17.32, p <0.001).  Results of the multivariable analysis 
(Table 3) demonstrated MRI inflammation to be independently associated with arthritis 
development.  Presented are the HRs of the multivariable analysis involving  142 
patients with CSA that underwent MRI of which 27 (19%) developed IA.  The sensitivity 
and specificity of MRI positivity within the CSA cohort was 81% and 63% respectively.  
Within the CSA population, individuals with no MRI inflammation had a low chance of 
developing arthritis (6%).    
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Table 3 Results of multivariable Cox regression analysis of clinical and serological 
factors and MRI-detected subclinical inflammation at baseline in relation to 
arthritis development. 
 HR (95% CI) p Value 
Age, per year 0.96 (0.93 to 0.996) 
 
Ref 
2.35 (0.41 to 13.61) 
4.30 (1.70 to 10.86) 
0.028 
 
Ref 
0.34 
0.002 
Localisation of initial symptoms  
   Small joints only 
   Large joints only 
   Small and large joints 
CRP level, per mg/L 1.05 (1.01 to 1.09) 0.021 
ACPA-positive 6.43 (2.57 to 16.05) <0.001 
Presence of any MRI-detected inflammation 5.07 (1.77 to 14.50) 0.002 
The authors presented data from 124 individuals with CSA  that underwent MRI of which 27 
developed clinical arthritis. They sought to ascertain if the association of subclinical MRI 
inflammation with arthritis was  independent of the association of the other listed factors.  
Results suggest an increased hazard for younger individuals, patient with initial localisation 
of symptoms in small and large joints compared to small joints only (reference), patient with 
higher CRP, ACPA positivity and patient with subclinical MRI inflammation.  Ref, reference 
Adapted from [325] 
  
In this study, ACPA positivity was strongly associated with progression (HR 6.43, 95% CI 
2.57, 16.05), emphasising the importance of this high risk group.  Sixty three percent of 
ACPA positive individuals developed arthritis within a year (15/24).  Within the ACPA 
positive subgroup, the chance of progression to arthritis, if subclinical MRI inflammation 
was present was 71% (PPV).  However, in those with a negative MRI, 60% did not 
develop an arthritis within a year (NPV).   Unfortunately, the small number of ACPA 
positive individuals with MRI findings limits the ability to comment on MRI performance 
compared to other markers.  
 
MRI in other inflammatory arthritis populations: 
Individuals with UA share clinical and imaging characteristics with the at-risk cohorts 
(inflammatory arthritis continuum Figure 2).  MRI studies in these individuals aimed to 
- 59 - 
identity predictors of persistence or progressive disease.  Findings from several studies 
have confirmed that MRI, including tenosynovitis, can predict progression from UA to 
RA [315, 326-329].   Authors have also sought to construct prediction models to assist 
physicians in evaluating and managing their patients [329, 330].  Similar principles apply 
in the at-risk populations and therefore form the basis for studies predicting progression 
to arthritis.   
 
MRI finding in healthy individuals: 
For MRI to be used as a diagnostic tool for early detection of RA, knowledge of the 
prevalence of MRI abnormalities in health is essential.  It is recognised that MRI changes 
are more frequent in older patients [331].  However there were until recently, no 
published reference ranges for MRI abnormalities within the general population.  The 
majority of data that informed a recent review came from MRI studies with control 
groups [332]. The reviewers summarised that erosions (RAMRIS ≥1) occur in 33-55% of 
healthy individuals (symptom free) dependent on joint(s) considered.  Synovitis 
prevalence showed the greatest variation between the studies evaluated (0%-44%).   
Given the paucity of data in healthy cohorts, a study of 193 symptom free individuals 
has recently been established. The study has reported BME, synovitis and tenosynovitis 
(all with score≥1) to be present in 57.5%, 48.2% and 16.6% respectively [333].   Although 
only 28% had no single inflammatory-feature, scores of ≥2 were rare. Tenosynovitis was 
shown to be infrequent except for the extensor carpi ulnaris (ECU) tendon.  Raw 
frequency data from this study is available and permits the use of MRI as potential 
biomarker. 
 
4.2 Aims and overview 
This programme of work aims to address the unmet research needs regarding MRI in an 
at-risk population.  In a large cohort anti-CCP positive individuals with non-specific MSK 
symptoms this work aims to:  
1) Describe the imaging characteristics demonstrated on MRI. 
2) Determine whether MRI characteristics are associated with disease progression. 
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3) Evaluate the role of MRI in a predictive model for progression to inflammation 
arthritis. 
   
4.3 Patients and Methods  
4.3.1 Patients 
A gadolinium enhanced MRI scan was offered to all eligible participants at their baseline 
CCP clinic appointment (at-risk cohort).  Those with no contraindications to MR imaging 
attended the research unit for scanning of their dominant/most symptomatic hand and 
wrist.  For this analysis, 98 CCP+ individuals were available.  A large European database 
of MRI scans in symptom-free individuals (healthy controls) was available reporting the 
RAMRIS OMERACT scoring for joints, bones and tendons [333].  These authors have 
produced a reference range for abnormalities at specific joint per age category.  
 
4.3.2 Clinical assessments 
Clinical assessments were performed as previously described in Methods (Section 4.4 
Protocol).  All participants provided baseline demographic details, patient 
questionnaires, clinical history of symptoms and had a systems examination by a 
rheumatologist, (trained in the assessment of IA, [LH & CR]) including a joint count.  
Individuals then followed the study schedule as listed in Chapter 3.5 Protocol. 
Individuals attended 3 monthly visits for the first year and as clinically indicated 
thereafter or until they developed inflammatory arthritis; defined by the presence of at 
least one tender and swollen joint confirmed by a rheumatologist.   
 
4.3.3 Imaging methods and scoring 
 
4.3.3.1 Ultrasound assessments 
Ultrasound assessments conducted as stated in Methods (Section 3.6.2.2).  For this 
analysis, baseline ultrasound findings were limited to that reported in the MRI scanned 
hand.  Presence of ultrasound power Doppler score ≥1 in any joint and greyscale score 
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≥2 in any joint were extracted from the database for this analysis.  Flexor tendon scoring 
was available on a subset of the cohort (n=56).  
 
4.3.3.2 MRI Assessments 
The MRI protocol was followed as described in Methods (Section 3.6.2.3). 
 
Images were anonymised and randomised prior to reporting. Scoring was performed 
independently by two musculoskeletal radiologists for synovitis, bone marrow oedema 
(BME) and erosions according to the OMERACT RAMRIS [303].  Digital flexor tendons 
were scored using a method in which the tendons were assessed from 1 cm proximal to 
1 cm distal of each MCP joint [304]. Wrist tenosynovitis scores cover the tendons 
proximal to this using a previously described method [306].  Scoring of the anti CCP+ 
scans was undertaken in a case mix of healthy controls, RF+ arthralgia and early RA 
scans.  Radiologists provided independently scored and consensus scoring.  The 
consensus scores were used in this analysis.  For consensus scoring, If any discrepancies 
occurred the radiologists reviewed images and a final score derived.  
 
4.3.4 Statistical analysis  
Frequency data reported by Magnus et al was available for the 193 MRI scans of healthy 
controls [333].  The authors reported that higher age was positively correlated with a 
higher total inflammation-score.  The correlation was also demonstrated when 
considering each entity (erosions, tenosynovitis, BME, synovitis) separately.   Hence, 
within this publication, an age category stratified reference range for each MRI imaging 
finding is available.  Using this data, joint counts were created for each (erosion, 
synovitis, BME, tenosynovitis); a joint score was only positive and counted if <5% of age-
matched healthy control in Magnus et al. had pathology present in that joint at that 
score level.  This allowed age adjustment of scores calculated for MRI abnormalities. 
   
Maximum MRI imaging scores observed per patient across all joints scored were initially 
trichotomised at 0, 1 and ≥2.  Preparatory modelling indicated there was little difference 
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between scores of 0 and 1.  As such, erosion, BME, synovitis and tenosynovitis scores 
were dichotomised at <2, ≥2 for regression analysis.  This follows previous analysis 
evaluating ultrasound imaging of this cohort [237]. Continuous data was evaluated in 
the preliminary stages. However, dichotomisation facilitated the statistical modelling.  
 
Following descriptive analysis of imaging characteristics of all individuals at risk to IA, 
the cohort was risk stratified according to the clinical model previously published [217]. 
This model included:  
 Clinician-determined tenderness of small joints in the hands and feet (MCPs, 
PIPs, midtarsal and/or MTPs) (score 1 point),  
 RF and/or anti CCP titre ≥3xULN (score 2 points),  
 Early morning stiffness ≥30 minutes duration (score 1 point).  
 Power Doppler ultrasound (score 1 point) 
 
A total risk score of 0 indicated low risk, 1-2 moderate risk, 3-4 high risk.   
 
Mantel-Haenszel tests of homogeneity (for the association between each of the MRI 
variables and progression to IA), were used to assess whether the association was the 
same irrespective of clinical risk of progression according to the clinical model. 
 
Patient level analysis 
Cox proportional hazards regression was used to ascertain the association between each 
MRI abnormality and time to IA.  Modelling was performed using both total MRI 
abnormality scores and maximum score observed in any joint. The hazard ratios (HR) 
were adjusted for the clinical variables included in the risk score and additionally for 
ultrasound parameters; PD ≥1 and GS ≥2, which have previously been reported within 
this cohort [237].  Likelihood ratio tests were used to show whether each of the MRI 
variables improved model fit. Significance at p<0.1 was considered indicative of 
potential association with IA in this preliminary analysis.  This significance level was 
selected in order to allow for all possible association to be considered given the sample 
size and exploratory nature of this work.   
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Joint level analysis 
MCPs 2-5 and wrists scores were dichotomised as follows: ultrasound PD, ultrasound 
GS, MRI erosions, BME, synovitis and tenosynovitis (<2 or 2). At the wrist and MCP joints 
there are scores for multiple sites within each joint, the maximum score observed per 
joint was recorded. Cox proportional hazards models with standard errors adjusted for 
clustering of joints at the patient level were constructed, first on a univariable basis and 
then for each MRI feature adjusted for ultrasound GS and PD. 
 
Binary logistic regression models were constructed to explore associations between MRI 
findings and clinical features at the joint level.  
 
4.4 Results 
4.4.1 Patient Characteristics 
Ninety eight individuals from the CCP+ cohort were recruited to this study.  Thirty 
percent (29/98) progressed to IA during the follow-up period. The baseline 
characteristics of the 98 individuals are presented in Table 4.  Median time to 
progression was 31 weeks (IQR 24,67).  Of those who did not progress, median follow-
up was 132 weeks (IQR 75, 199).   
Table 4 Baseline and ultrasound imaging characteristics of 98 individuals at risk of 
progression to IA 
Characteristic  CCP cohort (n=98) 
Age: mean (SD)  47.9 (12.2) 
Female  69% (68) 
SE     
 
1 copy 
2 copies 
45% (43) 
22% (21) 
ESR: median (IQR)  14.7 (11.6) 
CRP    ≥5 mg/dL 23% (22) 
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Anti-CCP  
  
 
low positive 
high positive 
20% (20) 
80% (78) 
RF     
 
low positive 
high positive 
10% (10) 
36% (35) 
Antibody (RF or CCP)  high positive 87% (85) 
EMS    ≥30 mins 32% (31) 
Small joint tenderness  present 46% (45) 
US power Doppler ≥2  present 9% (9) 
US grey scale ≥2  present 23% (23) 
All values are % (n) unless otherwise stated 
Anti-CCP: anti-citrullinated cyclic peptide antibody, EMS: early morning stiffness, RF: 
rheumatoid factor, SD: standard deviation, SE: Shared epitope, US: ultrasound 
 
In two individuals, both of whom did not progress to IA, no baseline ultrasound scan was 
available.  The next available follow up scan results were used instead.  Three patients 
did not receive gadolinium during their scan and therefore scores for tenosynovitis and 
synovitis were not available.   
 
4.4.2 MR imaging findings in the at-risk cohort 
Comparison to healthy controls 
As described, MRI scores are adjusted using a healthy reference range.  A 
joint/bone/tendon MRI finding was considered positive if the score obtained was 
present in <5% of age-matched healthy control population.  For example, a synovitis 
score of 1 in MCP joint 2 in a 40 year old was considered negative if ≥5% of healthy 
controls in the same age category demonstrated this pathology.  Tables 5-8 lists the 
values before and after adjustment.  In a some cases this adjustment meant that scores 
were corrected to a lower score resulting in a greater number of individuals scoring 1, 
for example, than prior to adjustment (see Table 5 erosion adjusted scores for BMC1, 
trapezium and Table 8 tenosynovitis score for index).   
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Table 5 Number of individuals achieving MRI erosion score by location, before and 
after correction for age using healthy control data. 
 Unadjusted erosion score (n=98) Adjusted erosion score (n=98) 
Bone 0 1 2 ≥3 0 1 2 ≥3 
MCPs 
MCP2 91 5 2 0 96 2 0 0 
MCP3 92 5 1 0 98 0 0 0 
MCP4 97 1 0 0 98 0 0 0 
MCP5 93 3 2 0 96 2 0 0 
WRIST 
BMC1 89 3 4 2 92 4 2 0 
BMC2 92 5 0 1 92 5 0 1 
BMC3 96 1 1 0 96 1 1 0 
BMC4 97 1 0 0 97 1 0 0 
BMC5 98 0 0 0 98 0 0 0 
Trapezium 86 6 4 2 88 7 2 1 
Trapezoid 89 7 1 1 96 1 0 1 
Capitate 72 23 3 0 95 3 0 0 
Hamate 90 7 1 0 92 6 0 0 
Scaphoid 83 13 2 0 95 3 0 0 
Lunate 81 12 4 1 93 4 1 0 
Triquetrum 83 11 4 0 94 3 1 0 
Pisiform 93 4 1 0 94 4 0 0 
DRadius 91 5 2 0 91 5 2 0 
DUlna 89 8 0 1 97 0 1 0 
BMC base of metacarpal, MCP metacarpophalangeal, DRadius distal radius, DUlna distal ulna  
 
Table 6 Number of individuals achieving MRI BME score by location, before and after 
correction for age using healthy control data. 
 Unadjusted BME score (n=98) Adjusted BME score (n=98) 
Bone 0 1 2 ≥3 0 1 2 ≥3 
MCPs 
MCP2 96 2 0 0 97 1 0 0 
MCP3 96 2 0 0 97 1 0 0 
MCP4 96 2 0 0 96 2 0 0 
MCP5 97 0 1 0 97 0 1 0 
Wrist 
BMC1 90 6 0 2 94 2 1 1 
BMC2 97 1 0 0 97 1 0 0 
BMC3 98 0 0 0 98 0 0 0 
BMC4 97 1 0 0 97 1 0 0 
BMC5 98 0 0 0 98 0 0 0 
Trapezium 88 7 2 1 88 7 2 1 
Trapezoid 94 4 0 0 96 2 0 0 
Capitate 87 10 1 0 87 10 1 0 
Hamate 91 5 2 0 92 5 1 0 
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Scaphoid 90 8 0 0 98 0 0 0 
Lunate 80 15 2 1 95 2 1 0 
Triquetrum 92 3 3 0 95 0 3 0 
Pisiform 97 1 0 0 97 1 0 0 
DRadius 96 2 0 0 96 2 0 0 
DUlna 92 6 0 0 98 0 0 0 
BMC base of metacarpal, MCP metacarpophalangeal, DRadius distal radius, DUlna distal ulna  
 
Table 7 Number of individuals achieving MRI synovitis score by location, before and 
after correction for age using healthy control data. 
 Unadjusted synovitis score (n=95) Adjusted synovitis score (n=95) 
Joint 0 1 2 ≥3 0 1 2 ≥3 
MCPs 
MCP2 58 26 9 2 79 14 2 0 
MCP3 70 24 1 0 93 2 0 0 
MCP4 80 12 3 0 80 12 3 0 
MCP5 69 18 7 1 74 17 4 0 
Wrist 
DRUJ 62 31 1 1 90 4 1 0 
ICJ 39 47 9 0 79 16 0 0 
RCJ 35 46 13 1 77 15 3 0 
MCP metacarpophalangeal, DRUJ distal radioulnar joint, ICJ intercarpal joint, RCJ radiocarpal 
joint 
 
Table 8 Number of individuals achieving MRI tenosynovitis score by location, before 
and after correction for age using healthy control data. 
 Unadjusted tenosynovitis score 
(n=95)  
Adjusted tenosynovitis score (n=95) 
Tendon 0 1 2 ≥3 0 1 2 ≥3 
Digital (flexor) 
Thumb* 90 4 1 0 - - - - 
Index 68 24 2 1 73 19 3 0 
Middle 78 13 3 1 84 7 3 1 
Ring 80 12 3 0 86 7 2 0 
Little 81 13 1 0 81 13 1 0 
Wrist (extensor and flexor) 
FCR 72 20 3 0 72 20 3 0 
FPL 81 13 1 0 81 13 1 0 
FDSFDP 71 22 2 0 71 22 2 0 
FCU 92 3 0 0 92 3 0 0 
I 85 7 3 0 85 7 3 0 
II 86 8 0 1 86 8 0 1 
III 89 3 3 0 89 3 3 0 
IV 70 22 3 0 70 22 3 0 
V 78 15 2 0 78 15 2 0 
VI 55 28 10 2 76 17 1 1 
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FCR flexor carpi radialis, FPL flexor pollicis longus, FDSFDP flexor digitorium superficialis and 
flexor digitorium profundus, FCU flexor carpi ulnaris, Extensor compartments I – extensor pollicis 
brevis and abductor pollicis longus, II extensor carpi radialis brevis and extensor carpi radialis 
longus, III extensor pollicis longus, IV extensor digitorium communis and extensor digitus 
proprius, V extensor digiti quinti porprius, VI extensor carpi ulnaris. 
*Thumb was not included in paper by Mangnus et al and was not adjusted for age. 
 
Reviewing the adjusted versus unadjusted data several findings are evident.  An 
unadjusted erosion score equalling 1 was relatively frequently reported in the carpal 
bones (particularly capitate, lunate and scaphoid).  As this finding was also prevalent in 
the healthy controls the adjusted scores are lower.  BME scores remained largely 
unchanged following adjustment, with the exception of the carpal bone scores which 
were adjusted from 1 to 0.  Both synovitis and tenosynovitis were the most prevalent 
findings on MRI.  Synovitis scoring ≥1 were reported in 48.2% of healthy controls in the 
Mangnus et al data.  Subsequently, adjusted scores in this data set were reduced. In 
comparison, the adjusted scores for tenosynovitis demonstrated only minor variation as 
a consequence of the low prevalence of tenosynovitis scores in healthy controls.   
 
Prior to adjustment, MRI scores of greater than 2, in an individual joint was reported in 
a total of 40 bones for erosions (40/1862, 2.1%),  15 bones for BME (15/1862, 0.8%), 48 
joints for synovitis (48/665, 7.2%) and 42 tendons for tenosynovitis (42/1425, 2.9%).    
Following adjustment, an MR imaging score greater than 2 was reported in a total of 15 
bones for erosions (15/1862, 0.8%), 12 bones for BME (12/1862, 0.6%), 13 joints for 
synovitis (12/665, 2%) and 31 tendons for tenosynovitis (31/1425, 2.2%).  For all MRI 
findings an adjusted score of 0 for joints, bones and tendons  was the most frequent. 
 
Cumulative probability plots illustrate the total adjusted MRI scores for each MRI finding 
(Figure 7).  The cohort has been divided into those who developed IA and those who did 
not (No IA).  The individuals who developed IA had higher tenosynovitis and synovitis 
total scores at baseline imaging compared to the no IA.  
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Figure 7 Cumulative probability plots of adjusted total MRI finding score for a) erosions, b) bone marrow oedema, c) synovitis, d) tenosynovitis. 
a) 
b)
) 
 a) 
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Figure 7 Cumulative probability plots of adjusted total MRI finding score for a) erosions, b) bone marrow oedema, c) synovitis, d) tenosynovitis.
c)
) 
 a) 
d)
) 
 a) 
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MR imaging findings in at-risk individuals 
Table 9 Maximum MRI imaging scores observed per patient across all joints. 
MRI Imaging  CCP Cohort (n=98) 
Erosion score  0 
1 
≥2 
72% (71) 
18% (18) 
9% (9) 
BME score   
 
0 
1 
≥2 
70% (69) 
19% (19) 
10% (10) 
Synovitis score  
 
0 
1 
≥2 
52% (49/95) 
39% (37/95) 
9% (9/95) 
Tenosynovitis score  
 
0 
1 
≥2 
38% (36/95) 
40% (38/95) 
22% (21/95) 
 
Table 9 presents the maximum MRI scores per patient across all joints and summarises 
the main MRI baseline reporting.  The adjusted scores by location are presented in 
Figure 8-11.  (The data for score 0 is listed in tables 5-8 and is not presented in the 
figures.)  Location of abnormalities were variable with some distinct patterns emerging.    
BME and erosions (scores ≥2) were reported in 10% and 9% of individuals respectively, 
with a preferential location of the carpal bones.  In comparison, synovitis and 
tenosynovitis were seen more frequently, individuals scoring 1 reported in 39% and 40% 
respectively.  Within at-risk individuals, synovitis score ≥1 were most commonly 
reported at MCP 5 (22.5%), radiocarpal joint (18.9%) and MCP 2 and intercarpal joint 
(16.8% for both).  Synovitis was less commonly seen at MCP 3 and distal radioulnar joint 
(2% and 5% respectively).  Only 9% (9/95) individuals had a synovitis score at any joint 
of ≥2.  In comparison, tenosynovitis scores of ≥2 were reported in 22% of individuals 
(21/95).  Tenosynovitis scoring ≥1 was reported in 25% of individuals at compartment IV 
(comprising of extensor digitorium communis and extensor digitus proprius), flexor 
digitorium superficialis/flexor digitorium profundus, and flexor carpi radialis tendons.  
Within the digital tendons, the index tendon had the highest reporting of abnormality 
(scores ≥1 in 23.1%).  Figure 12 and Figure 13 show examples of tenosynovitis at the 
wrist and flexor tendons where the individual progressed to IA.      
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Figure 8 Number of individuals with adjusted MRI scores (1, 2 and ≥3) by location 
for erosions. 
Figure 9 Number of individuals with adjusted MRI scores (1, 2 and ≥3) by location 
for BME. 
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Figure 11 Number of individuals with adjusted MRI scores (1, 2 and ≥3) by location 
for tenosynovitis. 
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Figure 12 Axial reconstructions of Gadolinium enhanced 3D Spoiled Gradient Echo MRI 
image of the flexor tendons of an at-risk individual prior to the development of 
inflammatory arthritis. 
 
 
 
(ECU extensor carpi ulnaris, EDM extensor digiti minimi , T Triquetrum) 
Figure 13 Axial reconstructions of Gadolinium enhanced 3D Spoiled Gradient Echo MRI 
images of the wrist tendons of an at-risk individual prior to the development of 
inflammatory arthritis. 
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Risk stratification and MRI findings  
The cohort was risk stratified using the previously reported clinical model (including 
ultrasound PD) [217] and Section 4.3.4 statistical analysis Table 10.  Individuals with a 
MRI abnormality score ≥2 for each feature were compared in each level of progression 
according to whether or not they had progressed to IA (Figure 14).  It was found that the 
moderate and high-risk categories demonstrate higher frequency of abnormalities ≥2 in 
the IA progression group compared to no IA.  This was most evident when considering 
synovitis and tenosynovitis (Figure 14 c and d).  The low risk category had no individuals 
with MRI scores ≥2 in either progression status, although the denominators are small.   
One individual progressed to IA in this strata and had no MRI abnormalities ≥2.  Mantel-
Haenszel test for homogeneity demonstrated that the effect of MRI is the same no 
matter which risk group an individual belongs (ranging from p=0.230 for BME to p=0.836 
for tenosynovitis).    
 
Table 10 Number of individuals with each MRI finding following risk stratification into 
low, moderate and high risk. 
 Number with erosions Number  with BME 
Risk No IA IA No IA IA 
Low 0/5 0/1 0/5 0/1 
Mod 1/37 1/9 1/37 1/9 
High 3/27 4/19 4/27 4/19 
  
 Number with synovitis Number  with tenosynovitis 
Risk No IA IA No IA IA 
Low 0/5 0/1 0/5 0/1 
Mod 1/34 3/9 4/34 2/9 
High 1/27 4/19 5/27 10/19 
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Figure 14 Risk stratification and MRI imaging: Proportions of individuals with score ≥2 according to progression status at each level of 
progression risk (a) erosions (b) BME (c) synovitis (d) tenosynovitis. 
IA, Inflammatory arthritis 
Total risk score: 
0 low risk  
1-2 moderate risk 
3-4 high risk 
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4.4.3 MRI (and ultrasound) findings and progression to IA  
a) At the patient level: 
Prior to adjustment, all ultrasound and MRI abnormalities were associated with risk of 
progression to IA. Ultrasound GS, ultrasound PD, MRI synovitis & tenosynovitis were 
statistically significant at p<0.05 and MRI erosion & BME at p<0.1 (Table 11).   
 
Following adjustment controlling for the variables in original clinical model and for 
ultrasound features, the HR for MRI erosions, BME and synovitis decreased.  HR for 
tenosynovitis was found to increase.  In the adjusted analyses there was evidence that 
MRI-detected tenosynovitis was independently associated with time to IA (HR 
(90%CI)=3.89 (1.95, 7.76), p=0.001); Table 11. The hazard ratio for synovitis was 
substantive (HR (90%CI)=2.01 (0.92, 4.42), p=0.144) but, at this sample size the 90% 
confidence interval crossed 0.  Ultrasound PD and GS remained substantive and 
statistically significant (at p<0.1) in adjusted models accounting for each of the MRI 
features.  The clinical variables were not associated with progression in the model that 
included ultrasound variables and MRI tenosynovitis; small joint tenderness (1.34 (0.68, 
2.65), p=0.478), high titre antibodies (1.07 (0.30, 3.79), p=0.930) nor EMS ≥30 minutes 
(1.37 (0.67, 2.82), p=0.473). 
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Table 11 Patient-level Cox proportional hazard modelling of associations between baseline MRI abnormalities and time to development of IA 
    Adjusted* HR (90% CI) , P value 
Abnormality No IA 
(n=69) 
(%) 
IA 
(n=29) 
(%) 
Unadjusted HR 
(90% CI) , P 
value 
GS & PD only +erosion +BME +synovitis +tenosynovitis 
US PD ≥2 1% (1) 28% (8) 7.57 (3.80, 
15.09), p<0.001 
3.93 (1.63, 
9.47), p=0.010 
3.93 (1.61, 
9.57), p=0.011 
3.66 (1.47, 
9.09, p=0.019 
3.14 (1.25, 
7.88), p=0.040 
5.38 (2.04, 
14.17), p=0.004 
US GS  ≥2 12% (8) 52% 
(15) 
4.71 (2.55, 
8.71), p<0.001 
2.51 (1.15, 
5.49), p=0.053 
2.51 (1.14, 
5.52), p=0.056 
2.55 (1.7, 
5.58), p=0.049 
2.45 (1.11, 
5.41), p=0.064 
2.38 (1.08, 5.26), 
p=0.073 
MRI erosion ≥2 6% (4) 17% (5) 2.26 (1.01, 
5.08), p=0.098 
 1.01 (0.39, 
2.61),p=0.988 
   
MRI BME ≥2 7% (5) 17% (5) 2.40 (1.05, 
5.47), p=0.080 
  1.31 (0.51, 
3.36), p=0.632 
  
MRI synovitis ≥2 3% (2/66) 24% (7) 4.22 (2.03, 
8.75), p=0.001 
   2.01 (0.92, 
4.42), p=0.144 
 
MRI tenosynovitis
 ≥2 
14% (9/66) 41% 
(12) 
3.51 (1.89, 
6.55), p=0.001 
    3.89 (1.95, 7.76), 
p=0.001 
*Adjusted for presence of tenderness of small joints, EMS≥30 minutes, high antibody titre, maximum score MCPs, PIPs & wrists (bilateral) US GS ≥2 and US PD ≥2
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When the analysis was repeated using total MRI abnormality scores instead of the 
maximum score observed in any joint, there was no change in the conclusion that of the 
MRI variables, only tenosynovitis was independently associated with risk of progression. 
Similarly, ultrasound GS and PD were always independently associated with risk of 
progression to IA. 
 
b) At the joint level: 
As MRI was performed on the most symptomatic/dominant hand (with scoring at wrists 
and MCPs 2-5), the presented data represents the joints that progressed that were 
scored.  A total of 490 joints are considered.  Of these, 29 progressed to clinical synovitis.     
 
Prior to adjustment MRI BME, synovitis and tenosynovitis were all associated with risk 
of that specific joint progressing to clinical synovitis (CS) (HR 5.63, 4.45 and 5.96 
respectively, all p=<0.05) Table 12.  Of the ultrasound parameters, both GS and PD were 
also associated with joint progression.  MRI erosions were the only imaging pathology 
not to be associated with risk of joint progression (HR 2.82 90% CI 0.38, 20.94, p=0.310).   
 
When adjusted for the ultrasound variables previously demonstrated to be associated 
with progression (ultrasound PD≥2 and for GS≥2), HRs for MRI BME increased, Table 12.  
There was evidence that BME and tenosynovitis were associated with the risk of 
progression to clinical synovitis (HR=6.16, p=0.011 and HR=7.22, p<0.001 respectively).  
The adjusted HR for MRI erosions was substantive but not significant, HR 2.5, p=0.171.  
In contrast, the HR for MRI synovitis decreased.  
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Table 12 Joint-level Cox proportional hazard modelling of associations between baseline MRI abnormalities and time to development of clinical synovitis (MCPs 2-
5 and wrists only) 
    Adjusted* HR (90% CI) , P value 
Abnormality No CS 
(n=466) 
(%) 
CS (n=24) 
(%) 
Unadjusted HR 
(90% CI) , P 
value 
GS & PD only +erosion +BME +synovitis +tenosynovitis 
US PD  
≥2 
<1% (3) 4% (1) 7.09 (1.08, 
46.54), p=0.087 
1.51 (0.14, 
16.32), p=0.776 
1.33 (0.20, 
8.72), p=0.801 
1.44 (0.13, 
16.16), 
p=0.806 
1.71 (0.15, 
19.58), 
p=0.717 
1.23 (0.24, 6.34), 
p=0.832 
US GS   
≥2 
3% (14) 21% (5) 8.40 (4.08, 
17.29), p<0.001 
6.98 (3.09, 
15.80), p<0.001 
7.23 (3.28, 
15.93), p<0.001 
7.81 (3.39, 
18.00), 
p<0.001 
5.77 (2.40, 
13.87), 
p=0.001 
6.79 (2.91, 
15.85), p<0.001 
MRI erosion  
≥2 
2% (7) 4% (1) 2.82 (0.53, 
15.18), p=0.310 
 2.50 (0.83, 
7.51), p=0.171 
   
MRI BME  
≥2 
2% (8) 8% (2) 5.63 (1.82, 
17.37), p=0.012 
  6.16 (1.91, 
19.90), 
p=0.011 
  
MRI synovitis  
≥2 
2% 
(10/451) 
8% (2) 4.45 (1.51, 
13.11), p=0.023 
   2.20 (0.67, 
7.17), p=0.274 
 
MRI tenosynovitis 
≥2 
4% 
(17/451) 
25% (6) 8.46 (4.21, 
16.98), p<0.001 
    7.22 (3.66, 
14.25), p<0.001 
CS = Clinical synovitis, *Adjusted for presence of tenderness of small joints, EMS≥30 minutes, high antibody titre, US PD≥2 and US GS≥2
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In the adjusted models, ultrasound GS remained significant while the adjusted HRs for 
ultrasound PD were close to 1. 
 
4.4.4 Association to clinical variables  
Table 13 and Table 14 demonstrate the logistic regression analysis for physician and 
patient reported joint tenderness with respect to imaging findings (MRI and ultrasound).  
All variables were dichotomised to >1 since none of the tender joints had score >2 for 
ultrasound PD, MRI erosions and BME.  The results indicate that no imaging modality or 
finding was significantly associated with physician determined joint tenderness.  Patient 
reported joint tenderness was recorded as any recent pain at fingers/hand and wrist.  
The regression analysis indicates that ultrasound PD was associated with patient 
reported tenderness (HR 3.95, 90% CI (1.33, 11.69), p=0.037).  It is noted that PD signal 
was only detected in a minority of painful joints.  The remaining imaging variables were 
not associated.  This analysis indicates there is limited evidence to associate MRI findings 
with joint tenderness, either physician or patient reported.   
 
Table 13 Results of logistic regression models of physician-determined tenderness at 
the joint level. 
Abnormality Not tender 
n=446 
Tender 
n=44 
Unadjusted HR 
(90% CI) , P value 
Adjusted HR 
(90% CI) , P value 
US PD ≥1 3% (14) 5% (2) 1.47 (0.41, 5.30), 
p=0.621 
2.09 (0.67, 6.57), 
p=0.289 
US GS  ≥1 18% (82) 16% (7) 0.84 (0.34, 2.07), 
p=0.750 
0.77 (0.33, 1.80), 
p=0.613 
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MRI erosion ≥1 6% (28) 7% (3) 1.09 (0.44, 2.73), 
p=0.874 
1.44 (0.48, 4.33), 
p=0.579 
MRI BME ≥1 6% (28) 7% (3) 1.09 (0.42, 2.81), 
p=0.878 
1.07 (0.33, 3.49), 
p=0.928 
MRI synovitis ≥1 18% (76/431) 9% (4) 0.47 (0.19, 1.14), 
p=0.159 
0.46 (0.20, 1.07), 
p=0.131 
MRI tenosynovitis
 ≥1 
23% (97/431) 16% (7) 0.65 (0.30, 1.41), 
p=0.360 
0.68 (.29, 1.58), 
p=0.452 
 
Table 14 Results of logistic regression models of patient-reported pain at the joint area 
level.  
Abnormality Not painful 
n=115 
Painful 
n=71 
Unadjusted HR 
(90% CI) , P value 
Adjusted HR 
(90% CI) , P 
value 
US PD ≥1 3% (4) 13% (9) 4.03 (1.49, 
10.89), p=0.021 
3.95 (1.33, 
11.69), p=0.037 
US GS  ≥1 32% (37) 37% (26) 1.22 (0.74, 2.00), 
p=0.512 
0.95 (0.54, 1.68), 
p=0.892 
MRI erosion ≥1 17% (19) 15% (11) 0.93 (0.46, 1.87), 
p=0.858 
0.84 (0.36, 1.99), 
p=0.741 
MRI BME ≥1 17% (20) 15% (11) 0.87 (0.44, 1.73), 
p=0.740 
0.84 (0.38, 1.85), 
p=0.714 
MRI synovitis ≥1 30% 
(33/109) 
31% (22) 1.03 (0.59, 1.81), 
p=0.921 
0.91 (0.51, 1.60), 
p=0.775 
MRI tenosynovitis
 ≥1 
40% 
(44/109) 
51% (36) 1.52 (0.90, 2.56), 
p=0.186 
1.57 (0.91, 2.70), 
p=0.174 
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4.4.5 Performance of ultrasound and MRI for tenosynovitis scoring 
MRI tenosynovitis scores included wrist and digital tendons, whereas ultrasound scoring 
was restricted to the flexor tendons.  For comparison between modalities the analysis is 
therefore limited to findings reported at the digital tendons. Fifty seven percent (56/98) 
of individuals in the CCP+ cohort had complete ultrasound tendon scores.  A total of 224 
tendon scores were available for comparison.  None of these tendons had an ultrasound 
PD score >0 and therefore ultrasound GS only is compared.   
 
The cross-tab table below illustrates the MRI score and ultrasound GS score for the 224 
tendons.  Eighty eight percent agreement was seen between the two modalities 
(prevalence-adjusted, bias-adjusted Kappa 0.77).  However, this was largely due to 
agreement in the reporting of the absence of tenosynovitis (score 0).  Only 2.6% (6/224) 
of tendons had a ultrasound GS score >0, whilst MRI detected tenosynovitis >0 was 
found in 10.3% (23/224).  Considering each category individually, agreement was 94% 
for scores of 0 and just 19% for scores >0.  This suggests that MRI detects more 
tenosynovitis, or alternatively is more sensitive.   
 
Table 15 Comparing MRI tenosynovitis score to ultrasound GS score 
 Ultrasound GS score  
MRI score 0 1 2 Total 
0 195 3 0 198 
1 20 2 0 22 
2 3 0 1 4 
Total 218 5 1 224 
 
In an unadjusted analysis of this restricted patient group; MRI tenosynovitis (of flexor 
tendons only) was still predictive of future development of clinical synovitis (HR (90% 
CI)=18.3 (3.5, 95.8), p=0.004).  None of the 8 joints that developed clinical synovitis had 
ultrasound GS scores of >0, whilst 6 of the 220 of the joints that did not develop clinical 
synovitis did have ultrasound GS scores >0.  
- 83 - 
 
Table 16 Restricted cohort MRI scoring and development of clinical synovitis (CS) 
 Restricted patients and joints 
MRI score 
No CS 
n=216 
CS 
n=8 
0 89% (193) 63% (5) 
1 9% (20) 25% (2) 
≥2 1% (3) 13% (1) 
 
4.5 Discussion 
In RA, MR imaging of patients with clinical synovitis demonstrates significant pathology, 
which is predictive of future disease progression and joint damage [317, 334-337].  
There are limited data available regarding MR findings of at-risk individuals without 
detectable clinical synovitis.  In this chapter, the MRI findings of 98 CCP+ individuals from 
the Leeds at-risk clinic are reported.  This is the largest analysis of MRI findings in an at-
risk population.   
 
Contrast enhanced MR images obtained from a 3.0 Tesla scanner have facilitated the 
RAMRIS scoring of all four MRI variables: erosions, BME, synovitis and tenosynovitis.  
This is in contrast to previous studies which have failed to comment on erosions [325] 
and tenosynovitis [233, 234].  The moderate levels of inflammatory pathology reported 
in healthy control populations necessitates the adjustment of RAMRIS scores to 
abnormalities seen in healthy controls [332].  Following adjustment, whilst a proportion 
of the synovitis and erosion scores were within the normal range, less correction was 
required in tenosynovitis and  BME scores.  Overall, maximum scores ≥2 for each MRI 
finding were reported in a small proportion of individuals.   
 
MRI synovitis was most prevalent in the wrist joints similar to that reported in the CSA 
population.  In contrast, MCP 5 joint had greater reports of synovitis compared to the 
other MCP joints.  The carpal bones had the highest reports of BME and erosions.  
Tenosynovitis had preferential location for flexor tendons of the wrist and extensor 
tendon compartments VI, V and IV which is similar to that reported in CSA [324].  The 
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index finger had the highest reports of tenosynovitis and MCP3 (middle finger) one of 
the least, which is in contrast to findings in the  CSA population.  Cross study comparison 
is possible due to both correcting to the same healthy control data.  However, it is 
important to note that the study populations differ with regards to autoantibody status 
and therefore potential risk;  16% of the CSA being ACPA positive as opposed to 100% 
in the Leeds cohort.   
 
Previous studies have attempted to determine the significance of MRI findings in similar 
at-risk populations.  Unfortunately, sample size had limited reporting on associations to 
progression [233, 234].  In this cohort, adjusting for other imaging variables, MRI 
tenosynovitis has been shown to predict future development of IA in at-risk individuals 
(HR 3.89, p=0.001).  Furthermore, the joint level findings indicate that MRI BME and 
tenosynovitis predicts development of clinical synovitis in individual joints (HR=6.16, 
p=0.011 and HR=7.22, p<0.001 respectively).  This reflects findings from a recently 
published study in a much smaller cohort of 20 ACPA+ individuals [235].  Here, 
tenosynovitis was reported in 80% (16/20) of the cohort and is importantly absent in 
their healthy control population.  On an exploratory level, the authors were able to 
report that presence of tenosynovitis in 2 or more sites was associated with later 
development of IA.  Results reported in this chapter verify findings from Kleyer et al and 
provide further evidence that tenosynovitis is one of the earliest features reported on 
MR imaging in those at risk to IA progression.   
 
Further stages of multivariable modelling were limited due to study size and lack of 
individuals that have progressed to IA.  However, the clinical utility of MRI findings are 
illustrated through both the Cox proportional hazard regression analyses and the risk 
stratification exercise.  In the former, the clinical variables were not associated with 
progression in the model that included ultrasound variables and MRI tenosynovitis.  At 
the patient level, MRI tenosynovitis association with risk to IA progression is comparable 
to ultrasound findings, whilst at a joint level there is additional benefit.  It is suggested 
that MRI is a feasible or even a preferred option in some units where experienced MSK 
ultrasonographers may be lacking.  In the risk stratification exercise, the original model 
[217] was applied.  Within each strata of risk, the proportion of individuals with MRI 
- 85 - 
 
score ≥2 as per progression status was presented.  It was hypothesised that MR imaging 
findings may be particularly useful in those individuals at low risk for progression.  
However, the denominators for these groups were very small; there were only 6 
individuals at low risk and just 1 progressed to IA.  This one patient did not have any MRI 
abnormalities scoring ≥2.  The test of homogeneity suggested that MRI findings were 
strongly associated with progression in all strata. As illustrated in Figure 13, MR imaging 
could be used as an adjunct to previous models to stratify individuals.  With continual 
recruitment and follow-up of existing participants, it is anticipated that a larger risk 
stratification exercise involving all parameters would assist in the development of 
combined model.   
 
The ability of both ultrasound PD and GS has been reported to be predictive of IA 
development [237].  However, within this analysis, although both imaging variables 
remained significant at a patient level, only GS seemed to be associated with the risk of 
progression to CS at the joint level.  This was an unexpected finding.  It is noted that in 
this study, ultrasound analysis is limited to unilateral hand as opposed to the previously 
bilateral hands finding.  Furthermore, very few of the joints were found to have PD≥2 in 
unilateral MCPs2-5 and wrist.  This may account for some of the findings.  However, 
repeating the analysis using PD≥1 did not affect the outcome.  It is recommended that 
a larger cohort should be analysed for clarification.   
 
The association to progression with MRI tenosynovitis calls into question whether these 
features can be detected on ultrasound.  Not all tendon compartments of the wrist are 
routinely imaged in ultrasound and the protocol for this study was only recently changed 
to include flexor tendon in the baseline ultrasound assessment.  The direct comparison 
between the two modalities is therefore limited.  However, results suggest that MRI 
reports greater frequency of tenosynovitis compared to ultrasound.  Furthermore, in 
this limited analysis, MRI tenosynovitis was associated to development of clinical 
synovitis in a joint, in contrast to ultrasound GS tenosynovitis. This finding correlates 
with other studies which have compared modalities in the identification of tenosynovitis 
[338].    
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As discussed in the introduction (Section 2.1.2.1), there has been increased interest 
surrounding the pathogenic role of ACPA and osteoclast activation with subsequent 
bone damage [49]. The presence of BME and erosions detected by MRI in at-risk 
individuals offers an opportunity to explore potential relationships.  Bone mineral 
density has been assessed with respect to MRI detected inflammation in the CSA cohort 
[339]. The authors demonstrated that severe bone loss was associated with MRI 
inflammation and progression to IA.  It is difficult to draw to many conclusion from this 
as only 13% (14/108) of individuals were ACPA positive.  Reviewing the results from the 
adjusted data of this CCP+ cohort, it is apparent that just under a third of individuals had 
evidence of either BME or erosions.  Thus, the presence of ACPA does not equate to MRI 
pathology.  BME was associated with progression to clinical synovitis within a joint but 
not an individuals’ risk of progression.  This does suggest that BME is an important 
finding in the joints of at-risk ACPA+ individuals.  It was hypothesised that BME and joint 
damage would correlate with joint tenderness.  In this study there is no evidence to 
suggest BME or indeed any other MRI finding is associated with patient or physicians 
reported joint tenderness.  Patient reported joint tenderness was collected through 
questionnaires which recorded location of pain experienced in the last 7 days. This may 
not be a true reflection of pain pattern in the preceding months.  However, very few of 
the tender joints had any detectable pathology.  This limits the plausibility of strong 
association between MRI features and tenderness in the majority of these patients.  
Ultrasound PD did have a substantive HR 2.09 (90% CI 0.67, 6.57) which therefore 
supports further analysis of joint tenderness and imaging findings in a larger sample size.  
 
Cost, duration of examination, comfort and accessibility are still the main barriers to the 
widespread application of MRI in clinical practice [340]. In the research setting, these 
images are RAMRIS scored by radiologists trained in musculoskeletal radiology.  
Whether this is feasible in all clinical departments is questionable and may limit the 
transferability of this modality into common practice.  However, this study has 
demonstrated a clear benefit of MR imaging in evaluating individuals at risk of IA 
development.   
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4.6 Limitations  
This study has established that MRI findings are associated to risk of progression in at-
risk individuals.  However, further multivariable modelling to consider all variables 
would require a larger data set.  It is hoped that this will be achievable with ongoing 
recruitment.   
 
Healthy control data has been provided by a large European database [333].  It is 
acknowledged that the data originates from different MRI scanners and RAMRIS scoring 
from other scorers.  It was felt that despite these discrepancies, using healthy control 
data to correct scores allowed for a robust analysis.   
 
The presented analysis was restricted to imaging of the most symptomatic or dominant 
hand.  It was considered imperative to first focus on features reported in the hands 
following the ultrasound analysis of 136 individuals from the same cohort.  Here, 
ultrasound GS reported at the metatarsal phalangeal (MTP) joints was less 
discriminating at differentiating between progressors and non progressors [237].  MRI 
is able to provide detailed evaluation of MTP which may follow a similar pattern of 
abnormality as described in the ultrasound analysis.  van Steenbergen et al reported on 
the MRI features at the feet in the CSA cohort [324].  Whilst, low grade synovitis and 
BME (scores of ≥1) was reported in a fifth of individuals, scores ≥2 were infrequent.  In 
the combined inflammation score (sum of tenosynovitis, synovitis and BME), MTP joint 
location had the lowest scores.  Furthermore, scanning extra regions would require 
longer scan time and there are time implications to both the individual scanned and the 
radiologist reporting images.  Restricting the imaging assessment to the hand is thought 
to be a more feasible option for assessment of relevant inflammation.   
 
As alluded to earlier, it is challenging to compare these findings with other studies in the 
field since only one other study has corrected for changes found in health controls [324, 
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325]. However, in this population of at-risk, the CSA cohort, under a third were 
autoantibody positive and hence drawing comparisons is limited.  Specifications of MRI 
scanners, radiologists/specialists scoring and changes to the OMERACT RAMRIS scoring 
for tenosynovitis are all important factors to consider when comparing across studies 
[304].   
 
4.7 Key points 
 MRI tenosynovitis at initial assessment independently predicts likelihood to IA in 
individuals with systemic autoimmunity and MSK symptoms. 
 At a joint level, MRI tenosynovitis and BME are associated with the risk of 
progression to clinical synovitis. 
 There is limited evidence to suggest that MRI findings are associated with joint 
tenderness, either physician or patient reported.   
 MRI reported tenosynovitis appears to be more sensitive at detecting 
tenosynovitis compared to ultrasound, although further validation is required. 
 
4.8 Conclusions 
This study has presented the largest MRI data set for an autoantibody positive at-risk 
cohort.  The correction of the data to a healthy control reference range permitted the 
clinical utility of MR imaging as a viable biomarker to assist in evaluation of risk.  Baseline 
MRI characteristics, following adjustment, indicated that tenosynovitis was the most 
reported finding in these at-risk individuals.  The levels of MRI detected inflammation 
and bone change was otherwise relatively modest.  However, MRI findings, particularly 
tenosynovitis, provided predictive capability over and above the variables included in 
the clinical model and ultrasound GS & PD.  There has been no analysis considering 
ultrasound determined tenosynovitis in this cohort due to a limitation in the dataset 
numbers.  Further clarification is required as to the benefit of MRI detected 
tenosynovitis compared to ultrasound detected tenosynovitis.  This may have 
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implication on the future management pathways of at-risk individuals and will therefore 
be an important focus of future work.   
 
In this cohort of anti CCP+ individuals, there is insufficient evidence to suggest an 
association between tender joints and MRI features.  However it is acknowledged that 
the current study had limitations in the data collection of painful joints.  
 
Conclusions drawn from this study confirm preliminary pilot data.  MRI in at-risk 
individuals has been confirmed as an effective imaging biomarker for predicting 
development of arthritis.  These results supports the inclusion of MRI markers, in 
particular tenosynovitis, in future risk stratification models.  It is recommended that 
larger sample size studies be conducted to confirm the conclusions from this study.   
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5. MicroRNA profiling of matched samples in individuals with systemic 
autoimmunity and arthralgia who progress to RA 
In this chapter, the potential of microRNAs (MiRNAs) as a biomarker in identifying 
individuals at risk of RA is explored.  Basic science techniques were applied to a clearly 
defined cohort to identify possible pathogenic mechanisms and specifically the clinical 
utility of miRNAs.  
5.1 Introduction 
MiRNAs are a highly conserved class of short non-coding RNAs (21-25 nucleotides) that 
serve as transcriptional negative regulators, involved in fine tuning of genes involved in 
cell differentiation, metabolism and immunity  [82, 83].   Within the nucleus, miRNAs 
are transcribed by RNA polymerase II into molecules called primary miRNAs (pri-MRNAs) 
(Figure 15).  They are then cleaved in association with a RNA binding protein (labelled 
DGCR8) by a RNase III enzyme (Drosha) to form precursor miRNAs (pre-miRNAs).  Pre-
miRNAs are characterised by a stable hairpin like structure.  Once exported to the 
cytoplasm, the pre-miRNA undergo further cleavage by another RNase III enzyme to 
form unstable double stranded miRNA duplexes.  The unwound miRNA can then enter 
the RNA-induced silencing complex (RISC) where it induces a gene silencing effect on 
transcribed messenger RNA (mRNA).   
 
 
Figure 15 Schematic of the biogenesis of miRNA 
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Note the dashed line represents an alternative pathway in which pre-miRNA can be formed form 
direct splicing of introns these are termed as mitrons.  Reprinted by permission from BMJ 
Publishing Group Ltd & British Cardiovascular Society [341]. Copyright 2015    
 
The mode of action of miRNAs are presented in Figure 16.  There are 3 main endpoints 
for mRNA.  In the absence of miRNA, protein translation occurs (A).  In the presence of 
miRNA with a ‘near-perfect’ complementarity, the miRNA binds (usually in the 3′ 
untranslated regions of mRNAs) and represses translation, effectively ‘silencing’ the 
gene, inhibiting protein synthesis (B). When there is a perfect complementarity, the 
miRNA binding inhibits protein synthesis through the induction of mRNA degradation.   
 
Figure 16 Mode of action of miRNA (simplified schematic) 
Reprinted by permission from BMJ Publishing Group Ltd & British Cardiovascular Society [341]. 
Copyright 2015    
 
Around the time of their discovery in the 1990s, miRNAs were thought to have little 
importance in cellular processes.  However, within 10 years, advances in epigenetics 
enabled miRNAs to be recognised as pivotal regulators of gene expression, regulating at 
least 30% of mRNA [84, 85].  They have significant influence over diverse biological 
activities including apoptosis, immune functions, development, metabolism and 
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proliferation.  Over 2000 miRNAs have now been identified [342].  Specific targets are 
known in only a small proportion, although their emerging role in autoimmune disease 
is becoming apparent [343-346].   
 
Circulating miRNAs have been shown to have diagnostic and prognostic potential in 
malignancies [347-349].  Interest in miRNAs as a candidate biomarker for other diseases 
is based upon; (1) relative stability in the circulation and (2) detection in a wide range of 
readily accessible biologic sources (including serum and plasma) [350-353]. Consistency 
and reproducibility of results are even seen when frozen samples were investigated 
[354].   
Research in the field of RA, has reported several miRNAs to be dysregulated, possibly 
suggesting a pathogenic role [355]. Initially studies focused on expression from synovial 
fibroblast cells.   Dysregulation was reported in two key miRNAs; miR-146a, miR-155 [88, 
89, 356].  Subsequently, further miRNAs have been reported. The well characterised 
miRNAs, patterns of dysregulation and proposed function are presented in Table 17. 
 
Table 17 MiRNAs found to be dysregulated in patients with RA 
miRNA Pattern of dysregulation Proposed function 
miR-16 ▶ Upregulated in RA PBMCs, SF 
level lower than plasma levels 
in patients with RA. 
Regulate TNF-α signalling. [356, 357] 
miR-18a ▶ Upregulated in RASFs.   Increase in MMPs and mediators of inflammation 
via NF-κB signalling.  [358] 
miR-21 ▶ Upregulated in RA plasma, 
downregulated in PBMCS, PB 
CD4+ cells & SF CD4+ 
Maintaining balance between immune activation 
and tolerance regulation  -  Th17/Treg imbalance 
[359] 
miR-22 ▶ Downregulated in RA ST.  Inhibits CYR61. CYR61 stimulates RASF 
proliferation & IL-6 secretion – thus promotes 
synovial tissue hyperplasia) [360] 
miR-34a ▶Downregulated in RASFs. Regulator of cell death. Contributes to impaired 
apoptosis of RASFs. [361] 
miR-132 ▶ Upregulated in RA PBMCs, SF 
level lower than plasma levels 
in patients with RA. 
Regulation of T lymphocytes  & TNF-α production. 
[356, 357] 
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miR-146a ▶ Upregulated in RA ST, RASFs 
and RA PBMCs, Upregulated in 
RA CD4+ from PB and SF. 
Downregulated in 
serum/plasma 
Regulation of TNF-α. 
Th1 and Treg homeostasis [88, 89, 356, 357, 362] 
 
miR-155 ▶ Upregulated in RA ST/SF, 
RASFs, PBMCs and whole 
blood. Downregulated in 
serum/plasma 
Regulation of cytokines including TNF-α, IL-6,IL-8, 
IL-1β and IL-10.  Homeostasis of Treg cells and IL-
17 producing cells. [89, 363] 
miR-203 ▶Upregulated in RASFs.   Increased secretion of MMP-1 and IL-6 via the NF-
κB pathway. [87] 
miR-223 ▶ Upregulated in RA CD4+  & 
RASFs, Abundance lower in SF 
than in plasma of patients with 
RA.   
Involvement in osteoclastogenesis. [357, 364, 
365] 
(PB peripheral Blood, RASF Rheumatoid arthritis synovial fibroblasts, SF synovial fluid, ST synovial 
tissue.) 
Original data from Wittmann J et al, permission from BMJ Publishing Group Ltd [355] Copyright 
2011.  Table updated with current literature regarding proposed function and additional miRNAs.   
 
Other miRNAs that have been reported in RA include miR-23b, miR-30a, miR-24, miR-
26a, miR-124a, miR-125a-3p/-5p, miR-125b/ miR-99a/ miR-100, miR-126-3p, miR-133a, 
miR-142-3p/5p, miR-150, miR-221/ miR-222, miR-363, miR-498 and miR-451 (review 
summarising findings [86]).  The biomarker potential of miRNA has been explored more 
recently in serum and plasma expression.  These studies have tended to focus on 
established RA and predicting response to therapy [251, 366].  To date there have been 
no other studies which have studied an at-risk cohort.   
 
5.2 Aims and overview: 
In a cohort anti-CCP positive individuals with non-specific MSK symptoms this work 
aims to: 
1) Compare miRNA expression patterns between health and disease along the 
inflammatory arthritis continuum.  This includes individuals at risk of and those 
that develop RA. 
2) Evaluate the change in expression of miRNA from at-risk to early RA.  
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3) Explore whether miRNAs expression could produce a signature predictive of 
progression from at-risk to RA. 
 
Two phases were proposed (Figure 17).  An initial pilot phase; where miRNAs of interest 
were identified and a validation phase evaluating the miRNAs of interest in a secondary 
cohort.   
 
 
Figure 17 MiRNA study outline. 
HC healthy controls; TLDA TaqMan Low Density Arrays; VERA Very early RA.  
 
5.3 Patients and Methods 
5.3.1  Patients  
Pilot Phase 
Previous work has demonstrated ultrasound detectable synovitis at baseline visit in 
CCP+ individuals [237].  These individuals are in essence considered to already have 
developed inflammatory pathology, albeit subclinical.  For this analysis, therefore only 
those without ultrasound detectable synovitis (defined as no power Doppler signal) 
were considered.   
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Random selection of 12 CCP+ patients who were known to have progressed to RA, 
termed as very early RA (VERA), were identified (Figure 18A).  Blood samples were taken 
at baseline and at the point of synovitis detection.   These samples formed the matched 
element of the analysis.  Twelve healthy controls (HC) were also included.   Samples 
were profiled for >700 miRNAs (5.3.4 Laboratory Method). 
 
 
Figure 18 Patients cohorts of serum miRNA profiling. 
 (17A) Pilot Phase: Healthy Controls (n=12), CCP positive (CCP) group n=12 progressed to Very Early 
RA (VERA) group. (17B) Validation Phase including HC n=12, CCP+ progressor and 12 CCP+ non 
progressor groups. 
 
Validation Phase  
To verify pilot phase findings a further 12 CCP+ progressors were identified.  The 
biomarker potential of candidate miRNAs was evaluated by studying expression in 
‘negative control’ samples.  This comparator group consisted of 12 CCP+ individuals who 
had not progressed to VERA, ‘non-progressors’ (Figure 18B).  It was hypothesised that 
CCP+ non-progressors would not have the pattern of dysregulation seen in the VERA 
development of progressors.  A further 12 HC were also included.  Similarly to the pilot 
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phase, only those with no evidence of inflammation at baseline ultrasound scan were 
included.   
 
During the observation period, individuals who progressed to VERA had a matched 
blood sample at detection of synovitis.  The 12 non-progressors had a matched sample 
36 weeks from baseline. The 36-week sample was selected following pilot phase data, 
indicating a median time to progression to synovitis of 34.5 weeks.  This enabled closely 
matched sample point between the two groups.  A CCP+ individual was only considered 
a non-progressor if there had been no VERA development in a minimum of 2 years 
observation.    
 
Custom cards were used to validate the miRNAs of interest from the pilot phase and the 
miRNAs previously cited in the literature (Table 17 and 5.3.4 Laboratory Method). 
 
5.3.2 Clinical Assessments  
Clinical assessments were performed as previously described (Methods Section 3.5 
Protocol).  All participants provided (1) baseline demographic details, (2) patient 
questionnaires, (3) a clinical history of symptoms, (4) MSK examination including a joint 
count by a rheumatologist (LH & CR).  Participants followed the study schedule as 
outlined in (Chapter 3.5 Study Protocol). Individuals attended 3 monthly visits for the 
first year and as clinically indicated thereafter, or until they developed inflammatory 
arthritis; defined by the presence of at least one tender and swollen joint confirmed by 
a rheumatologist.  Blood sampling was performed at baseline and then at regular 
intervals until the development of IA. 
 
5.3.3 Ultrasound Assessments 
Ultrasound examination was performed by a rheumatologist trained in MSK ultrasound 
(JLN), blinded to the clinical examination [237].  Patients recruited to the study had scans 
of the wrists, MCPs, PIPs and MTPs bilaterally. The scans were performed at baseline, 6 
and 12 months, then annually and at withdrawal to confirm an IA diagnosis.  All 
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participants required no features of power Doppler activity to joints of the hands and 
feet at baseline assessment.    
  
5.3.4 Laboratory Methods 
Isolation and profiling of serum microRNA  
Peripheral blood samples were collected in blood clot activator vacutainer tubes. 
Samples were left at room temperature for the blood to clot and were centrifuged at 
3000rpm for 10 minutes. Serum was separated into aliquots, centrifuged at 13,000g for 
10 minutes at 4°C. The serum collected was stored at -80°C until further use.  Stored 
serum samples were transferred to Wellcome Trust Brenner Building for microRNA 
analysis.   
 
Serum microRNAs were isolated according to the manufacturer’s protocol using 
miRNeasy serum plasma kit (Qiagen, UK). The protocol follows the recommendations 
and incorporates the advised alterations for using RNA purified from serum/plasma 
(manufactures guidance entitled “Optimised protocols for microRNA profiling with 
precious samples”). 
 
qRT PCR  for Global profiling  
Isolation of RNA 
200 µl of serum was transferred to a clean 1.5 ml microtube. 1 ml QIAzol was added and 
mixed by pipetting to denature the sample and incubated at room temperature for 10 
mins.  During incubation, the following was added: 
i. 1.25 µl of 0.8 mg/ml MS2 RNA (1 µg in total) (Roche)  - RNA stabiliser 
during cDNA synthesis. 
ii. 3.5 µl of 1.6 x 108 copies/µl c.elegans miR-39 miRNA mimic (Qiagen). 
200 µl chloroform was added and shaken vigorously at room temperature for 15 
seconds. The protocol supplied with the kit was followed until the final elution, ensuring 
that the correct volumes, consistent with the starting volume of the serum aliquot, were 
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used. The final elution was performed with 20 µl molecular grade H2O.  RNA was stored 
at -80°C until further use. 
 
Complement DNA synthesis (cDNA) 
Taqman miRNA reverse transcription kit was used (Life Technologies) for the reverse 
transcription reaction stage.   A reaction volume of 10 µl was recommended including 
the 3 µl RNA from serum:   
RNA input (isolated from serum) 3 µl 
10x Megaplex reverse transcription primers* 1 µl 
100 mM dNTP 0.27 µl 
Multiscribe reverse transcriptase (50 U/µl) 2 µl 
10x reverse transcription buffer  1 µl 
25 mM MgCl2 1.2 µl 
RNase Inhibitor (20 U/µl) 0.13 µl 
dH2O 1.4 µl 
* Primer A for Taqman array human miRNA card A and Primer B Taqman array human 
miRNA  card B 
  
The microtubes were placed in a thermal cycler (Life Technologies) set for the following 
cycling: 
16°C 2 minutes  
42°C 1 minute   x 40 cycles  
50°C 1 second  
85°C 5 minutes and then hold at 4°C. 
 
The end reverse transcription product equates to cDNA.  
 
Pre-amplification 
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For the pre-amplification reaction, 10 µl cDNA from the reverse transcription was used 
in a reaction volume of 50 µl consisting of: 
Reverse transcription product 10 µl 
2x Taqman pre-amplification mastermix  25 µl 
10x Megaplex pre-amplification primers* 5 µl 
dH2O  10 µl 
* Separate reactions required for primer set A and primer set B    
The microtubes were placed in a thermal cycler (Life Technologies) set for the following 
cycling: 
95°C 10 minutes 
55°C 2 minutes 
72°C 2 minutes 
95°C 15 seconds  
60°C 4 minutes  x 14 cycles 
99°C 10 minutes, and then hold at 4°C. 
 
The pre-amplification product was stored at -20°C until it was run on the miRNA Taqman 
Low density Array (TLDA) array plate.   
 
Preparations for TLDA plate: 
 
The undiluted pre-amplification product was added to the mastermix: 
Pre-amplification product 9 µl 
2x Taqman Universal Mastermix II, No UNG 450 µl 
dH2O 441 µl 
    
Pre-configured micro fluidic cards were used, enabling the quantification of 754 human 
miRNAs.  Taqman Low density microRNA cards A v3.0 and B set v2.0 (Life Technologies) 
were prepared according to the instructions in the manuals provided with the Megaplex 
primers.  100 µl of product per channel was loaded via the fill port using a 100 μL 
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micropipette.  The cards were centrifuge at 1200g 1 minute x2 using Heraeus Multifuge 
to distribute the reaction mix to the reaction wells. The array cards were sealed using 
the TaqMan Array Micro Fluidic Card Sealer.  Cards were loaded on an Applied 
Biosystems 7900HT fast real-time system (Life technologies).  Data was automatically 
analysed with SDS Relative Quantification software version 2.4 (Life Technologies).  
 
qRT PCR on custom miRNA cards  
TLDA custom cards (Life Technologies) were used in the validation phase once the 
miRNAs of interest had been established.  The TLDA custom cards, comprising of 384 
wells, allowed for 31 candidate miRNAs and RNU6B control for normalisation (as per 
manufacturer recommendation).  Extraction of serum RNA was as described in the 
above methods. Custom primers for the selected miRNAs were used for reverse 
transcription and pre-amplification steps. Four patient samples could be included on 
each card; baseline and follow-up samples for pairs of patients were assigned to each 
card. Data were automatically analysed with SDS Relative Quantification software 
version 2.4 (Life Technologies).  
 
5.3.5 Statistical Analysis 
This project generates large quantities of data despite the relatively small sample 
numbers, for which a comprehensive analytical approach was therefore required. 
Formal guidance regarding analysis of micro array data is sparse, however work within 
the field and a general consensus of opinion has resulted in an accepted approach.   
 
In qRT PCR a positive reaction is detected by accumulation of fluorescent signal.  The 
threshold cycle (Ct) is the fractional cycle number at which the fluorescent signal of the 
reporter dye passes the threshold (Figure 19).  A lower Ct value represents a high level 
of expression.   For this analysis, miRNAs with a Ct <33 were considered as adequately 
expressed.  MiRNAs Ct>33 were therefore excluded, as this would represent weak 
reaction and possible environmental contamination rather than true expression.   
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Figure 19 Real-time PCR output of the endogenous control RNU6 on custom cards 
(triplicate) 
The PCR was run for 40 cycles. The point at which the curve intersects the threshold (horizontal 
dashed black line) is the CT. The CT for this miRNA is 22.5. 
 
Pilot phase: Global profiling 
There is no current consensus of internal control for plasma miRNA.  Previous studies 
have used specific miRNA (e.g. Let-7a) as endogenous controls, whilst others have used 
the average value [251].  In this study, normalisation was achieved by calculating the 
average value across total expressed miRNAs for each sample.  Each miRNA was then 
subtracted from this value to give the delta Ct (dCt).  To validate the accuracy of using 
the average Ct value as a reference for normalization, NormFinder software was used.  
This software is recommended when assessing the optimum candidate for 
normalization by determining the most stably expressed microRNA [367].  Reassuringly, 
the result identified average Ct as the optimal and most stable normalisation method.  
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  To analyse the expression of miRNAs the median and mean dCt of each miRNA across 
each cohort was calculated.  Median was considered most appropriate given the sample 
size.  Mean dCt provided a comparator value for this pilot phase.  For ‘between-cohort’ 
comparisons, quantile regression, adjusting for age, was used to obtain adjusted 
between-group differences in median dCt.  This was converted into a fold difference 
(FD).  For ‘within-patient’ changes (CCP+  VERA matched samples), ddCt was 
calculated for each within-patient difference, then median fold change (FC) was 
calculated (FC= 2-[dCt (follow-up)-dCt (baseline)]). If FD or FC<1, -1/(value) was calculated.  
Negative values therefore indicate that expression was lower at follow-up compared to 
baseline (negative FC). 
 
Stringent criteria for the selection of miRNAs of interest was followed for this analysis.  
The primary criterion stipulated that there should be a FD/FC of four in expression level 
(FD/FC≥4).  Several other miRNA studies have considered FC at lower levels (e.g. FC>2), 
however a FD/FC≥4 was felt to have greatest biological significance.  For ‘within-patient’ 
change (CCP+  VERA, matched samples) pattern of dysregulation had to be consistent 
across ≥75% of the cohort.  Applying these criteria, a list of candidate miRNA was 
generated.  
 
On an exploratory level, miRNA expression levels were compared using Wilcoxon test to 
compare paired cohorts; p values <0.05 were considered significant.  Given the 
preliminary nature of the work, descriptive results and inferential statistics are 
presented.  
 
Validation: MiRNA Custom cards  
Custom cards (384 well) allowed for triplicates of each candidate miRNA to be 
measured. Normalisation was achieved using the mean of the endogenous control 
replicates (RNU6).  
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Undetermined Ct values were imputed at the replicate level prior to analysis using R 
package nondetects, which employs an expectation maximisation algorithm [368]. The 
algorithm models the probability of an undetermined value occurring as a function of 
the observed values in the dataset, on the assumption that values may be undetermined 
due to a failure to amplify, rather than the ‘true’ value of Ct being >40.  
 
  The same analytical approach used in the pilot phase was followed in the validation 
phase to assess for between group and within patient differences.  An additional analysis 
was required to determine whether specific miRNAs of interest could differentiate at-
risk individuals.  Baseline expression of candidate miRNAs were compared between the 
progressor and non-progressor groups to produce a FD.  The fold difference was 
calculated as FD= 2-[dCt (progressors)-dCt (non-progressors)].  As with FC and FD in the pilot phase, if 
the value was <1, it was transformed to -1/FD.  Negative values therefore indicate that 
expression was lower in progressors compared to non-progressors (negative FD).  The 
small numbers limits this to an exploratory analysis only.    
 
Associations with clinical variables were assessed using Spearman’s rank. Area under the 
ROC curve for classifying progressors/non-progressors was calculated for each 
microRNA. Sensitivity and specificity were calculated at the point which maximised the 
Youden index (sensitivity+specificity-1).  
 
In both phases, raw data was exported from SDS Relative Quantification software to 
Microsoft excel and then exported to SPSS v.21 and R for statistical analysis.  Graphpad 
Prism 5 was used to produce the figures.  Gene Cluster 3.0 and Java TreeView were used 
to generate MiRNAs heatmaps of the hierarchical clustering analysis.   
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Power calculations 
As this is an exploratory study, no formal power calculations have been performed.  For 
both pilot and validation phases, a rule of thumb of n=12 per group was adopted [369].   
5.4 Results 
5.4.1 Patient Characteristics 
At time of analysis, 136 patients that had tested positive for CCP had been recruited to 
the prospective ‘at-risk’ clinic. Fifty-seven patients progressed to VERA after a median 
of 8.6 months (range 0.1-52.4). Of those 57, 29 had no ultrasound-detectable synovitis 
at baseline of which, 12 were randomly selected for the pilot phase. A further 24 
patients (12 that progressed to RA and 12 that did not) were randomly selected for 
validation phase.   Patient characteristics are listed in Table 18. 
 
In the pilot phase, the HC and CCP+ to VERA cohorts were well matched for gender 
although the HC were younger.  In the validation phase there were more females in the 
progression group compared to the non-progression group.  The pilot phase median 
weeks to progression was 34.5 (IQR 13.5-56.5) compared to 41 (IQR 25.8-65.0) weeks in 
the validation phase.  Individuals within the non-progression cohort were followed up 
for a minimum period of 127 weeks.   
Table 18 Baseline characteristics of individuals for pilot and validation phases 
Pilot phase HC CCP+ progression to VERA  
Number 12 12 
Median Age (IQR) 43 (38-55.3) 52 (43-70) 
Female  8 (67%) 8 (67%) 
Median weeks to 
synovitis (IQR) 
- 34.5 (13.5-56.5) 
Validation phase HC CCP+ progression to 
VERA 
CCP+  non- 
progression 
Number 12 12 12 
Median Age (IQR) 35.5 (29.8-43.8) 54 (39.0-59.2) 53.5 (50.0-65.5) 
Female  6 (50%) 10 (83.3) 6 (50) 
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Median weeks to 
synovitis (IQR) 
- 41 (25.8-65.0) - 
Median weeks 
follow-up (IQR) 
- - 152 (127.3-241.5) 
(HC Healthy controls, IQR Interquartile range, VERA Very early rheumatoid arthritis) 
 
5.4.2 Pilot phase 
5.4.2.1 Comparing health with CCP+ and VERA cohorts: 
 Table 19 lists the miRNAs that were dysregulated between the cohorts. For between 
cohort comparisons, miRNAs included in the table had a FD >4. For matched samples 
miRNAs with FC>4 and consistent pattern of dysregulation were selected.  Between HC 
group (n=12) and CCP+ (n=12), 8 dysregulated miRNAs were identified (4 down- and 4 
up-regulated); between HC and (matched CCP+ to) VERA cohort (n=12), 13 dysregulated 
miRNAs were recorded (to note, all bar one were upregulated).   The greatest FD was 
seen with miR-628-5p comparing health with CCP and VERA (FD 1176.3 and 59.7 
respectively).  These FDs were significantly higher than the remainder of the reported 
FDs.   
 
In addition to the 17 miRNA in Table 19 that met the criteria, there were several other 
miRNAs that demonstrated substantial changes.  MiR-579 was identified to be of 
interest as the mean FC 4.27 (despite the median value FC being <4).  Furthermore, this 
miRNA had consistent dysregulation in 11/12 patients.  In order to be inclusive of 
potential signals that may become significant with a powered study, this miRNA was 
highlighted.  For miR-15b and -335 the Ct was >32 for some CCP+ patients at baseline. 
As a result, the calculated fold changes may not be accurate.  These miRNAs were not 
deemed to have fulfilled the criteria for dysregulation but were retained for further 
investigation because the calculated FC was near or above the design cut-off.  On 
reviewing the raw data for these miRNAs, a pattern of expression emerged from CCP to 
VERA despite not having a significant fold change.  Furthermore, in the matched analysis 
all progressors showed consistent dysregulation.   
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  HC CCP VERA CCP vs. HC VERA vs. HC CCP to VERA (within 
progressors) 
 
 miR dCt median 
(IQR) 
dCt median 
(IQR) 
dCt median 
(IQR) 
FD 
between 
medians 
FD between 
medians 
Median (IQR) 
ddCt 
Median 
FC 
N 
upregulat
ed (/12) 
1 miR-16 -6.3 (-7.1, -6.0) -7.1 (-7.6, -7.0) -7.6 (-8.2, -7.4) 1.7 2.5 -0.4 (-1.1, -0.1) 1.3 10 
2 miR-18a 0.1 (-0.8, 1.3) 1.3 (0.3, 2.0) -0.1 (-1.0, 0.4) -2.3 1.1 -1.6 (-2.0, -1.0) 3.1 10 
3 miR-19a -0.9 (-1.6, 1.0) -2.4 (-2.8, -1.9) -3.2 (-3.5, -2.9) 2.8 4.9 -0.6 (-1.7, 0.1) 1.5 9 
4 miR-21 -2.8 (-4.1, -2.5) -3.8 (-4.4, -3.3) -4.3 (-4.8, -4.1) 2.0 2.8 -0.7 (-1.2, -0.2) 1.6 9 
5 miR-22 4.2 (0.5, 4.8) 3.0 (1.5, 5.1) 0.9 (0.6, 1.5) 2.3 9.8 -2.1 (-3.6, -1.5) 4.3 12 
6 miR-26b -1.4 (-3.0, 0.2) -3.1 (-3.4, -1.8) -3.6 (-4.2, -2.8) 3.2 4.6 -0.7 (-2.3, -0.3) 1.7 10 
7 miR-34a -0.2 (-2.1, 0.7) -0.1 (-0.3, 1.0) -0.6 (-2.1, 0.2) -1.1 1.3 -0.1 (-0.9, 0.3) 1.1 6 
8 miR-101 2.5 (1.7, 3.2) 1.6 (1.3, 1.8) 0.4 (-0.3, 0.9) 1.9 4.3 -1.1 (-1.9, -0.6) 2.1 11 
9 miR-132 -1.6 (-2.0, -1.4) -1.7 (-2.1, -1.6) -2.5 (-2.7, -2.2) 1.1 1.9 -0.8 (-1.1, -0.3) 1.7 11 
10 miR-142-3p -2.3 (-4.5, -1.3) -4.4 (-4.5, -3.8) -5.0 (-5.2, -4.5) 4.3 6.5 -0.4 (-1.1, -0.3) 1.4 10 
11 miR-142-5p 3.9 (2.9, 5.7) 3.0 (2.4, 5.5) 1.7 (1.5, 4.3) 1.9 4.6 -1.3 (-1.4, -0.3) 2.4 10 
12 miR-146a -7.3 (-7.5, -6.5) -7.1 (-7.6, -7.0) -7.5 (-7.7, -7.3) -1.1 1.1 -0.5 (-0.8, 0.2) 1.4 8 
13 miR-155 -0.9 (-2.3, 1.4) 0.2 (-0.5, 1.1) -0.5 (-0.7, -0.3) -2.1 -1.3 -0.3 (-1.3, 0.1) 1.2 8 
14 miR-195 -2.5 (-2.9, -1.6) -0.4 (-3.4, 0.2) -2.9 (-4.2, -0.5) -4.3 1.3 -1.1 (-2.0, -0.5) 2.1 11 
15 miR-197 -3.2 (-2.8, -1.3) 0.6 (-1.5, 2.9) 0.6 (-2.5, 2.2) -13.9 -13.9 -0.6 (-2.7, 1.3) 1.5 7 
16 miR-203 2.3 (1.8, 3.0) 3.0 (2.1, 3.0) 2.9 (2.6, 3.4) -1.6 -1.5 0.0 (-0.4, 0.6) 1.0 6 
17 miR-210 3.9 (0.8, 5.0) 3.1 (2.2, 3.6) 1.5 (1.1, 1.8) 1.7 5.3 -1.8 (-2.9, -0.3) 3.4 10 
18 miR-223 
 -9.3 (-9.6, -8.7)   -9.8(-9.9, -9.5) -10.3 (-10.5, -
10.2) 
           1.4                 2.0 -0.4 (-0.6, 0.2) 1.3 6/9* 
19 miR-361 -0.1 (-1.1, 1.1) 2.1 (-0.5, 2.5) 0.1 (-0.2, 0.7) -4.6 -1.1 -1.5 (-2.1, -1.0) 2.9 11 
20 miR-374‡ -2.2 (-3.2, -2.1) -3.2 (-3.7, -2.0) -4.1 (-4.3, -3.9) 2.0 3.7 -0.6 (-1.0, -0.4) 1.5 12 
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Table 19 List of miRNAs of interest with age-adjusted FC≥4 between the three studied cohorts 
(upregulated FC≥4, downregulated FC≤-4). MiRNA highlighted in bold in matched samples (CCP-VERA) met criteria of median FC≥4 and ≥75% consistent 
dysregulation. MiRNA previously reported in the literature are highlighted by shading. FD=fold difference; FC=fold change. If FD<1, FD=-1/FD. Estimates for each 
cohort were obtained at the mean age (52 years). 
 
*For 3 patients, Ct values at follow-up were extremely low (all ≈2, compared to ≈14 for the rest); these 3 values were considered to be inaccurate and in a conservative 
approach were excluded from analysis. 
 
†In these miRNAs, Ct was >32 for some healthy controls & CCP+ patients at baseline. As a result, the calculated fold differences & changes may not be accurate; 
therefore, these genes were not deemed to have fulfilled our criteria for dysregulation but were retained for further investigation in the validation cohort because 
the calculated FC were near or above our cut-off and all progressors showed consistent dysregulation. 
§In this MiRNA mean FC>4; miR-579 FC 4.27 (although median FC<4), furthermore consistent dysregulation seen in 11/12 patients.   As custom cards had capacity 
for 31 miRNAs to be evaluated these two miRNAs were selected as potentially important. 
‡The original selection of miR-454 (FD 4.1 between HC-VERA) and miR-374 (FD 4.6 between HC-VERA) from the pilot phase was based on unadjusted between-group 
differences; following age-adjustment they no longer met criteria. 
21 miR-382 -0.7 (-1.2, 0.5) 1.4 (0.9, 2.7) -0.1 (-1.2, 0.5) -4.3 -1.5 -2.0 (-2.8, -0.8) 4.1 11 
22 miR-454‡ -1.3 (-2.8, 0.1) -2.3 (-3.2, -0.1) -3.0 (-3.3, -1.3) 2.0 3.2 -0.5 (-1.1, -0.2) 1.4 10 
23 miR-486-3p 4.3 (2.5, 5.6) 4.9 (2.5, 6.2) 3.5 (3.1, 4.3) -1.5 1.7 -2.0 (-3.1, 0.2) 4.1 9 
24 miR-520c-3p 2.3 (0.3, 2.9) -0.4 (-1.6, 2.4) -1.1 (-1.4, 0.5) 6.5 10.6 0.3 (-1.7, 0.6) -1.3 5 
25 miR-579§ 4.0 (3.5, 5.0) 3.5 (3.1, 3.7) 2.8 (1.8, 2.9) 1.4 2.3 -1.2 (-1.7, -0.3) 2.2 11 
26 miR-590-3P 5.2 (2.9, 5.8) 3.2 (2.3, 4.2) 2.4 (2.2, 3.1) 4.0 7.0 -0.9 (-1.1, 0.2) 1.9 8 
27 miR-590-5p 1.2 (0.7, 1.4) -0.4 (-1.2, -0.2) -1.3 (-1.6, -0.7) 3.0 5.7 -0.5 (-1.1, -0.3) 1.4 10 
28 miR-598 3.7 (3.1, 4.3) 2.8 (2.5, 3.6) 1.5 (1.4, 1.9) 1.9 4.6 -1.2 (-1.7, -0.8) 2.2 12 
29 miR-628-5p 3.0 (-7.5, 7.9) -7.2 (-8.3, 3.9) -2.9 (-7.8, 2.2) 1176.3 59.7 0.4 (-1.6, 1.7) -1.3 5 
30 miR-15b# 10.1 (3.7, 11.9) 6.5 (5.6, 8.8) 3.5 (1.9, 4.7) 12.1† 97.0† -2.6 (-4.0, -1.8) 6.1†  11/11 
31 miR-335# 6.1 (5.6, 8.3) 6.5 (5.2, 8.1) 4.2 (3.9, 5.1) -1.3† 3.7† -1.9 (-3.9, -1.0) 3.8†  12 
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5.4.2.2 CCP+ to VERA matched sera miRNA evaluation:  
From paired analysis of the matched samples, the within-patient change of 3 circulating 
miRNAs were upregulated upon progression from CCP+ state to VERA (see Table 19, 
highlighted in bold, end column).  Serum miR-22 expression increased the most in 
patients from CCP+ to VERA [median FC 4.3 (IQR 2.8, 12.1; p=0.005)].  The expression of 
this miRNA increased in all patients (12/12). Comparable levels of upregulation were 
found for miR-382 [median FC 4.1 (IQR 1.7, 6.9; p=0.002; increased in 11/12] and miR-
486-3p [median FC 4.1 (IQR 0.9, 8.6; p=0.027; increased in 9/12]. Figure 20 represents 
the change in expression from CCP+ to VERA of these 3 miRNA. 
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Figure 20 Comparison of expression levels of miR-22, miR-382 and miR-486-3p in matched samples from CCP+ to VERA  
(A) Dot plot with median dCt represented by the middle horizontal line and 1st-3rd IQR represented by the whiskers. (B) represent median dCt from CCP+ to VERA per 
matched sample. A lower dCt value represents a higher level of expression. 
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MiR-628-5p, which had demonstrated very high levels of dysregulation in the CCP and 
VERA cohorts compared to health, did not meet the criteria in the paired analysis with 
a FC of -1.3.  This may be attributed to the majority of change in expression occurring in 
transition from health to autoimmunity and hence the transition to VERA is minimal.  
MiR-15b had a FC of 6.1, however it was noted that this miRNA had great variability in 
the Ct values and must be reviewed cautiously. 
 
5.4.2.3 Cited MiRNA associated with RA pathogenesis: 
The shaded rows featured in Table 19 indicate the 9 miRNAs frequently cited to have 
associations with RA.  None of these miRNAs reached the stringent FC/FD criteria set in 
this study.  Between cohort comparisons, miR18a had the highest FD of -2.3 between 
CCP+ and health.  Within the matched samples this miRNA had the highest FC 3.1 with 
a consistent pattern of dysregulation; upregulated in 10/12 individuals.  MiR-146a and 
miR-155 are the two most cited miRNAs in relation to RA.  Within this set of samples, 
both miRNA were upregulated in the majority (8/12) of the individuals who progressed 
to RA (Figure 21 A & B); however, the FCs were not substantive (median 1.4 and 1.2 
respectively).   
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Figure 21 Serum miR146a and miR-155 expression in the pilot phase. 
  (A) Relative expression levels of miR-146a and miR-155 in CCP and matched VERA groups, dot 
plot with median dCt represented by the middle horizontal line and 1st-3rd IQR represented by the 
whiskers (B) Comparison of expression levels (median dCt) of miR-146a and miR-155 in the 
matched samples: miR-146a FC 1.4 (-1.2, 1.8) and miR-155 FC 1.2 (-1.1, 2.6) (dCT, delta threshold 
cycle).   
 
The dysregulated MiRNAs highlighted from the between cohort comparisons and the 3 
miRNA identified in the matched analysis formed the basis of the tailored array cards.  
In addition, the 9 cited miRNAs involved in the pathogenesis in RA were included.  In 
total, 31 miRNAs were evaluated in the validation phase, maximising the use of the 384 
well custom cards. 
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5.4.2.4 Hierarchical clustering  
In order to ascertain whether expression of specific miRNAs grouped or clustered 
together within the cohorts, an unsupervised hierarchical clustering analysis was 
performed.  Using complete linkage, cluster analysis of the global expression profiles of 
the 31 miRNAs was generated Figure 22.  
 
Figure 22 MiRNAs heatmaps were generated using hierarchical clustering 
Green indicates low expression; Red indicates high expression levels. (Generated using software 
Gene Cluster 3.0 and Java TreeView). Top bar identifies each sample; light blue = HC samples, 
dark blue = CCP+ samples, purple = VERA samples. 
 
While the cohorts do not completely cluster into 3 distinct groups there was clear 
clustering of several samples within each cohort.  This highlights clear similarities in 
patterns of expression between CCP+ and VERA.  There was also greater variation in the 
healthy control samples.   
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5.4.3 Validation phase 
 
A list of the dysregulated miRNAs from the three studied cohorts (22 in total) and 9 
miRNAs (miR-21, miR-146a, miR-155, miR-18a, miR-34a, miR-203, miR-223, miR-16, and 
miR-132) that had been cited in the literature was thus established.   
 
To validate the findings, a further 24 CCP+ patients were randomly selected. This 
consisted of 12 CCP+ patients who progressed to VERA (progressor cohort) and had a 
matched blood sample available at detection of synovitis.  A comparator group, 
consisting of 12 CCP+ individuals that did not progress to VERA (non-progressor cohort) 
were also selected.  (Figure 18 and Table 18).  The 31 candidate miRNAs were then 
quantified.  
 
5.4.3.1 Comparing Health with CCP+ (progressor and non progressor) and 
VERA cohorts:  
Expression profiles of RNU6B (manufacturers recommended control) were stable across 
all samples with Ct values ranging between 23 and 26.  Table 20 lists the miRNAs that 
were dysregulated between the cohorts, the arrows indicate where there has been 
consistent dysregulation (FD >4) in both pilot and validation phase.  In contrast to the 
pilot phase, only 3 miRNAs (miR-22, -34a, 335#) were dysregulated (all up-regulated) 
between validation HC group and validation CCP+ progressors.   MiR-22 demonstrated 
significant upregulation with a FD 11.3.  The inclusion of the CCP+ non-progressor cohort 
provided an additional comparison to health.  Only miR-590-3P met the criterion of 
dysregulation compared to health.  Between HC group and VERA cohort, 6 dysregulated 
miRNAs were identified (all upregulated); and 4 miRNAs were validated from the pilot 
results (as indicated by ()); miR-19a, miR-22, miR-590-3p and miR-598.  MiR-628-5p 
high expression in the pilot phase failed to be validated in this phase.  
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Table 20 List of miRNAs of interest with age-adjusted FD≥4 between the three studied cohorts in the validation phase. 
 HC CCP (non-prog) CCP (prog) VERA CCP 
(non-
prog) 
vs. HC 
CCP (prog) vs. HC VERA vs. HC 
miR dCt median (IQR) 
 
dCt median (IQR) 
 
dCt median (IQR) 
 
dCt median (IQR) 
 
FD between 
medians 
FD between 
medians 
FD between 
medians 
miR-16 -7.9 (-8.8, -6.8) -8.2 (-8.8, -7.2) -8.9 (-10.5, -7.8) -9.5 (-11.3, -8.0) 1.2 2.0 3.0 
miR-18a 0.1 (-0.6, 0.6) -1.1 (-1.3, -0.7) -1.1 (-2.8, -0.5) -1.9 (-3.0, -0.4) 2.3 2.3 4.0 
miR-19a -0.8 (-0.9, -0.4) -1.7 (-2.3, -1.4) -1.9 (-3.3, -1.0) -2.8 (-3.6, -1.2) 1.9 2.1 4.0 () 
miR-21 -2.1 (-2.4, -1.6) -2.6 (-3.4, -2.4) -3.7 (-4.9, -3.0) -4.3 (-5.3, -1.5) 1.4 3.0 4.6 
miR-22 6.6 (3.8, 9.0) 7.4 (4.1, 8.2) 3.1 (1.8, 7.3) 3.3 (1.0, 4.3) -1.7 11.3 9.8 () 
miR-26b -0.4 (-1.0, -0.2) -1.5 (-1.9, -1.0) -1.3 (-3.2, -0.7) -1.8 (-3.4, -0.7) 2.1 1.9                         2.6  
miR-34a 3.4 (2.4, 4.8) 3.0 (1.7, 4.0) 1.4 (0.7, 3.2) 2.5 (1.0, 3.1) 1.3 4.0 1.9 
miR-101 2.3 (2.3, 3.7) 3.2 (2.6, 3.7) 2.1 (0.5, 3.3) 1.6 (0.2, 3.3) -1.9 1.1                          1.6  
miR-132 0.8 (-0.2, 1.4) 0.2 (-0.6, 1.3) -0.2 (-1.9, 0.1) -0.7 (-1.7, 0.3) 1.5 2.0  2.8 
miR-142-3p -3.8 (-3.7, -3.0) -3.9 (-5.1, -3.5) -4.4 (-5.2, -3.7) -4.4 (-5.2, -2.6) 1.1        1.5                          1.5  
miR-142-5p 2.0 (1.9, 2.5) 1.7 (0.8, 1.9) 1.4 (-0.1, 2.3) 0.6 (-0.4, 2.5) 1.2 1.5                          2.6  
miR-146a -6.2 (-6.9, -4.7) -6.1 (-7.3, -5.3) -7.3 (-8.3, -6.4) -7.1 (-8.3, -6.6) -1.1 2.1 1.9 
miR-155 -0.4 (-1.0, 0.4) -0.8 (-1.7, 0.3) -1.3 (-1.8, -0.4) -1.3 (-1.9, -1.1) 1.3 1.9 1.9 
miR-195 -1.4 (-2.0, -0.9) -1.9 (-2.4, -0.7) -2.9 (-3.6, -1.4) -3.0 (-3.5, -1.7) 1.4 2.8 3.0 
miR-197 -2.2 (-2.8, -1.1) -2.6 (-3.6, -1.7) -4.0 (-4.2, -2.5) -3.3 (-3.9, -2.9) 1.3 3.5                          2.1  
miR-203 5.3 (4.8, 7.8) 6.0 (4.6, 7.6) 5.2 (3.5, 6.0) 5.2 (3.9, 5.9) -1.6  1.1                                 1.1 
miR-210 1.9 (1.3, 2.6) 0.9 (0.3, 1.7) 1.3 (-0.5, 1.7) 0.1 (-0.7, 2.2) 2.0  1.5                          3.5  
miR-223 -10.7 (-11.1, -10.4) -10.7 (-12.0, -9.9) -11.5 (-12.4, -11.1) -12.2 (-13.2, -10.9) 1.0  1.7 2.8 
miR-361 2.4 (1.6, 3.3) 3.3 (1.8, 3.5) 1.6 (0.5, 2.5) 1.7 (0.5, 2.3) -1.9      1.7 1.6 
miR-374 0.1 (-0.3, 0.3) -0.7 (-1.3, 0.1) -0.8 (-1.3, -0.4) -0.8 (-2.5, 0.3) 1.7  1.9 1.9 
miR-382 1.3 (0.9, 2.2) 1.1 (0.0, 1.8) -0.2 (-0.5, 1.9) 0.5 (-0.2, 1.0) 1.1  2.8 1.7 
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miR-454 -1.3 (-1.6, -0.7) -2.0 (-2.6, -1.7) -2.0 (-2.6, -1.1) -2.2 (-3.1, -1.1) 1.6 1.6 1.9 
miR-486-3p 4.0 (2.8, 5.1) 3.4 (1.7, 3.9) 3.9 (2.6, 5.0) 2.6 (1.9, 4.0) 1.5 1.1 2.6 
miR-520c-3p -2.5 (-3.3, -0.8) -2.2 (-4.1, -2.1) -2.9 (-4.8, -2.7) -3.1 (-4.4, -2.3) -1.2 1.3                            1.5  
miR-579 5.1 (4.2, 5.9) 5.4 (4.4, 6.1) 3.9 (2.2, 5.9) 3.9 (2.4, 4.7) -1.2 2.3 2.3 
miR-590-3P 7.9 (6.7, 7.4) 5.4 (4.1, 7.7) 6.3 (5.1, 8.4) 5.9 (5.4, 7.7) 5.7 3.0 4.0 () 
miR-590-5p 2.8 (2.7, 3.2) 2.6 (1.7, 3.8) 1.9 (1.3, 3.1) 2.3 (0.7, 4.3) 1.1 1.9                          1.4  
miR-598 3.2 (2.2, 3.7) 2.1 (1.4, 3.3) 1.6 (0.9, 2.2) 1.1 (0.0, 2.7) 2.1 3.0 4.3 () 
miR-628-5p 4.1 (3.3, 5.3) 3.4 (2.4, 3.6) 3.5 (2.7, 4.4) 2.6 (2.1, 3.3) 1.6 1.5                           2.8  
miR-15b# 1.5 (1.0, 1.5) 0.7 (0.4, 1.3) 0.5 (-0.1, 1.6) 0.2 (-1.0, 0.6) 1.7 2.0 2.5 
miR-335# 5.3 (4.2, 6.6) 4.2 (2.9, 5.4) 2.8 (2.2, 3.7) 2.2 (1.6, 4.4) 2.1 5.7  8.6 
 
 upregulated FC≥4 in both phases, downregulated FC≤-4 in both phase. MiRNA highlighted in bold in matched samples (CCP-VERA) met criteria of median FC≥4 
and ≥75% consistent dysregulation in the pilot phase. FD=fold difference; FC=fold change. If FD<1, FD=-1/FD. Estimates for each cohort were obtained at the mean 
age (48 years). 
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5.4.3.2 Baseline miRNA profile of CCP+ progressor compared to CCP+ non-
progressor:  
Descriptively, there was varied expression of the selected miRNAs at baseline between 
the progressors and non-progressors.  Overall, baseline readings of miRNAs were mostly 
upregulated in the progressors, compared to the non-progressors.  There were 5 
miRNAs which were downregulated; miR-26b, miR-210, miR-486-3p, miR-590-3p and 
miR-628-5p (Table 21). Baseline FD between the two groups for the 3 miRNAs of 
interest, miR-22, miR-382 and miR-486-3p were 19.7, 2.5 and -1.4 respectively.  At 
baseline, miR-22 was only expressed at Ct<32 in 6/12 non-progressors compared to 
10/12 progressors, with a high fold difference between groups (FD 19.7).  This supports 
supporting pilot findings that miR-22 is possibly associated with progression to VERA.   
Table 21 Comparison of miRNA expression between baseline samples within the CCP+ 
progressors and CCP+ non-progressors cohorts. 
miRNA 
CCP+ non-progressors 
 
CCP+ progressors 
 
Progressors vs. 
non-progressors 
 B/L median dCt (IQR) B/L median dCt (IQR) 
FD between 
medians 
miR-16 -8.2 (-8.8, -7.2) -8.9 (-10.5, -7.8) 1.6 
miR-18a -1.1 (-1.3, -0.7) -1.1 (-2.8, -0.5) 1.0 
miR-19a -1.7 (-2.3, -1.4) -1.9 (-3.3, -1.0) 1.1 
miR-21 -2.6 (-3.4, -2.4) -3.7 (-4.9, -3.0) 2.1 
miR-22 7.4 (4.1, 8.2) 3.1 (1.8, 7.3) 19.7† 
miR-26b -1.5 (-1.9, -1.0) -1.3 (-3.2, -0.7) -1.1 
miR-34a 3.0 (1.7, 4.0) 1.4 (0.7, 3.2) 3.0 
miR-101 3.2 (2.6, 3.7) 2.1 (0.5, 3.3) 2.1 
miR-132 0.2 (-0.6, 1.3) -0.2 (-1.9, 0.1) 1.3 
miR-142-3p -3.9 (-5.1, -3.5) -4.4 (-5.2, -3.7) 1.4 
miR-142-5p 1.7 (0.8, 1.9) 1.4 (-0.1, 2.3) 1.2 
miR-146a -6.1 (-7.3, -5.3) -7.3 (-8.3, -6.4) 2.3 
miR-155 -0.8 (-1.7, 0.3) -1.3 (-1.8, -0.4) 1.4 
miR-195 -1.9 (-2.4, -0.7) -2.9 (-3.6, -1.4) 2.0 
miR-197 -2.6 (-3.6, -1.7) -4.0 (-4.2, -2.5) 2.6 
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miR-203 6.0 (4.6, 7.6) 5.2 (3.5, 6.0) 1.7† 
miR-210 0.9 (0.3, 1.7) 1.3 (-0.5, 1.7) -1.3 
miR-223 -10.7 (-12.0, -9.9) -11.5 (-12.4, -11.1) 1.7 
miR-361 3.3 (1.8, 3.5) 1.6 (0.5, 2.5) 3.2 
miR-374 -0.7 (-1.3, 0.1) -0.8 (-1.3, -0.4) 1.1 
miR-382 1.1 (0.0, 1.8) -0.2 (-0.5, 1.9) 2.5 
miR-454 -2.0 (-2.6, -1.7) -2.0 (-2.6, -1.1) 1.0 
miR-486-3p 3.4 (1.7, 3.9) 3.9 (2.6, 5.0) -1.4 
miR-520c-3p -2.2 (-4.1, -2.1) -2.9 (-4.8, -2.7) 1.6 
miR-579 5.4 (4.4, 6.1) 3.9 (2.2, 5.9) 2.8 
miR-590-3P 5.4 (4.1, 7.7) 6.3 (5.1, 8.4) -1.9† 
miR-590-5p 2.6 (1.7, 3.8) 1.9 (1.3, 3.1) 1.6 
miR-598 2.1 (1.4, 3.3) 1.6 (0.9, 2.2) 1.4 
miR-628-5p 3.4 (2.4, 3.6) 3.5 (2.7, 4.4) -1.1† 
miR-15b#* 0.7 (0.4, 1.3) 0.5 (-0.1, 1.6) 1.1 
miR-335#* 4.2 (2.9, 5.4) 2.8 (2.2, 3.7) 2.6† 
 
†In these miRs, Ct was >32 for some patients and/or some values were undetermined and had 
to be imputed.  MiRNAs highlighted in bold satisfied criteria for dysregulation in the pilot phase.  
 
5.4.3.3 Change in miRNA expression within matched sera of CCP+ to VERA 
progressor and CCP+ to non-progressor:  
In the validation phase, no miRNA reached the pre-defined criteria of FC≥4 with 
consistent dysregulation across ≥75% of the cohort.  From the three key miRNAs 
identified in the pilot phase, miR-486-3p increased in progressors by a median (IQR) FC 
2.2 (0.4, 6.0) with upregulation in 7/12 (Table 22,  
Figure 23 (A)) compared to stable expression within the non-progressor cohort FC 1.0 
(0.7, 3.0). Despite miR-22 demonstrating a significant FD (19.7) between baseline 
samples of progressors versus non-progressors, the median FC (IQR) within patients was 
increased in both groups.  This was found to be greatest within the non-progressors, FC 
3.4 (0.5, 12.1) versus FC 2.5 (0.5, 19.7) in progressors (Table 22,  
Figure 23 (B)).  Furthermore, it was upregulated in all 12 of the non-progressors 
compared to 8/12 progressors.  This result is not consistent with findings to date but 
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may reflect miR-22’s role in CCP+ individuals with higher expression in individuals that 
develop IA.  Similarly, with miR-382, a greater median FC (IQR) was observed in the non-
progressor cohort [FC 2.4 (1.0, 2.6)] versus progressor [FC 1.2 (0.5, 2.6)] ( 
Figure 23 (A)). This may reflect association of this miRNAs with the CCP+ phenotype. 
 
Two miRNAs were upregulated in the non-progressors baseline to follow-up but not in 
the progressor group: miR-203 [FC 3.1 (0.5, 6.9) vs. -1.1 (0.3, 4.3)] and miR-579 [FC 3.2 
(1.0, 3.7) vs. -1.1 (0.3, 3.3)] (Table 22,  
Figure 23 (B)).  For both miRNAs, the pattern of dysregulation in the non progressor 
cohort was consistent in 9/12 of the individuals.  MiR-203 has previously been identified 
as a miRNA involved in RA [87], but has not been studied before in CCP+ at-risk 
individuals.  Whilst, miR-579 was upregulated in VERA compared to HC; the significance 
of upregulation in both the inflammatory cohorts and the CCP+ non-progressors remains 
unclear. 
 
MiR-15b and -335 were included in the selected 31 miRNAs following calculated FC 
which were near or above the criteria of the pilot phase.  However, in the validation 
phase expression in both CCP progressors and non-progressors was stable.
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Figure 23 Expression levels of candidate miRNA in serum of individuals from validation phase. 
Baseline and follow-up relative expression in the progressor (P) and non-progressor (NP) cohorts of (A) miR-486-3p, miR-22 and miR-382 (B) miR-203 and miR-579. 
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5.4.3.4 Hierarchical clustering  
An unsupervised hierarchical clustering analysis of the global expression profiles of 31 
miRNAs of interest from the validation phase was generated using complete linkage.  
The cohorts analysed replicated those presented in the pilot phase and therefore the 
CCP+ non-progressor group was excluded.  As with the pilot phase findings, there are 
patterns of similarity with clustering of individuals in cohorts.   
 
 
Figure 24 Heatmap for validation phase. 
Healthy cohort (HC) and CCP progressors baseline (P BL) and CCP progressors follow up samples 
(P F). MiRNAs heatmaps were generated using hierarchical clustering (Gene Cluster 3.0 and Java 
TreeView) Green indicates low expression; Red indicates high expression levels. 
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Table 22 Within-patient changes in 31 miRNAs of interest for CCP+ patients in the validation phase.  
 
  Validation phase Pilot phase from Table18 
  CCP+ non-progressors CCP+ progressors CCP+ progressors 
 miR Median (IQR) ddCt, 
mean (SD) 
FC N 
upregulated  
(/12) 
Median (IQR) ddCt, 
mean (SD) 
FC N 
upregulated  
(/12) 
Median 
FC 
N 
upregulated  
(/12) 
1 miR-16 -0.3 (-1.5, 0.3), -0.7 (1.4) 1.2 8 -0.9 (-2.1, 1.3), -0.7 (2.3) 1.9 7 1.3 10 
2 miR-18a -0.1 (-1.0, 0.1), -0.5 (1.3) 1.1 8 -0.1 (-1.8, 0.7), -0.4 (1.7) 1.1 6 3.1 10 
3 miR-19a -0.4 (-1.4, 0.2), -0.7 (1.3) 1.3 7 -0.2 (-1.9, 0.6), -0.5 (1.8) 1.2 7 1.5 9 
4 miR-21 -0.5 (-1.3, 0.5), -0.5 (1.4) 1.4 8 0.0 (-1.4, 1.1), 0.0 (1.5) 1.0 6 1.6 9 
5 miR-22 -1.8 (-3.6, 1.1), -2.3 (1.7) 3.4† 12 -1.3 (-4.3, 1.1), -1.8 (3.6) 2.5† 8 4.3 12 
6 miR-26b -0.3 (-1.1, 0.4), -0.3 (1.3) 1.3 7 -0.4 (-1.9, 0.4), -0.5 (1.6) 1.3 7 1.7 10 
7 miR-34a -0.4 (-1.7, 0.9), -0.4 (1.8) 1.3 7 0.3 (-1.9, 1.6), -0.1 (1.9) -1.2 6 1.1 6 
8 miR-101 -0.4 (-1.8, 0.1), -0.8 (1.3) 1.3 8 -0.1 (-1.8, 1.0), -0.3 (1.8) 1.1 7 2.1 11 
9 miR-132 -0.5 (-1.2, 0.3), -0.4 (1.3) 1.4 8 0.3 (-1.7, 1.4), -0.2 (1.8) -1.2 5 1.7 11 
10 miR-142-3p -0.1 (-1.3, 0.6), -0.2 (1.5) 1.1 7 -0.1 (-1.1, 1.2), 0.2 (1.4) 1.1 6 1.4 10 
11 miR-142-5p -0.6 (-1.2, 0.3), -0.4 (1.3) 1.5 7 -0.1 (-1.3, 0.7), -0.3 (1.3) 1.1 6 2.4 10 
12 miR-146a -0.5 (-1.3, 0.0), -0.5 (1.4) 1.4 9 0.1 (-1.0, 1.1), -0.2 (1.5) -1.1 6 1.4 8 
13 miR-155 -0.5 (-1.2, 0.4), -0.3 (1.2) 1.4 8 0.1 (-1.3, 0.9), -0.2 (1.4) -1.1 6 1.2 8 
14 miR-195 -0.2 (-1.4, 0.4), -0.6 (1.4) 1.2 7 -0.1 (-2.0, 1.4), -0.5 (2.2) 1.0 6 2.1 11 
15 miR-197 -0.6 (-1.3, 0.2), -0.5 (1.2) 1.5 8 0.5 (-1.1, 0.9), -0.1 (1.5) -1.5 5 1.5 7 
16 miR-203 -1.6 (-2.8, 0.9), -0.9 (2.8) 3.1† 9 0.1 (-2.1, 1.8), -0.2 (2.6) -1.1† 5 1.0 6 
17 miR-210 -0.4 (-1.2, 0.1), -0.5 (1.2) 1.3 8 -0.2 (-1.9, 1.7), -0.1 (2.1) 1.2 7 3.4 10 
18 miR-223 -0.7 (-1.6, 0.4), -0.5 (1.5) 1.6 8 -0.3 (-1.1, 0.4), -0.4 (1.2) 1.3 8 1.3 6/9 
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19 miR-361 -0.6 (-1.5, 0.5), -0.4 (1.3) 1.5 8 0.3 (-1.2, 0.9), -0.2 (1.6) -1.2 5 2.9 11 
20 miR-374 -0.5 (-0.7, 0.3), -0.3 (1.3) 1.4 7 -0.3 (-1.3, 0.6), -0.2 (1.5) 1.2 6 1.5 12 
21 miR-382 -1.3 (-1.4, 0.0), -0.7 (1.4) 2.4 9 -0.2 (-1.4, 1.1), -0.3 (1.6) 1.2 6 4.1 11 
22 miR-454 -0.1 (-0.9, 0.3), -0.2 (1.1) 1.0 7 -0.5 (-1.8, 1.1), -0.3 (1.6) 1.4 8 1.4 10 
23 miR-486-3p 0.0 (-1.6, 0.5), -0.5 (1.4) 1.0 6 -1.1 (-2.6, 1.3), -0.9 (2.8) 2.2 7 4.1 9 
24 miR-520c-3p -0.8 (-1.4, 0.2), -0.4 (1.6) 1.7 9 0.3 (-1.1, 2.1), 0.4 (1.9) -1.2 4 -1.3 5 
25 miR-579 -1.7 (-1.9, 0.0), -0.8 (2.0) 3.2† 9 0.1 (-1.7, 1.6), -0.5 (2.5) -1.1 5 2.2 11 
26 miR-590-3P -0.4 (-1.2, 1.9), 0.0 (2.1) 1.3† 6 -0.5 (-0.9, 1.3),  -0.2 (1.8) 1.4† 7 1.9 8 
27 miR-590-5p -0.5 (-1.2, 0.5), -0.5 (1.4) 1.4 8 -0.4 (-1.3, 1.6), 0.1 (1.5) 1.3 7 1.4 10 
28 miR-598 -0.5 (-1.0, 0.0), -0.5 (1.1) 1.4 9 0.2 (-1.2, 1.3), 0.0 (1.6) -1.1 5 2.2 12 
29 miR-628-5p -0.3 (-0.8, 1.1), 0.1 (1.9) 1.2† 7 -1.0 (-1.9, 0.6), -0.8 (1.6) 2.0† 7 -1.3 5 
30 miR-15b -0.6 (-1.4, 0.0), -0.6 (1.3) 1.5 9 -0.1 (-1.2, 0.2), -0.3 (1.5) 1.1 7 6.1†  11/11 
31 miR-335 -0.2 (-1.6, 0.7), -0.5 (1.6) 1.2† 8 -0.7 (-1.7, 0.6), -0.5 (1.7) 1.7 9 3.8†  12 
 
MiRNA highlighted in bold met criteria of median FC≥4 and ≥75% consistent dysregulation in the pilot phase. The last two columns allow for comparison of results 
between the two phases. † In these miRs, Ct was >32 for some patients at one or both time points and/or some values were undetermined and had to be imputed. 
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5.4.3.5 Association of MiRNAs to clinical variables 
Pooling results from both phases enabled associations of clinical variables for the 3 
miRNAs of interest to be evaluated Table 23.  MiR-382 and 486-3p were both associated 
(|rho|>0.3) with tender joint count and DAS28ESR.  All three miRNAs were substantively 
associated with patient disease activity visual analogue score.  
Table 23 Associations between clinical variables and dCt at baseline for key miRs 
Baseline variable miR-22 miR-382 miR-486-3P 
Age 0.31 0.01 -0.10 
EMS -0.19 0.07 -0.10 
TJC28 -0.23 -0.46 -0.39 
Patient DA VAS -0.33 -0.49 -0.65 
Physician DA VAS 0.24 -0.31 -0.28 
hsCRP 0.30 -0.03 0.01 
ESR 0.05 -0.12 -0.19 
DAS28ESR -0.08 -0.40 -0.40 
Values presented are Spearman’s rho  
EMS early morning stiffness, TJC28 tender joint count 28, DA VAS disease activity visual 
analogue score, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28ESR disease 
activity score using 28 joints and ESR 
 
5.4.3.6 Predicting progression using baseline miRNA expression 
As illustrated by Table 24, only miR-197 and miR-335#* performed better than chance 
(with 90% confidence) at predicting progression with AUC ROC 0.69 (90% CI 0.52, 0.85) 
and 0.71 (90% CI 0.52, 0.85) respectively.  Considering the three miRNAs of interest; 
MiR-22 had a sensitivity and specificity of 63% and 100% respectively, with an AUC ROC 
curve 0.68 (90% CI 0.48, 0.82).  MiR-22 did however result in a high Youden index, 
highlighting the importance of re-evaluating this in a larger sample size.  MiR-382 and 
miR-486-3p performed less well reflecting in poorer sensitivity and specificity analyses 
and AUC ROC curve 0.57 (0.40, 0.75) and 0.55 (0.36, 0.72) respectively.  
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Table 24 Baseline miRNAs expression as predictors for progression. 
miRNA Progressors vs. non-progressors 
 AUC ROC (90% CI) Sensitivity* Specificity* Youden J 
miR-16 0.59 (0.40, 0.75) 33% 92% 0.25 
miR-18a 0.55 (0.36, 0.72) 83% 42% 0.25 
miR-19a 0.53 (0.36, 0.72) 83% 42% 0.25 
miR-21 0.65 (0.44, 0.79) 50% 83% 0.33 
miR-22 0.68 (0.48, 0.82) 63% 100% 0.63 
miR-26b 0.53 (0.36, 0.72) 83% 50% 0.33 
miR-34a 0.63 (0.44, 0.79) 75% 58% 0.33 
miR-101 0.64 (0.44, 0.79) 83% 67% 0.50 
miR-132 0.66 (0.48, 0.82) 50% 92% 0.42 
miR-142-3p 0.53 (0.36, 0.72) 42% 75% 0.17 
miR-142-5p 0.58 (0.40, 0.75) 67% 67% 0.33 
miR-146a 0.65 (0.48, 0.82) 42% 92% 0.33 
miR-155 0.63 (0.44, 0.79) 75% 58% 0.33 
miR-195 0.63 (0.44, 0.79) 83% 50% 0.33 
miR-197 0.69 (0.52, 0.85) 92% 58% 0.50 
miR-203 0.60 (0.44, 0.79) 50% 83% 0.33 
miR-210 0.57 (0.40, 0.75) 92% 42% 0.33 
miR-223 0.60 (0.40, 0.75) 33% 92% 0.25 
miR-361 0.67 (0.48, 0.82) 67% 75% 0.42 
miR-374 0.51 (0.32, 0.68) 17% 92% 0.08 
miR-382 0.57 (0.40, 0.75) 75% 58% 0.33 
miR-454 0.53 (0.36, 0.72) 50% 67% 0.17 
miR-486-3p 0.55 (0.36, 0.72) 50% 75% 0.25 
miR-520c-3p 0.64 (0.44, 0.79) 58% 83% 0.42 
miR-579 0.68 (0.48, 0.82) 83% 67% 0.25 
miR-590-3P 0.54 (0.36, 0.72) 75% 50% 0.25 
miR-590-5p 0.58 (0.40, 0.75) 83% 42% 0.25 
miR-598 0.62 (0.44, 0.79) 33% 92% 0.25 
miR-628-5p 0.55 (0.36, 0.72) 17% 100% 0.17 
miR-15b#* 0.58 (0.40, 0.75) 83% 50% 0.33 
miR-335#* 0.71 (0.52, 0.85) 50% 92% 0.42 
*At cut-off that maximised Youden J (sensitivity +specificity-1), prioritising specificity if tied. 
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5.5 Discussion  
As identified in the literature review (section 2.2.2) and subsequent chapters, several 
characteristics have been considered as biomarkers for within at-risk cohorts.  However, 
this is the first miRNA study to be performed in individuals with autoimmunity at risk to 
progression to RA.  Previously, research groups have focussed on identifying specific 
miRNAs highly and/or uniquely expressed in (established) RA (Table 17). More recently, 
there have been studies evaluating the change in expression with therapy [251] as well 
as whether miRNAs can predict response to treatment [366].  Given the heterogeneity 
of RA, it is not surprising that these studies have included cohorts that have often been 
poorly characterised.  This at-risk study has aimed to improve the characterisation of 
the cohorts by limiting the inclusion criteria to those autoantibody positive individuals 
with no synovitis on ultrasound scan (as ultrasound synovitis can be considered 
immunopathologically closer to RA disease).  This enabled the recruitment of a clearly 
defined cohort in whom miRNAs identified were to be of importance in disease initiation 
or, conversely, may offer a protective function.  Furthermore, this study has enabled a 
unique opportunity to observe dynamics of miRNA expression associated with 
progression or non-progression to RA with the use of matched samples. The variability 
in laboratory and analytic techniques employed in miRNA studies makes reliability and 
comparison between studies challenging.  Steps have been taken to ensure a robust 
analytical approach has been adopted through working closely with a biomedical 
statistician.   
 
Global profiling of over 700 miRNAs in the pilot phase enabled a vast number of 
potentially influential miRNAs to be considered.  The expression of miRNAs across the 
continuum from health to RA or VERA identified several highly expressed miRNAs.  The 
hierarchical clustering analysis also suggested that the studied cohorts (HC, CCP+ and 
VERA) could be broadly distinguished on their miRNA expression.   As might be expected, 
the number of miRNAs that are dysregulated is greatest comparing health to VERA (12 
upregulated, 1 downregulated) as opposed to health and CCP+ (4 upregulated, 4 
downregulated).  Similarities between the two states compared to health were seen 
with miR-142-3p, -520c-3p, -590-3p and -628-5p which were upregulated and miR-197 
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which was downregulated in both CCP+ and VERA cohorts.  However, the within patient 
change from CCP+ to VERA in matched samples for these miRNAs did not meet criteria.  
This may be a consequence of significant biological change already present in the CCP+ 
state.  The results suggest that transition from health to a state of active inflammation 
(VERA) requires additional miRNAs to be activated compared to states of autoimmunity 
without inflammation (CCP+ arthralgia).  Although disease onset and inflammation 
cannot be solely accounted for by the change in miRNAs reported, their association with 
inflammation requires further investigation in larger cohorts.    
 
MiRNAs role in disease initiation was explored through the matched sample component 
of the pilot phase.  The three miRNA (miR-22,-382, 486-3p) that met the study criteria 
were significantly upregulated from CCP+ to VERA and offer insights into a mechanistic 
role in RA initiation.  However, due to logistical difficulties having two time point samples 
to measure change in expression, their clinical utility as biomarkers may be limited.   
 
The validation phase enabled the 31 miRNAs of interest to be evaluated in a new cohort 
of matched samples.  Establishing whether the changes identified in the progressors 
were unique to transition from CCP+ to VERA was achieved through observations in an 
additional cohort of CCP+ non-progressors.  This cohort also allowed for insights into 
how miRNAs may be used as biomarkers.  It is acknowledged that the non-progressors 
findings have not been validated.  Comparisons across the cohorts resulted in 4 miRNAs 
being validated from the pilot phase.  These were within the VERA to health comparisons 
and include miR-22 (FD 9.8).  Similarly, in the comparison of CCP+ (progressors) and 
health, miR-22 was also upregulated (FD 11.3).  Notably, upregulation in the non-
progressor CCP+ group was not demonstrated.  This provides further evidence to 
support miR-22 role in disease initiation and inflammation.   In order to ascertain 
whether this miRNA could have a biomarker role in predicting progression, sensitivity 
/specificity and area under the curve ROC analysis was performed.   Despite a specificity 
of 100% (sensitivity 63%) and a moderately good AUC ROC score, the 90% confidence 
interval crossed 0.5 and therefore suggests it is no better than chance at predicting 
progression.  This may be due to the small sample size and certainly requires further 
examination in a larger cohort in light of the good Youden Index score.  Of the remaining 
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signature miRNAs from the pilot phase, miR-382 showed similar expression while miR-
486-3p had higher expression in the non-progressors.  These findings are difficult to 
interpret given the small sample size and warrant further review in a larger cohort.   
 
In the validation matched analysis, expression levels of the signature miRNAs did 
demonstrate consistent upregulation in the progressors. However, these did not meet 
the study’s predefined criteria.  Initially adopting such stringent criteria allowed highly 
dysregulated miRNAs to be identified and assisted in filtering out intermediary levels.  
MiR-486-3p and MiR-22 had a FC of ≥2 in the validation phase – it should be noted that 
this is a value that is consider to be of biological significance in the field and therefore 
should not be discounted.   
 
The role of this new cohort in the validation phase was to ascertain the change in 
expression levels of the miRNA of interest.  It was hypothesised that the miRNA with the 
greatest levels of change in the progressor cohort would demonstrate stable expression 
in the non-progressor cohort.  In fact, the results indicated that two of the three key 
miRNAs were upregulated to some degree in the non-progressors.   One can speculate 
that these miRNAs are therefore upregulated throughout the cohort over time and are 
a feature of autoimmunity (CCP positivity) and at-risk states rather than being associated 
with progression to inflammatory disease.  Furthermore, recognition of the dynamic and 
evolving nature of this cohort of individuals is important.  Although no progression had 
occurred during observation period, individuals remain on a continuum and there is the 
possibility that they may evolve to inflammatory disease in the future and hence some 
upregulation is plausible.   
 
Although this analysis has not had sufficient sample size to allow for inclusion of miRNAs 
within a predictive model, association with clinical variables has been considered.  All of 
the 3 miRNA identified in the pilot phase were associated with the patient reported 
disease visual analogue score.  MiR-382 and -486-3p were also associated with tender 
joint and disease activity scores (DAS28ESR).  Interpreting these finding remains difficult.  
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However, the fact associations exist with other clinical variables that assist in the 
diagnosis of inflammatory arthritis is encouraging.   
 
The miRNAs previously reported to be associated with inflammation (miR-146a and -
155) were found to be upregulated in our pilot study, although not sufficient enough to 
be part of the predictive signature. There was negligible upregulation in the validation 
phase.  This is perhaps unsurprising as it is the first time a matched pre-RA to RA 
population has been studied, and we would anticipate that different miRNAs might be 
involved in disease initiation compared to previously studied established disease 
cohorts. Furthermore, techniques to measure miRNAs in sera have only been 
established relatively recently.  Previous studies have predominantly focused on 
synovial tissue/fluid and whole blood expression rather than sera.  Therefore, miRNA in 
the sera may be unlikely to be the same as those found within the joint.   
 
It is apparent from reviewing the literature that analysis of pre and post progression to 
disease data are limited.  This is undoubtedly due to the lack of availability of such 
unique samples.   Studies of other ‘pre-disease’ states have considered the utility of 
miRNAs in differentiating at-risk individuals e.g. Barrett’s oesophagus prior to 
development of oesophageal malignancy [253].  These have been cross sectional and no 
study investigating the change in miRNA expression in an individual pre- and post- 
disease onset.   Within the field of autoimmunity, a recent cross-sectional project 
evaluated the expression of MiRNAs associated with development of lymphoma in 
primary Sjogrens syndrome (PSS) [370].  In this study, 12 PSS patients with lymphoma, 
12 PSS patients without lymphoma, and 12 healthy controls were considered.  MiRNA 
array profiling revealed a clear clustering of the 3 subject groups with 44 dysregulated 
miRNAs.  The expression levels of these 3 miRNAs (with the highest FC) enabled 
sufficient differentiation of PSS patients with lymphoma from those without.  Certainly, 
for identifying biomarkers this is the optimum methods to adopt.   In comparison, the 
use of matched samples would provide insights into potential mechanistic processes 
involved in disease initiation.  
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The possible functional role of the three miRNAs identified has been preliminary 
assessed using the bioinformatics platform MetaCoreTM which considers pathway 
prediction for miRNAs  (LO conducted analysis).  The expanded networks generated for 
miRNAs of interest represent predicted targets.  Canonical interaction between the 
transcription factor p53 and miRNA-22 is highlighted; p53 plays a central role in a 
number of cellular functions, and is overexpressed in RA synovial tissue, and also 
activates miR-22 by binding to its promoter region.  Predicted network shows that MiR-
486-3p has an inhibitory effect on the bone morphogenetic protein 1 (BMP-1), indicative 
of miRNA function. MiR-382 negatively regulates the phosphatase and tensin homolog 
PTEN, which is upstream of the AKT/mTOR signalling pathway.  This analysis assists 
development of potential functional work focusing on these miRNAs.   
 
MiR-22 has been highlighted as a potential biomarker of disease, whilst its change in 
matched samples suggests a possible mechanistic function.  MiR-22 was originally 
reported as a tumour supressing miRNA  [371, 372].  Recently, studies have reported its 
role in oncogenic disease development of several cell lines including those associated 
with lung, colorectal and hepatocellular carcinoma [373-375].  Its pathway response 
with the transcription factor p53 may account for these functions.  The tumour 
suppressor protein p53, plays a central function in cell cycle regulation, DNA repair, and 
apoptosis and has been shown to engage miRNAs for tumour suppression including miR-
22 [376].  Somatic mutations in p53 and its overexpression has been observed in RA 
synovial tissue [377, 378].  There are no studies reporting on serum miR-22 levels in RA, 
however one group has identified an interaction of p53 and miR-22 with regulation of 
Cyr61.   In synovial samples the secretion of the extracellular matrix protein Cyr61 by 
FLS has been shown to i) contribute to the hyperplasia of synovial lining and ii) 
perpetuate the IL-6/Th17 inflammatory cycle [379, 380].  Subsequently, a novel 
mechanism has been identified in which Cyr61 production is regulated by p53 via its 
activation of miR-22 [381].  MiR-22 was shown to target and inhibit Cyr61 expression, 
resulting in the negative correlation with Cyr61.  The authors demonstrate that in RA, 
mutant forms of p53 are unable to activate miR-22 transcription.  The reduction in miR-
22 leads to uninhibited expression the Cyr61 contributing to proliferation of FLS and 
inflammatory Th17 pathways.  Within this study low levels of miR-22 are reported at the 
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synovium.  As previously alluded to, it is difficult to correlate finding from synovial level 
studies in established RA to that of serum studies in at-risk individuals.  However, the 
potential of miR-22 in the pathogenesis of RA supports further validation within at-risk 
cohorts.     
 
5.6 Limitations  
When working with a unique study cohort one of the most challenging aspects is 
devising a project which provides sufficient numbers for statistical or meaningful 
analysis.  The modest numbers and subsequent limitations is acknowledged.  This 
project has involved a well-phenotyped group of individuals with positive 
autoantibodies, no clinical synovitis, and in addition no ultrasound evidence of synovitis 
(as deemed by absence of PD).  The numbers included in the pilot phase reflect common 
practice for exploratory phases of studies.  However, a greater number of samples would 
have ideally been incorporated in the validation study.   At the time of random selection 
of samples the number within the cohort with no Power Doppler on baseline imaging 
was 91/136 (66.9%).  This included both individuals that progressed and those that did 
not.  Within the progressor group (n=57 of the 136 (42%)) only 29 of these individuals 
had no PD at baseline.  The availability of samples for eligible individuals was a further 
limitation as specific time points were occasionally not available. This limited the 
number of individuals eligible for random selection and entry into the validation phase.   
 
In the validation phase, imputation of undetermined Ct values was performed by the 
departmental statistician.  The authors of this statistical software package used reported 
how undetermined values of >40 were actually miRNAs that failed to amplify rather than 
lack of presence.  The package uses the observed values in the dataset to determine the 
likely undetermined values. This allowed a mean value of all the Cts within the triplicate 
to be determined.  This may be considered a possible solution to handing undetermined 
values.   
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This study followed the accepted format for miRNA studies with a pilot phase evaluation 
of a large number of miRNA via global profiling followed by a focused validation phase.  
Global profiling generates a vast amount of data and is an expensive approach not 
feasible for larger clinical cohorts.  Therefore, for validation, custom cards plates are 
frequently used in which a selection of the miRNAs of interest are evaluated.  Use of 
custom cards and difference in normalisation techniques may account for the 
differences found in expression of miRNAs in the validation phase.  In the pilot phase, 
normalisation was achieved by calculating the average value across total expressed 
miRNAs for each sample (Normfinder software).  Whereas, with custom cards in 
validation phase, the manufacturers’ recommendation to use the mean of the 3 
endogenous control replicates (RNU6) was applied.  It is acknowledged that in this and 
similar translation projects the analytical approaches can be very disparate.  In order to 
ascertain the degree of correlation between these normalisation methods, future 
studies are required.   
 
Use of global profiling and then custom cards is common place in PCR/miRNA studies.  
The manufactures of the custom cards and the global profiling plates are the same and 
hence deemed transferable.  However, in this study, no specific quality control 
experiment was performed to ensure uniformity in the two types of plates used.  Ideally, 
additional experiments should have been conducted allow for several pilot phase 
samples analysed on the global profiling cards to be run on the custom cards and vice 
versa for the validation phase.  This would produce ddCts for each miRNA of interest 
generated using both methods.  This would allow for direct comparisons and quality 
control.  It would be expected that a moderate degree of correlation would be achieved 
between the two methods.  Retrospective analysis may not be beneficial given that 
experimental conditions may fail to replicate those at the time of the initial study e.g. 
age of reagents, quality of samples.    
 
Alternatively, the limitations listed above could be eliminated by applying global 
profiling cards in both phases, thus enabling the same normalisation method and cards 
to be used.  However, this would have considerable financial implications and it would 
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not be realistic to anticipate clinical utility of such a test to be made transferable at such 
costs.   
 
Despite efforts to ensure the cohorts between phases were similar clinically, the 
variation in methods to analyse miRNA expression in the two phases may account for 
the difference in expression.   
 
5.7 Key points 
 Individuals can be broadly distinguished by their serum miRNA expression from 
health to at-risk (CCP+) and on to early arthritis (VERA), although expression 
remains varied.   
 The use of matched samples prior to and at point of inflammatory arthritis 
enabled insights into the mechanistic role of specific miRNA. The 3 miRNA 
identified in the pilot phase failed to meet the study criteria in the validation 
phase.  However, miR-486-3p and miR-22 did have a FC >2, a potentially 
biologically significant result.    
 Within a cohort of at-risk individuals (CCP+ progressors and non-progressors), 
MiR-22 has potential as a biomarker to differentiate those at risk to arthritis 
development.  
 
5.8 Conclusions 
The findings and limitations identified by this work demonstrates the challenges 
common place in translational research. It is acknowledged that despite attempts to 
accurately phenotype individuals, there is likely to still be heterogeneity within cohorts.   
It is also apparent that the inconsistencies in experimental and analytical methods 
within this area may impact the validity of these and other published results.  At this 
time, an exact miRNA signature cannot be easily defined.  Instead there are several 
miRNAs which are expressed during the CCP+ state and on through to progression to 
VERA.  This is the first study which has adopted a comprehensive miRNA array method 
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to consider miRNAs in an at-risk cohort.  The use of matched samples has allowed for 3 
miRNAs to be identified that appear to be associated with autoimmunity (at risk to RA) 
and the progression to RA inflammation.  In particular, miR-22 potentially has utility in 
identifying which individuals within an at-risk cohort may progress to inflammatory 
arthritis.   
 
Further clarification and validation of these findings will be possible through analysis of 
MiRNA expression in larger cohorts alongside additional functional work of the 
candidate miRNAs.   A further area of interest would be to widen the inclusion criteria 
to include those individuals with autoimmunity and ultrasound evidence of synovitis but 
not clinical detectable synovitis.  This may not have a biomarker role but perhaps offer 
insights into the changes occurring along the IA continuum.  It would be expected that 
individuals with ultrasound detected synovitis would have a similar miRNA profile as 
those with VERA and provide further evidence that these are individuals that warrant 
therapy.   
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6. T-cell subsets in individuals with systemic autoimmunity and 
arthralgia: an immunological biomarker. 
This chapter describes the immunological phenotyping of individuals within the at-risk 
cohort using T-cell subset.  Use of a prospective study design allowed statistical 
modelling to be performed to quantify and qualify whether T-cell subsets predicted 
progression to IA.  Work featured in this chapter has been peer reviewed and published 
[382]. 
 
6.1 Introduction  
The exact pathogenesis of RA remain uncertain, although immune cells and their 
interactions are thought to be essential [383].   The affiliation of disease with 
autoantibodies and the mechanisms for major histocompatibility complex linkage 
support the T-cell driven concept.  The demonstration of multiple immune cells within 
the RA synovium, particularly high levels of both CD4+ and CD8+ T-cells, further endorse 
the potential pathogenic role of T-lymphocytes [384-386].   More recently, the 
identification of T-cell related genes and disease response to T-cell modulation therapy 
has strengthened this view point [383, 387-389].  As research in the field has evolved, 
there is mounting evidence to suggest that T-cells are not the only mechanism of disease 
initiation and perturbation [390].    
 
T-cell subset quantification is one method of gaining insight into the immune status of 
patients with RA [391].  Of the subsets, regulatory T-cells (Treg), defined as 
CD4+CD25+FOXP3+ have been the focus of many studies [247, 392-394].  Their 
capability of suppressing T-cell activation, proliferation and effector function facilitates 
the maintenance of self-tolerance and regulation of autoimmune responses.  In synovial 
fluid, studies have demonstrated increased Treg cell numbers, suggesting a migration 
and expansion of Tregs to the synovium.  In peripheral blood studies the findings have 
been less consistent, although differences in phenotype of RA individual evaluated (early 
disease vs established and untreated vs DMARD), may account for some of the 
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inconsistencies [247, 394-396].  Furthermore, as experience within the field has grown, 
the cell markers used to define cell populations have evolved.   A highly purified 
population of Treg cells are can be identified using cell markers CD4+, CD25high, Foxp3+, 
CD127low [397, 398]. 
 
Inflammation has a direct effect on T-cell differentiation in RA. Work from Leeds and 
other centres has focussed on the significance on CD4+ T-cells including naïve T-cells 
[399].  It is postulated that inflammation acting on the thymus causes a reduction in 
circulating naïve cells [399, 400].  Initial findings demonstrated a reduction of both naïve 
and regulatory CD4+ T-cell frequency in the peripheral blood of individuals with active 
RA [247, 399].  Evaluation of T-cell subsets in patients along the IA continuum has 
demonstrated naïve CD4+ T-cells to be an important T-cell biomarker for treatment 
response [248-250].  Sustained remission was associated with low levels of 
immunological dysregulation (as defined by higher proportions of naïve and Treg cells), 
suggesting that once immunological equilibration is achieved successful withdrawal of 
therapy is possible [249].  Specific levels of T-cells subsets have been shown to predict i) 
methotrexate-induced remission [250], ii) relapse following DMARD-induced remission 
[248], and iii) discontinuation of TNF-blockers in RA individuals without subsequent flare 
[249].   
 
In addition to Treg and naïve cells, a novel T-cell subset expressing both naïve and 
memory differentiation markers was noted in the peripheral blood of RA individuals.  
Retention of cell markers CD45RA and CD45RB suggested that these were immature T-
cells.  These  so-called, inflammation-related cells (IRC), occur following differentiation 
of naive T-cells into other subsets influenced by pro-inflammatory cytokines such as IL-
6 and TNF [399].  Other groups have reported a similar subset and demonstrated 
through functional work that they can express chemokines receptors such as CXCR4 
[401-403].  In active RA, IRC frequency in the peripheral blood correlates directly with 
systemic levels of inflammation as measured by CRP [399].  In vitro studies have 
demonstrated that IRCs isolated from synovial samples express chemokine receptors 
(that direct them towards inflamed tissue when disease is active [248].  Unexpectedly, 
their presence has also been observed in patients with RA in remission [248].  In these 
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patients, however, the IRCs did not proliferate or act as responsively as in active disease.  
In this population, their presence was associated with flare of disease within 18 months.  
It is proposed that in the remission setting, detectable IRCs in the peripheral blood are 
a product of T-cells released from the synovium which have a resistance to apoptosis.  
They remain in the circulation and are primed for reactivation with the next 
inflammatory trigger or event.  Their measurement and prognostication value has not 
been assessed in individuals at risk of IA/RA.  
 
This programme of work considers the potential of T-cell subsets (consisting of naïve, 
Treg and IRC) as a biomarker to predict progression to IA in at-risk individuals. 
  
6.2 Aims and overview 
The aim of this study was to report on the extent of T-cell subset dysregulation in CCP+ 
individuals with non-specific musculoskeletal symptoms (from a single baseline blood 
sample) compared to healthy individuals.  Furthermore, the study looked to establish 
whether dysregulation was associated with progression to IA.  Given that a clinical model 
for progression to IA has already been reported (Section 2.3 and [217]), it was important 
to determine the confounding effect of clinical parameters on any T-cell model that was 
generated.   It was hypothesized that in CCP+ individuals with non-specific symptoms, 
those with the greatest T-cell subset dysregulation (as determined using naïve CD4+T-
cells (naïve), inflammation related cells (IRC) and regulatory T-cells (Treg) quantification) 
would have a greater propensity for progression to inflammatory arthritis.  Immune 
dysregulation is one of the primary events in disease onset.  It was therefore 
hypothesized that an early predictor of disease progression could be dysregulated T-cell 
subsets. 
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6.3 Patients and Methods  
6.3.1 Patients 
Individuals who were CCP+ and had non-specific musculoskeletal symptoms were 
recruited for the study as detailed in the methods chapter (Section 3.4 Study 
Population).  One hundred and three participants were recruited.  Inclusion required 
both a valid sample for T-cell subset quantification at baseline and prospective follow-
up for over 6 months duration.  One hundred and six individuals (known to be anti-CCP 
negative) formed a healthy control group for comparison.   
 
6.3.2 Clinical Assessments: 
All participants provided baseline demographic details, patient questionnaires, and 
clinical history of symptoms and had a clinical examination by a rheumatologist (LH & 
CR) which included a joint count.  Individuals then followed the study schedule as 
outlined in Section 3.5 Study Protocol. Individuals attended 3 monthly visits for the first 
year and as clinically indicated thereafter for up to 6.5 years.  Participants were able to 
attend in between visits if they developed any new symptoms.  A number of blood tests 
were undertaken at baseline including inflammatory markers and HLA status.  HLA-DRB1 
shared epitope status (low-resolution) was considered positive in the presence of one 
or two copies of the following alleles: HLA- DRB1*01, DRB1*04 and DRB1*10 in the HLA-
DRB1 locus [404, 405].  All the clinical parameters that had been used in the initial clinical 
prediction model were performed.  However, baseline ultrasound data was not available 
for all the participants.   
 
6.3.3 Laboratory Methods: 
6.3.3.1 T-cell subset analysis:  
Peripheral blood (up to 6mls) was collected into standard vacuettes containing ethylene 
diamine tetracetic acid (EDTA) solution and processed for red cell lysis within 2 hours of 
collection. Following red cell lysis, six-colour flow cytometry was performed on 
peripheral blood mononuclear cells using several cell markers (Box 5 & Figure 25). The 
antibodies used for each panel are listed below; identification of naïve and IRC CD4+T-
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cell subsets required CD45RB-FITC (clone MEM-55, Serotec, Oxford, UK), CD45RA-PE 
(clone F8-11-13, Serotec), and CD62L-APC (clone 145/15 Coulter, High Wycombe, UK). 
Tregs quantified by cell surface marking for CD4-Pacific blue (clone RPA-T4, BD, Oxford, 
UK), CD25-APC (clone 2A3, BD) and CD127-PE (R34.34, Beckman coulter), followed by 
intracellular staining for FOXP3-FITC (clone PCH101 eBioscience, San Diego, CA) using 
the anti-human Foxp3 staining kit (Insight Biotechnology, Wembley, UK).  
The flow cytometry analysis was performed on a LSRII cytometer (BD), using BD 
Biosciences FACSDIVA software.  Subset frequencies were reported as percentage of 
gated CD3+/CD4+ T-cells.   
Flow cytometry gating was performed by a senior colleague (FP).   
 
Box 5 T-cell Subset flow cytometry markers 
T-cell subset Cell markers  
Naïve CD4+T-cells CD4+, CD45RBhigh, CD45RA+, CD62L+ 
T-regulatory cells  CD4+, CD25high, Foxp3+, CD127low 
Inflammation Related Cells CD4+, CD45RBhigh, CD45RA+, CD62L− 
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Figure 25 Flow cytometry gating strategies 
Reprinted by permission from BMJ Publishing Group Ltd [250]. 
The top panels represent flow cytometry analysis of naïve cell & IRC frequency. For naïve cell and 
IRC subsets, CD4+ T-cells were gated using double positivity for CD3/CD4. High expression of 
CD45RB was used to gate CD4+/CD45RBhigh cells and the gate was applied to a dual plot of 
CD45RA and CD62L. The bottom panels represent flow cytometry analysis for Tregs. CD4+ T-cells 
were gated using scatter properties and CD4 levels. Tregs were quantified using high expression 
of CD25 and Foxp3. The Treg phenotype was confirmed by documenting a low level of CD127 
expression.  
 
6.3.4 Statistical analysis: 
 
Reference limits for the T-cell subsets 
Reference limits for each T-cell subset were calculated (lower 95% limit of normal for 
naïve cells and Tregs, upper 95% limit of normal for IRC) using data from 106 healthy 
controls.  This involved multiple linear regression to assess whether T-cell subset 
frequencies varied with age or sex. Where associations with age were found, one-sided 
95% prediction intervals for the association were obtained by calculating two-sided 90% 
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intervals and discarding the upper or lower interval accordingly; a 90% confidence 
interval around the prediction interval was calculated. Otherwise, the 5% or 95% centile 
and 90% confidence interval were calculated. T-cell subset frequencies found to be 
skewed were log transformed prior to analysis. Back-transforming to the original units 
yielded asymmetric confidence intervals. 
 
Description of T-cell subsets compared to health: 
The development of reference limits allowed the dichotomisation of T-cell subset values 
as normal or abnormal. One-sample binomial tests were used to assess whether the 
proportion with abnormal value differed from the expected 5%.  Analysis was restricted 
to patients with complete T-cell subset data.  Pearson’s Chi-square test was used to 
identify associations between shared epitope and T-cell subset abnormalities.   
 
Unadjusted associations between T-cell subset frequencies and progression to IA: 
Non-parametric area under the receiver operator curve (ROC) was calculated for each 
subset.  Additionally, sensitivity and specificity of each subset for predicting progression 
to IA at any time during follow-up were calculated, with 95% confidence intervals 
estimated by the Wilson method.  
 
Adjusted associations between T-cell subset frequencies and progression to IA: 
Binary logistic regression models of the occurrence of progression to IA and Cox 
proportional hazards models of time to progression were constructed to adjust for the 
following variables, 1) age; 2) SE status (negative/positive); 3) smoking (never/ever); 4) 
CCP titre. Clinical variables from a previously published model were also considered 
[217].  These included, physician assessed small joint tenderness (absent/present) and 
duration of early morning stiffness (<30 minutes/≥30 minutes). Models were produced 
sequentially to investigate the effects of adding in covariates. 
 
An adjusted model containing only the T-cell subsets and age was specified (model 1). 
This was compared to the published clinical model (model 2) and subsequently a 
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combined model consisting of both clinical and T-cell subsets (model 3). Analysis was 
first performed on the subset of patients with complete data to test model performance. 
Akaike Information Criteria (AIC) values were used to compare different models (lower 
AIC value indicates a superior model).  To account for any missing data, analysis was 
repeated following multiple imputation with chained equations in 20 complete datasets. 
The general results were combined according to Rubin’s rules.  Predictive mean 
matching was used as the imputation model for all continuous variables; for binary 
variable, logistic regression was used.  
 
The predicted probability of progression obtained from the final logistic regression 
model (model-3) was calculated for patients with full data.  Patients were then 
categorised as being at low (<20%), moderate (20-80%) or high risk (>80%). Kaplan-
Meier plots and associated log-rank tests were then produced for time to progression, 
using these risk groups.   
 
Power calculation 
Previous studies from the literature informed the numbers required for development of 
clinical reference ranges/limits [406].  For the logistic regression modelling of 
progression to IA the same statistical approach was taken as the previously published 
clinical model [217].  Guidance recommends that there are at least 10 cases in the 
smallest outcome category (‘events’) per variable (EPV) [407].  Subsequently, the final 
analysis was performed once there was sufficient follow-up and hence ‘events’, in this 
case progression to IA.  It was proposed that T-cell abnormality would form a single 
variable alongside the previously established variables – early morning stiffness, joint 
tenderness and >3 x upper limit of normal antibody titre.  Therefore at least 40 events 
were required.   
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6.4 Results 
6.4.1 Patient Characteristics 
Forty eight of the 103 (46.6%) patients developed synovitis during follow-up, with the 
majority of individuals, 30/48 (62.5%) progressing within 12 months. Baseline clinical 
and demographic data are presented in Table 25. 
Table 25 Clinical characteristics of CCP+ individuals.  
Characteristic Result           
Progressed (ever): % (n) 46.6% (48) 
Duration of follow-up (months) median 
(range) 
18.4 (0.1 to 79.6) 
Age (years) mean (SD; range) 52.6 (11.7; 27 to 79) 
Female: % (n) 71.8% (74) 
SE positive* :  %(n)  73.5% (72) 
High positive CCP+ and/or RF ‡:  % (n) 85.4% (88) 
Smoker: % (n)             
    Non- 
                                                     Ex- 
    Current 
 
30.1 (31) 
41.7 (43) 
28.2 (29) 
EMS≥30 mins: % (n) 34.0% (35) 
Small joint symptoms: % (n) 43.7% (45) 
CCP cyclic citrullinated peptide; EMS early morning stiffness; IRC inflammation-related cells; RF 
rheumatoid factor; SE shared epitope. *available in 98/103 patients.   ‡determined as >3 X 
upper limit of normal   
 
6.4.2 Reference Limit 
Samples from 106 healthy controls enabled the development of reference limits for each 
T-cell subset.  The following section details the development of the reference limits.  
Descriptively, naïve cell frequency was lower in older HC [399] but did not differ by 
gender (Figure 26 and Table 26).  IRC were not related to demographic parameters 
(Figure 27). A clear positive association was found between Treg frequency and age 
(Figure 28, Table 27). There was no difference by gender.  
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Naïve cells 
Naïve cell frequency was available for 106 controls; mean (SD) age 43.54 (12.52), range 
19 to 69.  There was no significant evidence that naïve cell frequency differed between 
males and females [age-adjusted difference (95% CI) -1.44% (-4.77%, 1.89%); p=0.392], 
or that its association with age differed by sex [difference in slope -0.02% (-0.24%, 
0.27%) per year; p=0.910].  However, there was a highly significant tendency for naïve 
cell frequency to be lower in older people [slope -0.54% (-0.67%, -0.42%) per year; 
p<0.001]. The reference limit was therefore adjusted for age but was not stratified by 
sex.  
 
Figure 26 Scatter plot of naïve cell frequency (% of CD4+ T-cell) and age. 
Solid line = Lower limit of normal, Dashed line = 90% CI 
 
To calculate a one-sided 95% prediction interval, a two-sided 90% interval was 
calculated and the upper limit discarded.  The naïve lower limit of normal (LLN) and 
corresponding 90% confidence interval around it were calculated as LLN. 
Table 26 Lower limit of normal naïve cell frequency for ages in the range 25 to 65 years 
Age Lower limit of normal (90% CI) 
25 36 (34, 39) 
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30 34 (31, 36) 
35 31 (29, 33) 
40 28 (26, 30) 
45 26 (24, 28) 
50 23 (21, 25) 
55 20 (18, 22) 
60 17 (15, 20) 
65 14 (12, 17) 
 
Outside this range of ages, it is possible that the association between age and naïve cell 
frequency may not be linear; therefore, more data is required for controls aged under 
25 or over 65.  The lower limit for these age groups are not provided.  
 
Inflammation-related cells (IRC) 
IRC frequency was available for 101 controls; mean (SD) age 43.50 (12.69), range 19 to 
69. Data was log transformed prior to analysis. There was no evidence that IRC differed 
between males and females [geometric mean ratio 0.98 (0.68, 1.41); p=0.900] or varied 
with age [change -0.41% (-1.73%, 0.93%) per year; p=0.544]. The calculated 95% centile 
and its 90% confidence interval (back-transformed to original units) were found to be 
3.70 (3.30, 7.00).  This corresponded to the upper limit of normal for IRC. 
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Figure 27 Scatter plot of IRC cell frequency  (% of CD4+ T-cell) and age. 
Solid line represents the upper limit of normal.  
 
T-regulatory cells (Tregs) 
Treg cell frequency was available for 98 controls; mean (SD) age 44.09 (12.30), range 19 
to 69.  There was no evidence that T-regulatory cell frequency differed between males 
and females [age-adjusted geometric mean ratio 1.03 (0.82, 1.22); p=0.976], or that its 
association with age differed by sex [ratio of differences in slope 1.00 (0.99, 1.02); 
p=0.677].  However, there was a statistically significant tendency for Treg cell frequency 
to be higher in older individuals [by 1.22% (0.50%, 1.94%) per year; p=0.001]. The 
reference range was therefore adjusted for age but was not stratified by sex.  
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Figure 28 Scatter plot of ln-transformed Treg frequency (% of CD4+ T-cell) and age. 
Solid line = Lower limit of normal, Dashed line = 90% CI 
 
Table 27 Lower limit of normal Treg cell frequency for ages in the range 25 to 65 years 
Age Lower limit of normal (90% CI) 
25 1.71 (1.46, 2.00) 
30 1.83 (1.59, 2.10) 
35 1.95 (1.72, 2.21) 
40 2.08 (1.86, 2.33) 
45 2.21 (1.98, 2.47) 
50 2.34 (2.09, 2.63) 
55 2.48 (2.18, 2.82) 
60 2.62 (2.26, 3.03) 
65 2.76 (2.33, 3.25) 
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This data allowed dichotomisation of values observed in CCP + individuals as within or 
below the normal range for naïve T-cell and Treg (defined by the lower limit of normal 
(LLN)) and within or above normal range for IRC (defined by the upper limit of normal 
(ULN)). 
 
6.4.3 Unadjusted T-cell analysis  
There were no abnormal lymphocyte counts in this cohort of individuals. The CD4+ T-
cell numbers did not differ between progressors and non progressors. 
 
6.4.3.1 Comparison to health: 
T-cell subsets of CCP+ individuals were categorised as normal if values fell within the 
95% confidence limits of normal healthy controls.  
 
Figure 29 represents the proportions of patients with abnormal T-cell subsets.  If values 
in the CCP+ patients were similar to those of controls, then no more than 5% of patients 
would be expected to have values outside the reference limit.  The dotted line denotes 
the expected proportion of abnormal values. 
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Figure 29 Proportions of patients with abnormal naive, IRC and Treg cell frequencies 
  
Descriptively, CCP+ individuals demonstrated reduced naïve and Treg cells frequencies 
with elevated IRCs compared to health.  In subjects with full T-cell data available 
(n=95/103), this variance from health was significant in each of the 3 T-cell subsets 
(Table 28, P<0.001 for all 3 subsets).   
 
6.4.3.2 T-cell subsets in CCP+ individuals 
Considering the frequency of abnormalities, over a third of CCP+ individuals had no T-
cell abnormalities (37.9%), 40.0% had one, and the remaining subjects had two (18.9%) 
and three (3.2%) T-cell abnormalities (Table 28).   
 
The figures below (Figure 30 & Figure 31) represents the proportion of patients 
progressing to IA according to (i) the T-cell subset status measured at baseline and (ii) 
the number of abnormal T-cell subsets.  Data are presented as progression within 12 
months and progression ever.   The descriptive data suggest that a greater proportion 
of progressors have abnormal T-cell subsets compared to normal.  Furthermore, those 
with the greatest dysregulation (2-3 abnormal T cell subsets) account for the largest 
proportion of progressors.   
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Figure 30 Proportions of patients progressing to IA within 12 months, or ever during 
follow-up, according their T-cell subset status at baseline 
   
 
Figure 31 Proportions of patients progressing to IA within 12 months, or ever during 
follow-up, according the number of abnormal T-cell subsets at baseline 
 
6.4.3.3 T-cell subset frequencies and progression to IA 
In an unadjusted analysis, the association between T-cells and progression to IA was 
considered.  The area under the receiver operator curve (AUC ROC) analysis 
demonstrated that T-cell subsets differed from 0.5 and were predictive individually, 
although weakly.  Naïve AUC=0.63 (95% CI 0.52, 0.74), IRC AUC=0.63 (95% CI 0.52, 0.74) 
and Treg AUC=0.66 (95% CI 0.55, 0.77, all p<0.03). The best individual predictor was 
Treg, then naïve calls and lastly IRC (Table 28).  
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For each subset, the sensitivity and specificity for the eventual progression to 
inflammatory arthritis was calculated.  Individually, naïve, IRC and Treg subsets 
demonstrated high specificities (Table 28, 71.7 – 83.0 %) for prediction of progression 
to IA, but had relatively low sensitivities (28.6 – 45.2%).  
 
Consistent with the AUC ROC analysis, the unadjusted OR for all three subsets indicated 
that each subset was associated with progression to IA, where no adjustment was 
provided other than age (naïve and Treg) (Table 28).  Higher naïve cell and Treg 
frequencies were protective (OR 0.94 95% CI 0.90, 0.98; OR 0.70 95% CI 0.56, 0.89 
respectively), as would be expected.  Higher IRC frequencies were associated with 
increased odds of progression (OR 1.15 95% CI1.00, 1.32), although the confidence 
interval includes one and therefore should be interpreted cautiously.  
Table 28 Unadjusted T-cell analysis of progression to IA 
 
Reduced naïve 
cell frequency 
Elevated IRC 
frequency 
Reduced Treg 
cell frequency 
Observed proportion of 
patients  (observed/n) 
22.5% 
23/102 
30.3% 
30/99 
35.4% 
35/99 
Calculated proportion† 
95% CI 
standardised binomial test z 
p  
22.1% 
14.2%, 31.8 
7.4 
<0.001 
29.5% 
20.6%, 39.7 
10.7 
<0.001 
35.8% 
26.2%, 46.3 
13.5 
<0.001 
AUC ROC † 
95% CI 
p  
0.63 
0.52,0.74 
0.029 
0.63 
0.52,0.74 
0.032 
0.66 
0.55,0.77 
0.008 
Sensitivity † 
95% CI 
28.6 % 
17.2, 43.6 
35.7 % 
23.0, 50.8 
45.2 % 
31.2, 60.1 
Specificity † 83 % 75.5 % 71.7 % 
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95% CI 70.8, 90.8 62.4, 85.1 58.4, 82.0 
 
Naïve 
(per %)* 
IRC 
(per %) 
Treg 
(per %)* 
Unadjusted OR † 
95% CI 
0.94 
0.90, 0.98 
1.15 
1.00, 1.32 
0.70 
0.56, 0.89 
† in patients with data for all 3 T-cell subsets n=95,  *Adjusted for age,  AUC ROC=area under the ROC 
curve; OR=odds ratio 
 
6.4.3.4 Unadjusted analysis for time to IA 
Time to development of IA from unadjusted data was achieved using Kaplan-Meier plots 
and log rank tests.  These compared time to IA between those with and without 
abnormal T-cell subsets.  Additionally, log rank tests were used to determine whether 
the total number of T-cell abnormalities (0, 1, 2-3) were related to time to progression 
to inflammatory arthritis (Table 29). Analysis was restricted to the 95 individuals with all 
3 T-cell subsets.  
Table 29 Median time to IA according to T-cell subset status (normal/abnormal) and 
number of abnormal T-cell subset frequencies present. 
 
  Time to IA (months): median (95% CI)  
Subset Cut-off Normal Abnormal Log-rank test 
Naïve Less than LLN for 
age 
50.1 (33.6, 66.7) 34.1 (0.0, 68.6) Χ2=2.2, 
p=0.142 
IRC >3.7 50.1 (40.2, 60.0) 22.1 (11.5, 32.6) Χ2=1.8, 
p=0.184 
Treg Less than LLN for 
age 
46.5 (31.6, 61.3) 23.7 (1.1, 46.3) Χ2=2.3, 
p=0.126 
 Time to IA (months): median (95% CI)  
Number of abnormal 
subsets 
0 1 2-3 Log-rank test 
 52.4 (36.7, 
68.2) 
44.4 (16.5, 
72.2) 
15.4 (0.0, 
33.5) 
Χ2=5.54, 
p=0.062 
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Comparing each subset, individuals with abnormal subsets did correspond to a shorter 
time to inflammatory arthritis although not significantly.  However, considering the 
number of abnormal subsets there was some indication that time to inflammatory 
arthritis did differ between patients with 0, 1 or ≥2 abnormal subsets (Chi-square=5.54, 
p=0.062).  
 
Figure 32 A-C demonstrates the Kaplan-Meier plots associated to this analysis with time 
to IA dependent on each T-cell subset status.  Figure 33 depicts the Kaplan-Meier plots 
when number of abnormal T-cell subsets are considered.   In some of the plots the 
survival curves cross, suggesting violation of the proportional hazards assumptions.  This 
was noted at the 48-month time point, when the number of patients still observed had 
reduced.  This may affect the accuracy of the survival estimates beyond this point.  It is 
reasonable to consider restricting analysis to progression to IA at 12 months given the 
imminent nature of the cohort.  
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Figure 32 Kaplan-Meier plots of time to IA according to the status of each T-cell subset.   
Figure 31A – Naïve cell, Figure 31B - IRC, Figure 31C - Treg.  Green represents normal, represents abnormal, dotted line represent the 12 month follow up point
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Figure 33 Kaplan-Meier plots of time to IA according to number of abnormal T- cell 
subsets.   
Figure 32A - complete duration of follow up included.  Figure 32B – restricted to only 12 
months follow up.  Green represents zero abnormal T-cell subsets, yellow represents one 
abnormal T-cell subset and red represents two to three abnormal t-cell subsets. Dotted line 
represents the 12 month follow up point. 
 
 
6.4.4 Patterns of T-cell abnormality and associations with SE 
The unadjusted analysis suggests an association between T-cells and progression.  
However, there are a number of confounding factors such as the presence of SE as 
well as environmental elements, in particular smoking [119, 408, 409].  A preliminary 
analysis of 90 individuals with both SE and T-cell data available was performed.  Sixty-
nine (72.2%) were found to be SE positive.  There was no association at the 5% 
significance level, however descriptively a substantively greater proportion of SE 
positive patients had abnormally high IRC and low Treg frequencies with OR 2.51 (0.76, 
8.23) and 2.25 (0.79, 6.38) respectively, (chi sq=2.39 p=0.122 for both).  Furthermore, 
the frequency of abnormal T-cell subsets (out of 3) was substantially greater in SE 
positive individuals (Mann-Whitney U standardised test statistic z=1.47, p=0.143) 
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Table 30.  The low number available for this analysis limits the significance of these 
findings.  The descriptive data do suggest an association and certainly provide 
evidence that it should be considered in an adjusted analysis.   
Table 30 Proportions of patients with 1, 2, or 3 abnormal subset values according to 
SE status. 
 Number of T-cell subsets with abnormal values 
 1 2 3 
Shared epitope  
           Negative 
 
48.0% (12/25) 
 
8.0% (2/25) 
 
- (0) 
 Positive 33.8% (22/65) 24.6% (16/65) 4.6% (3/65) 
 
 
6.4.5 T-cell Model of Progression to IA 
An adjusted multivariable analysis was required to ascertain whether there is value in 
measuring T-cell subsets over the clinical parameters routinely collected in clinic.  
These clinical parameters have previously been used to construct a prediction model 
([217] and section 2.3).   
 
In total, data from 103 patients were included in the multivariable models.  Regression 
modelling was performed using T-cell subsets frequencies, controlling for age, SE, 
smoking status and clinical parameters, thus totalling nine predictor variables.  
Continuous T-cell data were used to retain as much information as possible.   
 
Several intermediate models were developed to investigate the effect of confounding 
factors, such as genetic (SE) and environmental factors (smoking).  Three primary 
models resulted for further consideration; a T-cell only model (model 1), a clinical only 
model (model 2) and a combined model (model 3), Table 31.   In the combined model, 
some clinical parameters were removed since they were shown to be less predictive 
in intermediate models (see Model 3 for details).  This allowed for a reduced number 
of variables given the limitation imposed by the relatively small samples size. 
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Model 1 (T-cell only) 
When all three subsets were included in a model with age (Figure 34 and Table 31), 
naïve cell and Treg were independently associated with progression. The effect of IRC 
was less prominent. The AUC ROC for the predicted probability of progression from 
this model was 0.75 (95% CI 0.65-0.85), which represents an improvement over the 
prediction for all 3 individual subsets (Table 28). 
 
Model 2 (clinical) 
The clinical model consisted of antibody status (RF and/or CCP titre 3x the upper limit 
of normal), EMS >30 minutes and physician assessed small joint symptoms [217]. 
Within this particular group of CCP+ patients with arthralgia, EMS was not 
independently associated with the odds of progression to IA (Table 31, OR 1 95% CI 
0.41, 2.42, p=0.997) discordant to the previously reported model.  However, 
autoantibody status and the presence of small joint symptoms were still associated 
with progression (Table 31, OR 4.66 95% CI 1.21, 18.05, p=0.026 and OR 2.65 95% CI 
1.14, 6.19, p=0.024 respectively). The AUC ROC for Model 2 was 0.62 (95% CI 0.54-
0.76) Figure 34. 
 
Model 3 (combined) 
Adding the T-cell subsets to the clinical model was challenging due to the relatively 
small sample size for the number of variables assessed [407]. In such cases, it is 
recommended that the least significant of the variables in the full model are removed, 
provided this does not substantially affect the ORs for the remaining variables [410]. 
Considering the variables from model 1, model 2 and the confounders of SE and 
smoking; EMS (p=0.553) and smoking (p=0.627) were the least significant and were 
therefore removed. Removing smoking and EMS from the model did not substantially 
affect the ORs for the remaining variables.  Age was retained (p=0.668) because its 
removal affected the ORs for naïve cell and Treg.   
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Following adjustment for age, SE, autoantibody status and joint counts, both naïve cell 
and Treg frequencies remained independently associated with the odds of 
progression (Table 31, OR 0.94 95% CI 0.89, 0.98, p=0.008 and OR 0.72 95% CI 0.55, 
0.94, p=0.015 respectively), while the IRC association decreased (OR 1.05 95% CI 0.92, 
1.20, p=0.441). The AUC ROC was 0.79 (95% CI 0.70-0.89) Figure 34.  This is improved 
compared to models 1 and 2 showing the added value of combining both data sets. 
 
Model Evaluation 
In order to compare the performance of each model, AIC values were determined 
(lower values equate to better quality model).  The combined model 3 represented an 
improvement over the clinical model 2 (Table 31, AIC 116.3 vs. 125.0).  However, there 
was very little difference in the AIC between the combined model 3 and the T-cell 
alone model 1 (116.3 vs. 115.7).  Despite this, the area under the ROC for the 
combined model 3 (0.79) was better than for model 1 (0.75). Importantly, both of 
these adjusted models improved on the values achieved by each subset individually 
(AUCs 0.63-0.66) and from the clinical only model 2 (AUC 0.62).    
Table 31 Logistic regression models of progression to IA. 
Logistic regression model 
 
 
Model 1 
(T-Cell) 
 
Model 2 
(Clinical) 
 
Model 3 
(Combined) 
Naive (per %)*                       OR 
95% CI 
p 
0.93 
0.89, 0.97 
0.002 
 0.94 
0.89, 0.98 
0.008 
 
IRC (per %)*                           OR 
95% CI 
p 
1.07 
0.94, 1.23 
0.294 
 
1.05 
0.92, 1.20 
0.441 
 
Treg (per %)*                         OR 
95% CI 
p 
0.68 
0.53, 0.88 
0.003 
 
0.72 
0.55, 0.94 
0.015 
 
Age (per year)                      OR 
95% CI 
 
1.01 
0.97, 1.05 
  
1.01 
0.97, 1.05 
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p 0.492 0.668 
 
SE positive(%)                       OR 
95% CI 
p 
  
2.36 
0.76, 7.36 
0.138 
 
Smoker 
 
  
removed† 
 
High positive RF /CCP‡      OR 
95% CI 
P 
 4.66 
1.21, 18.05 
0.026 
2.79 
0.58, 13.34 
0.198 
 
Small joint symptoms          OR 
95% CI 
p 
 
2.65 
1.14, 6.19 
0.024 
2.14 
0.84, 5.46 
0.110 
 
EMS ≥30 mins                        OR 
95% CI 
p 
 
1.00 
0.41, 2.42 
0.997 
removed† 
 
 
AIC 
 
 
115.7 
 
125.0 
 
116.3 
AUC ROC  
95  % CI 
0.75 
0.65, 0.86 
0.62 
0.54, 0.76 
0.79 
0.70, 0.89 
 
* adjusted for age, AIC=Akaike information criterion; AUC ROC=area under the ROC curve, 
‡determined as >3xULN=upper limit of normal   †removed from final model to reduce the number of 
covariates.  
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Figure 34 ROC graphical representation of the three logistic regression models. 
Binary logistic regression models of the occurrence of progression to IA using model 1 T-cell 
subset only (orange line), model 2 clinical parameters (red line) and the combined model 3 
(green line) were constructed.  The area under the ROC for the predicted probability of 
progression from model 1 was 0.75 (95%CI=0.65-0.85), which represents an improvement over 
model 2 0.62 (95%CI=0.54-0.76). Model 3 showed the best results with area under the ROC at 
0.79 (95%CI=0.79-0.89). 
 
Model 3 was applied to the cohort enabling risk stratification into 3 categories 
according to their predicted risk of progression; low (0-19%, n=20), moderate (20-79%, 
n=56) or high (80-100%, n=14), Table 32.  This followed the same method employed 
to assess the previously published clinical model [217].  A higher proportion of 
individuals progressed over time from the high-risk group (64%, 9/14) compared to 
those in other risk groups.  The model also enables the low-risk group to be clearly 
identified with only 1/20 progressing ever. 
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Table 32 Proportions of patients progressing a) within 12 months or b) ever, 
according to their predicted probability of progression from model 3. 
Predicted probability of 
progression 
% progressed to IA within 12 
months 
% progressed to IA ever 
Low (0-19%) 5% (1/20) 5% (1/20) 
Moderate (20-79%) 38% (21/56) 57% (32/56) 
High (80-100%) 29% (4/14) 64% (9/14) 
 
  
6.4.6 Adjusted modelling for time to IA 
Clinically, it is beneficial to provide patients with a time frame as to their likely 
progression.  Therefore, similarly to the unadjusted analysis, a time to progression 
analysis was performed.  Cox regression models were constructed using the three 
logistic regression models to investigate time to progression (Table 33). The trends 
identified were similar. All three T-cell subsets demonstrated association with the 
odds of progression in model 1 and 3 (Table 31).  However, IRC were the most 
significant in this analysis.  Using Harrell’s C as an indication of performance of the Cox 
regression, the combined model 3 provided the best result.  This allowed for 69% of 
randomly chosen pairs of progression times to be correctly ordered compared to 65% 
for the T-cell only model 1 and 60% in the clinical only model 2 (Table 33). 
 
Table 33 Results of Cox regression models of time to progression to IA. 
COX regression model 
 
Model 1           
(T-cell) 
Model 2 
(Clinical) 
Model 3 
(Combined) 
Naive (per %)*                      HR  
95% CI  
p 
0.97 
0.94, 0.99 
0.018 
 
 0.97 
0.95, 1.00 
0.044 
 
IRC (per %)                            HR  1.08  1.08 
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95% CI 
p 
1.02, 1.15 
0.006 
 
1.01, 1.15 
0.016 
 
Treg (per %)*                        HR  
95% CI 
p 
0.83 
0.70, 0.98 
0.027 
 
 0.86 
0.72, 1.02 
0.091 
 
Age (per year)                      HR  
95% CI 
p 
1.01 
0.98, 1.03 
0.598 
 
 1.00 
0.98, 1.03 
0.791 
 
SE positive                            HR  
95% CI 
p 
  1.60 
0.66, 3.86 
0.297 
 
Smoker 
 
   
not entered† 
 
High positive RF / CCP‡        HR  
95% CI 
p 
 2.44 
0.75, 7.92 
0.139 
 
1.45 
0.41, 5.08 
0.561 
 
Small joint symptoms        HR  
95% CI 
p 
 1.73 
0.96, 3.12 
0.071 
 
1.54 
0.86, 2.77 
0.149 
 
EMS ≥30 mins                      HR  
95% CI 
p 
 1.21 
0.66, 2.21 
0.536 
not entered† 
 
  
Harrell’s C 
 
 
0.65 
 
0.60 
 
0.69 
 
AIC 
 
 
329.6 
 
335.7 
 
332.4 
* adjusted for age, AIC=Akaike information criterion; ‡ determined as >3xULN=upper limit of 
normal   †removed from final model to reduce the number of covariates.  HR=hazard ratio.   
 
As in the unadjusted analysis, CCP+ subjects were stratified into 3 groups according to 
their predicted risk of progression: low (0-19%) moderate (20-79%) high (80-100%) 
calculated using model 1, 2 & 3.  Figure 35 presents Kaplan Meier plots for time to 
progression according to the predicted risk categories using each model. Time to 
progression differed significantly according to risk groups in both Model 1 (chi-
sq=6.04, p=0.049) and model 3 (chi-sq=13.43, p=0.001), although there seemed to be 
little difference between the curves for patients at moderate or high-risk of 
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progression.  In model 3 those within the high-risk group progressed to IA more rapidly 
(median 15.4 months, (95% CI=14.3-40.8)) compared to those in the moderate-risk 
(35.1 months (IQR 25.8-44.4)) and low-risk groups (63.4 months (IQR 57.9-69.3)).  For 
model 2, no individual was categorised as high-risk.  The median time to progression 
in the moderate risk group is 34.1 months with an overall significant difference 
between the two risk groups (chi-sq=4.60, p=0.032).   
 
 
 
Figure 35 Kaplan-Meier graph of cumulative IA-free survival according to predicted 
probability of progression in the three models.  
Kaplan-Meier plots for time to progression were constructed according to the predicted risk 
categories from logistic regression Model 1 2, & 3. Low risk (green line, 0-19%) moderate risk 
(orange line, 20-79%) high risk (red line, 80-100%).   
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6.5 Discussion  
This is the first report exploring the clinical utility of T-cell subset quantification within 
a prospectively-followed ‘at-risk’ population.  Given the paucity of data within this 
area it was first necessary to report on the pattern of T-cell subsets in CCP+ at-risk 
individuals compared to observations in health.  As there was no existing reference 
range, a reference limit has been created.  The development of reference limits 
permits the clinical utility of T-cell subsets as a biomarker.  Using this reference limit, 
around two thirds of the CCP + at-risk cohort demonstrated some disturbance in 
frequency of T-cell subsets compared to health.  Individuals at risk of IA had lower 
naïve and Treg cell frequency with elevated IRCs when compared to health.  These 
differences were shown to be statistically significant and predictive of progression to 
IA individually, albeit weakly (Table 28).  Although there is a lack of other studies which 
have considered T-cell subsets in at-risk individuals, the pattern of dysregulation 
reflects that seen in early RA with a reduction in naïve and Treg cells [247, 249, 250, 
400].  
 
These findings improve our understanding of the immuno-phenotype of these at-risk 
individuals.  However, in order to ascertain the additional value of T-cell subsets in 
predicting progression, an analysis which accounted for the existing clinical model was 
required. The adjusted analysis reported an added value of combining 3 T-cell subsets 
and clinical data (Figure 34 and Table 31).  The first step of this process demonstrated 
an added predictive value when combining the T-cell subsets into a model rather than 
using their individual value.  This supports the notion that T-cells subsets could be 
considered together as a single entity. The second step which considered the 
previously established clinical variables (model 2) resulted in a lower area under the 
ROC compared to the T-cell model (model 1).  Finally, in the combined model (model 
3), T-cell subsets remained independently associated with the odds of progression 
even after incorporating the remaining clinical variables (joint count, CCP+ titre and 
adjusting for SE status).  Area under the ROC was improved for this model when 
- 164 - 
 
compared to the T-cell and clinical models.  However, when comparing models, 
additional measures such as the AIC is applied.  The AIC is a measure that trades off 
the information a model provides about the outcome against its complexity.  
Analysing the AIC values, the final adjusted model (model 3) was similar to that of the 
T-cell model (model 1), although the AUC ROC was better for the combined model.  It 
may be that validation of these models in a larger cohort is required in order to 
ascertain which model is optimal.   
 
The survival analyses considering time to progression supported the hypothesis that 
those with the greatest T-cell subset dysregulation are at the highest risk of imminent 
progression (Figure 35, Table 33).  This was suggested in the unadjusted analysis and 
further evidenced in the adjusted analysis.  Here, all the models indicated that 
individuals who were categorised in the high risk group had a greater risk of imminent 
progression.  The Kaplan-Meier curves for model-2 (T-cell only) consisted of only a low 
and moderate groups, as no individual was categorised in the high risk group.  Since 
no individual in the low risk group progressed, a calculation for time to progression for 
that group was not possible.  The combined model did allow categorisation into the 
high risk group, although there was some crossing of curves.  Statistical significance 
however remained with the high risk group progressing earlier than the moderate risk 
group (15 months versus 35 months).  This model therefore identifies those at risk of 
imminent progression.  By establishing who is at risk of IA, clinicians can formulate 
better management plans and inform patients to be vigilant about change of 
symptoms.   
 
There are limited studies to support or refute the findings reported here.  No other 
research group has investigated T-cell subsets within a prospectively-followed at-risk 
population.  A small cross-sectional study of 26 seropositive patients with arthralgia 
reported on peripheral naïve T-cells (CD3+CD4+CD45RO-CCR7+).  However, no 
difference between health, RA and arthralgia was reported in this study [411]. It is 
worth noting that the antibodies used to measure naïve cells were not the same as 
has been reported in this work.  Naïve CD4+ T-cells are conventionally identified using 
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markers such as CD45RA+, CD62L+ CD44+ but less commonly using an exclusion 
marker (CD45RO-) and an activation marker (CD197/CCR7) to more precisely define 
the subset.  This makes a comparison of findings challenging.  Furthermore, this group 
studied a mixed cohort of seropositive individuals with arthralgia (ACPA+ and/or IgM-
RF+), compared to this study which recruited individuals based on CCP status alone. It 
is reasonable therefore to suggest there may be varying T-cell subset dysregulation 
between these cohorts.  
 
Interestingly, when the descriptive data were reviewed (Figure 30) it is apparent that 
some individuals with normal T-cell subset frequencies still progressed to IA.  This 
raises questions regarding the sequence of events leading to progression.  T-cell 
disturbance and dysregulation are thought to be very early changes and it could be 
hypothesised that all individuals would demonstrate dysregulation prior to 
development of IA.  One explanation for these findings may be related to the proximity 
of the sample acquisition and analysis from progression date.  Dysregulation may 
occur subsequently, or just prior to progression and therefore a more recent analysis 
of T-cell subsets is necessary to exclude progression.   Alternatively, it has been 
suggested that within the heterogeneous cohort of CCP+ at-risk individuals, not all will 
have (measurable) dysregulation in T-cell subsets and may exhibit a B-cell driven or 
alternative pathway of disease.  This theory is corroborated by the finding that not all 
individuals with RA have abnormal T-cell subsets [399].  T-cell subsets shift and evolve 
with the influence of external factors and therefore patterns of dysregulation and 
normality change with disease progression and states of remission.  Until the natural 
progression of T cell subsets in inflammatory disease is better understood these 
questions will be difficult to answer.   
 
This work has focused on the biomarker potential of T-cell subsets and as yet there is 
not sufficient functional work or longitudinal data to comment further on the insights 
into disease onset and pathogenesis.  Naïve and Tregs appear to be more important 
in the early stages of the IA continuum and in assessing progression risk.  Whereas, 
IRCs are mostly driven by inflammation and therefore their value appears to be in 
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assessing time to imminent progression. This is particularly pertinent in at-risk 
individuals where routine inflammation markers are normal.  
6.6 Limitations  
As has been highlighted during the results and discussion section of this chapter, T-
cell subsets are a dynamic biomarker which vary throughout an individual’s progress 
along the inflammatory arthritis continuum.  This analysis has used samples obtained 
from CCP+ (at-risk) individuals with arthralgia at their baseline appointment.  Given 
the imminent nature of the changes seen in T-cell subset frequencies, it is likely that 
for individuals presenting early in their at-risk status, their immunophenotype has yet 
to become dysregulated.  This resulted in an amendment to the protocol allowing for 
annual, sequential T-cell subset quantification.  Data on T-cell subsets over time in an 
at-risk population will hopefully enable better understanding of the changes in each 
T-cell subset with progression or non-progression to IA.   This data will be reviewed 
once sufficient sequential samples are available for meaningful analysis.  
 
This analysis has not considered the ultrasound findings performed at baseline of the 
study.  Baseline ultrasound scan reports were not available on a significant proportion 
of the individuals who had had T-cell subset quantification.  This will be considered 
once the cohort has increased with sufficient follow-up and progression to IA 
observed.  The lack of ultrasound data is acknowledged as a limitation in this current 
study.   
 
Although this is one of the largest studies of CCP+ at-risk individuals and the first to 
consider T-cell subset dysregulation, the sample size has limited the robustness of 
statistical modelling.  It is recommended that there should be at least 10 cases in the 
smallest outcome category (‘events’) per variable (EPV), although it has been shown 
that valid results can be obtained with EPVs between 5 and 9 provided the results are 
interpreted cautiously. In model 3 the EPV was 6.9, therefore these can be considered 
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as promising preliminary results, but this model must be considered exploratory until 
it is validated in a second cohort.  
 
To date, flow cytometry in RA patients has been predominantly performed in a 
research setting, however during and following this project, development of a 
pathway within the local National Health Service (NHS) has been established.  Several 
quality controls and audits have been performed to ensure replication of results 
between the clinical immunologists and the research scientists.  A small proportion of 
the samples used in this analysis were performed in the clinical laboratories.  
Additional quality control checks were performed on these samples and review of the 
gating strategy applied by the NHS laboratories.  However, it is acknowledged that 
during a time of transition there is the possibility that different technicians and 
laboratory equipment increase the opportunity for mis-reporting and errors.  The 
additional checks put in place aim to reduce these occurrences.  Despite the possible 
complications and difficulties during the transition period, this approach has 
demonstrated robust sample processing and importantly has significantly increased 
workload capacity compared to that within research laboratories.  This increased 
capacity will facilitate the validation of these results.  
 
6.7 Key points 
 CCP+ individuals have a dysregulated T-cell phenotype with reduction in naïve 
and Treg proportions and elevation in IRCs when compared to healthy 
controls. 
 T-cell subset quantification can be used for risk modelling to improve the 
prediction of progression to inflammatory arthritis.   
 Individuals with the greatest immune dysregulation are at highest risk of 
imminent RA disease progression.   
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6.8 Conclusions 
At-risk cohorts demonstrate great heterogeneity with regards to genetic 
predisposition, environmental factors, symptomatology, and ultimately progression 
towards arthritis.  Although 53.4% (55/103) of subjects studied here have yet to 
develop IA, some progressed imminently - these individuals may benefit from early 
treatment.  Identification of these individuals is therefore a clinical priority.  Whilst the 
development of a clinical model has assisted this identification, the opportunity to 
improve prediction with the inclusion of immunological markers has been explored 
here. 
 
This study has reported T-cell dysregulation within the CCP+ arthralgia cohort.  The 
development of a reference limit enabled the dichotomisation of T-cells into normal 
and dysregulated.   Clinical utility of T-cell markers has been explored through 
incorporation into regression modelling.  Construction and comparison of models has 
demonstrated that the combined model (using both clinical and immunological 
variables) offered a predictive advantage over each variable when considered 
separately.  Furthermore, the time to IA development was rapid in the high risk 
subgroup compared to the low risk subgroup.  This was best appreciated in the models 
which included T-cell data.   
 
To validate the findings of this study in a larger second cohort, further steps to ensure 
quality control measures for assessing T-cell subsets are required.  Refinement of the 
reference range should be sought, particularly at the extremes of age.  With ongoing 
recruitment to this prospective study the opportunity to include all biomarkers 
including ultrasound parameters is available.  This may assist in establishing the value 
of immunological markers in predicting progression to IA.  As indicated in the 
discussion, sequential samples will soon be available for these individuals and it would 
be beneficial to investigate the natural history of T-cell subsets following the 
development of IA.  One would hypothesise that those individuals who do not 
progress to IA have relatively stable subsets.  If so, this would provide an indication as 
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to whether progression is imminent and requires intervention or whether observation 
is appropriate.  Adopting such a personalised medicine approach to services is an 
attractive option for both patients and physicians.  
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7. Concluding remarks and future directions 
In this concluding chapter, a summation of results and implications of the research 
are presented.  An update of the recent developments within the field is provided 
and future directions explored.    
 
7.1 Summary and implications of findings  
This thesis has focussed on an at-risk population defined by anti-CCP positivity and 
non-specific MSK symptoms recruited from the county of Yorkshire, U.K.  The 
previously presented chapters report on the findings of imaging, molecular and 
cellular markers which contribute to our understanding of disease progression and 
prediction of IA development.   
 
Magnetic Resonance Imaging in individuals with systemic autoimmunity and 
arthralgia: MRI as an imaging biomarker 
For the first time, the MRI characteristics of a large cohort of CCP+ at-risk individuals 
have been reported.  Within this populations, tenosynovitis was found to be the most 
prevalent finding with comparatively low levels of BME and erosions.  Previous work 
concerning the clinical and ultrasound variables facilitated multivariable modelling to 
evaluate the ability of MRI features, including tenosynovitis, to predict IA.  MRI 
tenosynovitis was predictive of future IA development in at-risk individuals and 
predicted clinical synovitis in an individual joint.  In addition, BME was significantly 
associated and predictive of clinical synovitis development in a joint although did not 
predict progression at a patient level.    The study has confirmed that MRI variables, in 
particular MRI tenosynovitis, provide additional predictive ability over and above the 
variables included in the clinical model and ultrasound GS & PD.  Whether 
tenosynovitis and BME are the primary initiating lesions prior to IA development has 
not been confirmed by this analysis, but can be the focus of future investigation.    
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The results from this study may have significant implications for how at-risk individuals 
are assessed.  Although a preliminary report, the high HRs for MRI tenosynovitis 
suggest superiority with improved prediction compared to ultrasound in this at-risk 
cohort.  A comprehensive analysis comparing the detection of tenosynovitis by 
ultrasound and MRI is required to ascertain whether the modalities are comparable.  
Currently, individuals recruited to the study have both ultrasound and MRI.  However, 
outside of the research setting, it may be conceivable that one imaging examination 
is sufficient.  MRI offers an alternative and comparable, arguably superior option that 
may be more feasible, where ultrasound expertise is unavailable.   
 
MicroRNA profiling of matched samples in individuals with systemic autoimmunity and 
arthralgia who progress to RA 
In this exploratory study, miRNA global expression profiling identified several miRNAs 
of interest that were dysregulated with progression.  In contrast, to previous research, 
this project defined the study population further, by focussing on those individuals 
with no evidence of inflammation as determined by PD on ultrasound.  To date, there 
has been no other study which has reported on predictors of disease in such an early 
phase of autoantibody positivity.  At this time, an exact miRNA signature cannot be 
validated.  Instead there are several miRNAs identified which are expressed during the 
CCP+ state and on through to progression.  A multivariable analysis to evaluate 
prediction to progression was restricted given the sample size.  However, the potential 
utility of miR-22 as a biomarker to differentiate at-risk individuals was highlighted and 
through further validation may offer clinical utility.   The scientific value of the study 
design using sequential samples prior to and at point of progression should not be 
dismissed.  Such a design offers the opportunity for work evaluating the mechanistic 
functions of specific miRNAs.  
 
From a scientific standpoint, understanding the dysregulation in molecular markers 
provides insights into disease, although does not necessarily translate into clinical 
utility.  The identification of molecular biomarkers measurable from serum samples in 
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the validation phase, has significant potential implications.  Through further analyses 
and validation, it may be possible to improve prediction models or develop a pathway 
in which a blood test is sufficient to establish risk.  Furthermore, this is the first study 
to report on an at-risk population in which subclinical inflammation was excluded.  The 
fact that individuals still progress, exemplifies the need to identify those at greatest 
risk.  Whilst conducting this research, inconsistences with published methodology and 
analytical approaches in miRNA studies became evident. This impedes the ability to 
compare findings and highlights the importance of validation in different populations 
to establish the full extent of associations.  Future work may look to improve upon 
methodology used and move towards collaborative projects to reduce 
inconsistencies. 
 
T-cell subsets in individuals with systemic autoimmunity and arthralgia: an 
immunological biomarker 
The development of a healthy control reference range permitted the evaluation of T-
cell subsets as a novel biomarker in the prediction of IA progression within an at-risk 
cohort.  T-cell dysregulation was evident with the extent or depth of dysregulation 
appearing to be greatest prior to IA development.  Through quantification of T-cell 
subsets, prediction of IA was possible and superior to using the clinical model alone.  
A combined prediction model consisting of clinical and cellular markers demonstrated 
the greatest clinical utility.  The effect of ultrasound and other imaging markers has 
not been evaluated in this study and should be a focus for future work (section 7.3).   
 
Incorporation of cellular immune markers to the clinical model has demonstrated 
improved prediction and risk stratification.  This has implications for the assessment 
of individuals and also generates questions concerning the sequence of events leading 
to IA development.  Determining the earliest detectable change or patterns indicating 
stabilisation may assist identification of an optimal time point for intervention.   This 
study has also demonstrated how biomarkers identified through research can be 
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successfully transferred to a local NHS setting, improving the access of T-cell subsets 
quantification.   
 
7.2 Developments within the area of interest 
Developments in defining at-risk: 
Recruitment and investigation of several at-risk cohorts continues to provide further 
insights on the associations of disease progression.  The clinical symptoms and initial 
presentation of individuals at risk of RA development has been the focus of extensive 
qualitative research [412, 413].  Individuals with seropositive arthralgia have reported 
experiencing a multitude of symptoms akin to those with newly diagnosed RA.  A 
broad range of symptoms were reported including pain, stiffness, fatigue, burning 
sensations, loss of motor control, weakness, muscle cramps, sleep disturbance and 
abnormal skin sensations.  Such information can help in understanding health seeking 
behaviours in such individuals, however it is limited to the defined ACPA positive 
population. Interest in identifying individuals across all phases of risk (without limiting 
to those with positive serology), has resulted in a definition of the prodromal symptom 
phase prior to RA development.  Through assimilation of the available data, consensus 
of opinions and a validation exercise, the EULAR taskforce proposed 7 characteristics, 
listed in Box 6 [414].  This was designed to assist physicians in identifying individuals 
with clinical CSA prior to any laboratory or imaging investigations.  Its role in primary 
care setting has not been suggested or evaluated.  A high sensitivity (>90%) is obtained 
if ≥3 parameters are present, and a specificity (>90%) requires ≥4.  It has been 
validated in other large cohorts and will hopefully enable future work to develop a 
criteria for imminent RA [415].   
Box 6 EULAR defined characteristics describing arthralgia at risk for RA 
History taking:  
Joint symptoms of recent onset (duration <1 year) 
Symptoms located in MCP joints 
- 174 - 
 
Duration of morning stiffness ≥60 min 
Most severe symptoms present in the early morning 
Presence of a first-degree relative with RA 
Physical examination:  
Difficulty with making a fist 
Positive squeeze test of MCP joints 
Adapted from van Steenbergen et al [414] 
Note: These parameters are to be used in patients with arthralgia without clinical arthritis and 
without other diagnosis or other explanation for the arthralgia 
 
As the field moves towards prevention and interventional studies, investigators have 
conducted qualitative research to ascertain perceptions around risk.  Interviews and 
focus group discussions in both autoantibody positive individuals and FDRs have 
demonstrated key themes concerning the psychological implications of an at-risk 
status diagnosis [412, 413, 416, 417].  Within autoantibody positive individuals, the 
implications of symptoms on an individual’s well-being have been reported [412].  
Themes emerged regarding fear of future RA diagnosis, uncertainty, frustration and 
despair [413].  Acknowledging that an at risk of RA diagnosis may induce some 
psychological distress suggests care pathways need to be refined to assist in the 
management or indeed prevention of such conditions.  By appropriately risk 
stratifying and identifying those at low risk, management can be tailored to develop 
reassurance and educational resources to help understand their symptoms.   Similar 
studies in FDRs have also indicated anxiety around future diagnosis of RA  [416, 417].   
Concerns were raised as to the negative implications of predictive testing, although 
many did recognise how research in the area assists development and implementation 
of preventive strategies [417].  These studies concluded that communication of risk 
needs to be appropriate and address the psychological burden associated with 
predictive testing and involvement in studies.    
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Currently, limited data are available with regards to perceptions concerning 
interventional therapy in these cohorts.  Interviews with FDRs have reported a 
willingness to receive ‘prophylactic’ treatment, which the majority of participants 
considered would be medication [418].  There was also a willingness to participate in 
RCTs to prevent or delay disease.  A larger study analysing survey responses from 32 
FDRs was able to demonstrate an increased odds ratio for likelihood of taking 
treatment if a risk reduction >20% of RA development was demonstrable, with a low 
probability of adverse events of therapy (<10%) [419].  Interventional studies should 
consider the acceptability of preventative therapies as these can vary depending on 
the patient population, communication of risk and duration, mode and safety of 
therapy offered.    
 
Developments concerning interventional studies: 
Preliminary results from the PRAIRI study have been presented [420].  This 
multicentre, randomised, double-blind, placebo-controlled clinical trial successfully 
recruited 82 autoantibody positive subjects.  The objective was to assess whether a 
single infusion of rituximab could delay or indeed prevent the onset of clinical arthritis.  
The inclusion criteria stipulated positivity for both ACPA and RF as well as CRP levels 
≥3 mg/l and/or subclinical synovitis on ultrasound or MRI of the hands. Each group 
received premedication 100mg methylprednisolone.  However, given the findings 
from the intramuscular steroid study this would not be expected to affect onset of 
arthritis (section 2.4.1 and [293]).  Eighty-one subjects were randomised and were 
observed for a median of 27 months (IQR 25 month).  Thirty subjects developed 
arthritis during the observation period: 16/40 (40%) in the placebo group and 14/41 
(34%) in the rituximab group, after a median period of 11.5 (IQR 12.5) months in the 
placebo group versus 16.5 (IQR 19.0) months in the rituximab group. In the preliminary 
analysis time to arthritis was significantly delayed in the rituximab compared to the 
placebo treated group (p<0.0001).  The authors acknowledge that further follow-up 
will be significant in clarifying impact of a single infusion of rituximab.   
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This study is the first to consider biological DMARDs in an at-risk population and has 
generated extensive discussion.  There are several areas for consideration when 
evaluating the significance of this study.  Firstly, only one dose of therapy was 
administered in this trial.  It is plausible to hypothesise that a longer duration of 
therapy may have led to further delay and potentially prevention.  Furthermore, the 
inclusion criteria required individuals to have either elevated inflammatory markers 
or imaging findings of subclinical inflammation.  From the findings of the Leeds cohort, 
it is recognised that individuals with subclinical inflammation (as determined by 
ultrasound and MRI) are a greater risk of IA development and as the goal posts shift 
may even be considered as early RA.  It is therefore, not surprising that early 
intervention delayed but did not prevent clinical disease presentation.  As a first step 
this study has been beneficial in demonstrating delay in clinically evident disease 
progression, however it could be viewed as successful therapy with relapse rather 
than prevention.  Understanding the benefit of therapy in earlier phases of at risk is 
also required.  Whether individuals at lower risk as defined by the absence of clinical 
imaging synovitis would benefit from interventional therapy is not known.  There is a 
possibility for potential side effect of treatment outweighing any risk reduction 
benefit.  Certainly, evaluating a moderate or lower risk group would require longer 
observational periods as the time to onset of disease may be longer.   
 
A UK based study (Arthritis Prevention in the Pre-Clinical Phase of RA with Abatacept- 
APIPPRA) is hoping to add further evidence as to the implications of targeted 
intervention in at-risk individuals with the use of abatacept (2.4.3 and [421]).  The 
protocol in this study is for 52 weeks of abatacept therapy.  Additionally, the exclusion 
criteria include subclinical inflammation as determined by ultrasound findings.  This 
longer duration of therapy and in a different population of at-risk individuals, 
potentially at lower risk, offers the opportunity to target disease at the earliest phase.  
Recruitment continues and preliminary results are eagerly awaited.   
 
The inclusion and exclusion criteria of these studies have enabled a defined phenotype 
of at-risk individuals to be evaluated.  However, as yet, an interventional study that 
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risk stratifies eligible individuals for the purpose of therapeutic management has not 
been described.  Such study protocols of stratified biomarker RCTs have been 
pioneered in oncology and enable several biomarkers and therapies to be evaluated 
in a biomarker enriched population [422, 423].  In the context of individuals at risk of 
RA, use of biomarkers followed by risk stratification would allow for targeted therapy 
to those at greatest risk.  Additionally, those at low risk may be offered health 
promotion and symptom management education.  Given the dynamic nature of these 
cohorts, it is important that individuals are re-evaluated throughout the observation 
period since some individuals will change risk status.  Adopting such a personalised or 
tailored approach to patient care should provide the optimum outcomes without 
exposing individuals at low risk to therapy side effects.   
 
Developments in primary prevention: 
In the U.K, a national registry of FDRs has been established [424]. Following work 
conducted in similar cohorts in the U.S, this registry aims to consider the interactions 
between the environment, genes and development of immune and inflammatory 
responses.  A sub-study of the registry will also consider cardiovascular risk factors of 
disease.   As yet, no data have been published and ongoing recruitment is required for 
sufficient numbers to enable a meaningful analysis.  It is hoped that research findings 
will inform researchers and clinicians as to which FDRs are at greatest risk of RA and 
possible identification for intervention strategies.    
 
Lifestyle modification may provide the opportunity to achieve true primary prevention 
in individuals at-risk. In support of this approach, qualitative research in FDRs has 
suggested that preferred risk reduction strategies would consist of lifestyle 
modification measures as opposed to medication [416].  In the U.S. a RCT entitled 
‘Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) Family Study’, is testing 
the effects of personalised risk education including modifiable factors such as oral 
health, diet, weight and smoking status in FDRs [425].   Results have recently been 
published and demonstrate that individuals in the intervention arm were statistically 
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more likely to demonstrate changing behaviours than those receiving standard RA 
education [426].  This study has provided evidence that educational tools personalised 
to an individual can increase motivation to alter behaviour.  It is hoped that such 
intervention will prevent RA progression, as well as the other significant health 
benefits.   
 
7.3 Future directions 
Through the summation of the results presented in this thesis, it has been possible to 
refine existing models of prediction and provide insights into potential new markers.  
There are however, several areas to direct future work.   
 
The MRI study has highlighted the improved prediction of RA development offered by 
MRI tenosynovitis in seropositive (CCP+) individuals.  Preliminary results comparing 
both MRI and ultrasound tenosynovitis reporting, suggested that MRI was more 
sensitive.  Limitations, as previously stated, inhibited a comprehensive comparison. 
Through validation in a larger cohort the associations with ultrasound tenosynovitis 
should be clarified.  This would enable researchers to provide recommendations as to 
which imaging modality is superior in evaluating individuals at risk and negate the 
need for unnecessary investigations. 
 
An area of interest that has arisen from this work relates to analysis of the MRI 
dynamic sequences.  OMERACT RAMRIS scoring was used in this analysis based on its 
reproducibility and transferability for multicentre use [427].  Within this study, MRI 
synovitis was not associated with development of future clinical synovitis in a joint.  
Synovitis, as determined by RAMRIS scoring, is an ordinal measure that does not give 
any indication of severity or intensity of synovitis.  Alternative assessments which 
provide continuous measures are available and are suggested to be more sensitive 
[428].  Such quantitative scores include synovial volume and dynamic contrast 
enhancement (DCE) MRI which have been successfully used [429].   
- 179 - 
 
 
Synovial volume is a good marker of disease activity however, the process of manually 
outlining synovitis is laborious.  There are now automated and semi-automated 
systems available which provide a feasible option for larger scale studies [430, 431].  
DCE-MRI offers assessment of the uptake and washout of gadolinium based contrasts 
and provides data on the synovial perfusion and capillary permeability [429, 432, 433].  
Difficulties ensuring the consistency in characterisation of the enhancement curves 
and defining the regions of interest have limited its widespread use.  However, it has 
been demonstrated that DCE-MRI can be used in multicentre trials and with good 
repeatability [434].  In RA cohorts, DCE-MRI has been shown to correlate with clinical 
features including joint swelling, pain and disease activity scores [435-437] and 
differentiate between active versus inactive synovial change [435].  DCE-MRI has also 
been shown to correlate with US PD [438, 439].   This may be particularly pertinent to 
at-risk cohorts since active synovitis may theoretically be associated with a progressive 
outcome.  Furthermore, the value of DCE-MRI may be particularly useful for evaluating 
change in synovitis across longitudinal scans.     
 
The miRNA and T-cell subset studies have illustrated how novel biomarkers can be 
identified and applied to a clinical cohort.   Whilst, the miRNA work is preliminary, the 
possibility of a signature of miRNAs to assist in evaluating individuals at the very 
earliest phase of at-risk (without ultrasound powerDoppler) has been explored.  It 
would be important to report on whether this miRNA dysregulation is also seen in 
those individuals with inflammation at baseline imaging.  A correlation between 
miRNA dysregulation and ultrasound or MRI determined tenosynovitis has not been 
performed but should form the basis of future work.  Similarly, association with T-cell 
subset and ultrasound findings has not been reported and is an area that requires 
consideration.   
 
Other T-cell subtypes have been proposed in RA pathogenesis, including Th17 cells.  
Since the discovery of the CD4 effector T helper cell which produces interleukin 17 (IL-
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17), the focus of many studies has evolved to consider the relationship between Th17 
and disease [440-443].  The pro-inflammatory properties of IL-17 as well as its 
stimulation of osteoclastogenesis and degradation of cartilage has implicated Th17 as 
the driving force for autoimmunity [444-446].  However, there have been 
discrepancies in the surrogate markers used for Th17 identification, which may have 
contributed to the inconsistencies in results presented.  Th17 is detectable in early 
disease, although levels are thought to reduce with therapy and disease chronicity 
[443].  Prior to the development of arthritis, IL-17 is markedly elevated, with a 
reduction at disease onset [196].  Within a seropositive arthralgia cohort (n=26), Th17 
lineage cells (CD4+CD161+) were reported to be elevated [411].  The quantification of 
Th17 alongside naïve, Treg and IRC would provide a comprehensive immunological 
picture of at-risk individuals.  Future work aims to address this. Furthermore, through 
the development of a reference range for Th17, the clinical utility can be assessed in 
prediction models.    
 
Ultimately, there remains no single biomarker or ‘magic bullet’ that can predict 
progression in these individuals to date.  Instead, risk stratification is possible through 
the integration of multiple cellular, molecular, imaging and clinical markers.  As a 
consequence of relatively modest numbers of individuals in at-risk cohorts, the 
evaluation of all markers in a hazard regression analysis has currently not been 
performed.  Future work requires such an analysis in order to determine whether 
progression can be predicted and which markers provide greatest information.  With 
ongoing recruitment, the opportunity to include all biomarkers in an analysis to refine 
and adapt the models should be achievable.    
 
Thus far, studies in this cohort, have reported on the predictors of progression to 
enable early identification of those at greatest risk [217, 237, 382].  However, the 
prospective design of this study enables data collection at multiple time points.  There 
is the opportunity therefore, to assess disease evolution and natural history, from at 
risk with autoimmunity to RA development.  Evaluation of imaging, cellular, molecular 
and clinical variables could provide evidence as to the sequence of events leading to 
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persistent joint inflammation and disease.  It is apparent from the risk stratification 
exercises conducted to date, that predicting development of RA from baseline 
characteristics is not yet fully achievable.  These individuals, by virtue of being part of 
a dynamic continuum, will inherently evolve and change phenotype.  The miRNA 
project illustrates the concept of following an individual from presentation to 
progression and evaluating change in miRNAs expression.  Similarly, several 
individuals within the cohort had sequential T-cell subsets quantified during follow-
up.  Preliminary data has been reviewed descriptively to determine stability of T-cell 
subset and whether there is change in dichotomisation groups with time to RA 
development.  Analysis has been limited to a subset of patients and typically focussed 
on one characteristic or variable. An overview of changes in all variables is therefore 
warranted.   
 
Obtaining data on changing phenotypes with RA development will assist in developing 
effective care pathways.  It is hypothesised that immunological markers would be one 
of the first indicators of change followed by imaging and finally, the reported clinical 
symptoms.  This analysis will require a near complete dataset with imputation to 
account for missing variables.  Initially, it is proposed that latent growth curve models 
are used to evaluate change in characteristics of the progressors.  This can then be 
compared to analysis within the non-progressors.  By establishing the natural history 
of change, individuals can be re-evaluated and stratified throughout their care 
pathway.  A personalised approach is proposed in which an individual can be identified 
as their markers evolve to represent a higher risk phenotype, providing the 
opportunity for communication of risk and possible management options.   
 
As illustrated by the health promotion study in the U.S, aiming for primary prevention 
is a potentially achievable goal in at-risk cohorts [426].  Establishing the contributors 
and triggers to disease has resulted in studies considering the first sites of possible 
antigen presentation such as the mucosa (Section 2.2.3.5).  Within our department, 
studies are underway to determine the associations between periodontal disease and 
RA progression through comprehensive periodontal examinations and mucosal 
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sampling in the CCP positive, at-risk cohort [283].  Similar work is planned for the 
assessment of autoimmunity at the site of the lungs through induced sputum analyses.  
However, it is recognised that in studying individuals with systemic autoimmunity the 
prospect of primary prevention is limited.  Future plans therefore are to offer similar 
assessments to FDRs who are known to have genetic susceptibility, but as yet not 
developed systemic autoimmunity.  By determining the significance of mucosal 
autoimmunity prior to systemic, there is the opportunity to intervene.  These are 
currently pilot designed studies however, depending on their findings, could prove an 
important focus for future work.   
 
It is apparent from the summation of findings and work proposed that there remain 
several areas which require consideration in the evaluation of risk in seropositive 
individuals.  A larger validation process is required to establish the appropriate 
biomarkers to be used for successful risk stratification of at-risk populations.  
Secondly, little is known as to the evolving nature of RA development in these 
individuals and therefore a programme of work considering change in biomarkers and 
characteristics has been described.  Since preliminary work has indicated a 
progression rate of around 50% in these individuals, identifying those at imminent risk 
remains a priority.  The heterogeneity seen within a CCP positive at-risk status 
illustrates the need to address those at moderate to low risk whom may change 
phenotype.  Similarly, there remain those considered at very low risk of progression 
whom should be appropriately reassured to minimise on psychological implications.  
To address these needs, a risk stratified interventional study is proposed.  Drawing 
upon what has been established in at-risk cohorts, a study design which successfully 
risk stratifies individuals with appropriate communication of risk to facilitate 
recruitment is suggested.  Whilst individuals with systemic autoimmunity remain a 
target population, FDRs and seronegative individuals with CSA features should be 
considered in studies moving forward.  The proposed work should provide evidence 
as to when the window of opportunity truly commences and if indeed intervention in 
these early phases can interrupt or prevent disease onset. 
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List of Abbreviations 
ACPA  Anti citrullinated protein antibody 
ACR  American college of rheumatology 
AIC  Akaike information criteria 
Anti-CCP Anti cyclic citrullinated peptide antibody 
Anti–Car P Anti carbamylated protein antibody 
APC  Antigen presenting cell 
Apo A1/B Apolipoprotein A1/B 
AUC ROC   Area under the receiver operator curve  
BMC   Base of metacarpal  
BMI  Body mass index 
BME  Bone marrow oedema 
CI  Confidence interval 
CRF  Case report form 
CS  Clinical synovitis 
CVD  Cardiovascular disease 
DCE  Dynamic contrast enhance-d/-ment 
DMARD Disease modifying anti-rheumatic medication 
DRadius  Distal radius 
DRUJ   Distal radioulnar joint  
DTT  Dithiothreitol 
DUlna   Distal ulna  
EMS  Early morning stiffness 
EQ-5d  Euroquol- 5d questionnaire 
ESR  Erythrocyte sedimentation rate 
- 184 - 
 
EULAR  European league against rheumatism 
EPV   Events per variable 
FCR   Flexor carpi radialis  
FCU   Flexor carpi ulnaris 
FDR  First degree relative 
FDSFDP  Flexor digitorium superficialis and flexor digitorium profundus  
FPL   Flexor pollicis longus 
FLS  Fibroblast-like synoviocytes 
GWAS  Genome wide association studies 
HAQ  Health assessment questionnaire 
HC  Healthy controls 
HDLc  High-density lipoprotein cholesterol 
HLA  Human leucocyte antigen 
HR  Hazard ratio 
HsCRP  High-sensitivity CRP 
IA  Inflammatory arthritis  
ICJ   Intercarpal joint  
INF-  Interferon- 
IQ  Interquartile range 
IRC  Inflammation related cells 
IL -  Interleukin - 
ILC   Innate lymphoid cell  
IRF  Interferon regulatory factor 5 gene 
LDLc  Low-density lipoprotein cholesterol 
MCP   Metacarpophalangeal  
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MiRNA  Micro ribonucleic acid 
mRNA  Messenger ribonucleic acid 
MR  Magnetic resonance 
MRI  Magnetic resonance imaging 
MSK  Musculoskeletal 
MTP   Metatarsal phalangeal  
NHS  National health service 
NPV  Negative predictive value 
OMERACT Outcome measures in rheumatology 
OR  Odds ratio 
PAD  Peptidyl arginine deiminase 
PB   Peripheral blood  
PBMCs  Peripheral blood mononuclear cells 
PCT  Procalcitonin 
PD  power Doppler 
PET  Positron emission tomography 
PIP  Proximal interphalangeal  
PPV  Positive predictive value 
PTPN-22 Protein tyrosine phosphate non-receptor-22 
PSS   Primary sjogrens syndrome  
qPCR  Quantitative polymerase chain reaction 
RA  Rheumatoid arthritis 
RAMRIS Rheumatoid arthritis MRI Score 
RASF   Rheumatoid arthritis synovial fibroblasts  
RCJ   Radiocarpal joint  
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RF  Rheumatoid factor 
RISC   RNA-induced silencing complex  
RNA   Ribonucleic acid  
ROC   Receiver operator curve 
SD  Standard deviation 
SE  Shared epitope 
SF   Synovial fluid  
SNP  Single nucleotide polymorphism 
SPLA2  Secretory phospholipase A2 
ST   synovial tissue  
TC  Total cholesterol 
TG  Triglycerides 
TLDA   TaqMan low density arrays  
TNF-alpha Tumour necrosis factor-alpha 
Treg  T-regulatory cells 
UA  Undifferentiated arthritis  
USS  Ultrasound scan 
US  Ultrasound 
VAS  Visual analogue score 
VERA   Very early RA 
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Appendix A  
ULTRASOUND JOINTS 
R/L HANDED:  
VISIT: Week  0 / 26 / 52 / annual (after week 52) / unscheduled visit / withdrawal 
DATE: 
RIGHT  LEFT 
EC* 
 
GE 
(0-3) 
#E 
 (0-
3) 
PD 
(0-3) 
GS 
(0-3) 
 GS 
(0-3) 
PD 
(0-3) 
E 
(0-3) 
GE 
 (0-
3) 
EC* 
 
     ICJ      
     UCJ      
     RCJ      
     GLOBAL 
WRIST 
     
     MCP1      
     MCP2      
     MCP3      
     MCP4      
     MCP5      
     PIP1      
     PIP2      
     PIP3      
     PIP4      
     PIP5      
     SHOULDE
R 
     
     ELBOW      
     KNEE      
     ANKLE      
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     MIDFOOT      
     1 MTP      
     2 MTP      
     3 MTP      
     4 MTP      
     5 MTP      
     OTHER      
     OTHER      
     OTHER      
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ULTRASOUND SCAN: TENDONS 
RIGHT  LEFT 
PD 
(0-3) 
GS 
(0-3) 
 GS 
(0-3) 
PD 
(0-3) 
  ECU   
  MCP2_FT   
  MCP3_FT   
  MCP4_FT   
  MCP5_FT   
  PIP2_FT   
  PIP3_FT   
  PIP4_FT   
  PIP5_FT   
  OTHER   
  OTHER   
  OTHER   
 
*EC = Extra-capsular abnormalities. If present enter the appropriate number. 
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Appendix B 
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Appendix C 
MRI Tenosynovitis Scoring 
Patient Number: _____________________         ER  /  AJG    
Wrist Flexor 
 FCR FPL FDS/FDP FCU 
Score (0-3)     
     
Wrist Extensor 
 I II III IV V VI 
Score (0-3)       
 
Hand flexor 
 Thumb Index Middle Ring Little 
Score (0-3)      
 
Score 0-3 
Grade 0: Normal 
Grade 1: <2mm thickening 
Grade 2: ≥2mm and <5mm 
Grade 3: ≥5mm thickening 
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